Macrocyclic compounds, their preparation methods and pharmaceutical uses

By designing a novel skeletal compound that selectively inhibits KRAS G12C, the problem of the lack of effective KRas inhibitors in the prior art is solved, and a compound with improved physicochemical properties is provided for the treatment of KRas-mediated cancers.

CN123076594APending Publication Date: 2026-11-10JIANGSU HANSOH PHARMA CO LTD +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202580026623.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-01-17
Filing Date
2025-04-01
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current technologies have not yet been able to develop KRas inhibitors with sufficient safety and efficacy to obtain regulatory approval, particularly inhibitors targeting the KRas G12C mutant, for the treatment of KRas-mediated cancers.

Method used

A novel skeletal compound with a unique chemical type is provided for selectively inhibiting KRAS G12C. It is used to prepare compounds of formula (I) and their pharmaceutically acceptable salts, solvates or prodrugs, including tautomers, isomers, etc., to form different ring structures and linking groups through specific combinations of substituents, thereby improving the selectivity and efficacy of the compound.

Benefits of technology

This compound is expected to become a KRAS G12C inhibitor with improved physicochemical properties, effectively inhibiting KRas G12C and providing a potential new treatment option for KRas-mediated cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123076594A_ABST
    Figure CN123076594A_ABST
Patent Text Reader

Abstract

The invention discloses a compound of formula (X) as an inhibitor of a specific target, a method for its preparation, a pharmaceutical composition comprising the compound, and its pharmaceutical use for treating diseases or conditions mediated by the specific target.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the pharmaceutical field and relates to macrocyclic compounds, their preparation methods, pharmaceutical compositions containing the compounds, and their pharmaceutical uses. Background Technology

[0002] Kirsten rat sarcoma 2 virus oncogene homolog (“KRas”) is a small GTPase and a member of the Ras oncogene family. KRas acts as a molecular switch that cycles between inactive (GDP-binding) and active (GTP-binding) states, transducing upstream cellular signals received from a variety of tyrosine kinases to downstream effectors to regulate a wide range of processes, including cell proliferation (see, for example, Alamgeer et al., (2013) Current Opin Pharmcol.13:394-401).

[0003] The role of activated KRas in malignant tumors was observed more than 30 years ago. Aberrant expression of KRas accounts for up to 20% of all cancers, and oncogenic KRas mutations have been reported in 25%-30% of lung adenocarcinomas. These mutations stabilize GTP binding and lead to constitutive activation of KRas and its downstream signaling pathways (see Samatar and Poulikakos (2014) NatRev Drug Disc 13(12): 928-942). Single nucleotide substitutions that cause missense mutations in codons 12 and 13 of the primary amino acid sequence of KRas account for approximately 40% of these KRas-driven mutations in lung adenocarcinomas. KRAS G12C mutations are present in 25.0% of patients with pancreatic ductal adenocarcinoma, 13.3% of patients with colorectal cancer, 10.1% of patients with rectal cancer, 4.1% of patients with non-small cell lung cancer, and 1.7% of patients with small cell lung cancer (see: AACRProject GENIE Consortium, (2017) CancerDiscovery; 7(8):818-831. Dataset version 4).

[0004] The role of KRas in malignant tumors is well-known, and these frequent mutations are found in KRas across multiple tumor types, making them highly attractive targets for cancer therapy in the pharmaceutical industry. Despite extensive exploration of the WO 2021 / 041671 patent over the past three decades to develop KRas inhibitors for cancer treatment, no KRas inhibitor has yet demonstrated sufficient safety and / or efficacy to warrant regulatory approval.

[0005] Compounds that inhibit KRas activity remain highly desirable and are under investigation, including those that disrupt effectors such as guanine nucleotide exchange factors (e.g., see Sun et al., (2012) Agnew Chem Int Ed Engl. 51(25):6140-6143) and recent advances in covalent targeting of the allosteric pocket of KRas G12C (e.g., see Ostrem et al., (2013) Nature 503:548-551 and Fellet et al., (2018) ACSMed.Chem.Lett. 9:1230-1234). Clearly, there remains ongoing interest and effort in developing inhibitors of KRas, particularly those targeting activated KRas mutants (especially KRas G12D). Therefore, it is necessary to develop novel KRas G12C inhibitors that demonstrate sufficient efficacy for treating KRas G12C-mediated cancers. Summary of the Invention

[0006] The invention disclosed herein provides a novel scaffold for selectively inhibiting KRAS G12C. This compound possesses the advantage of a unique chemical type, promising to achieve a KRAS G12C inhibitor with improved physicochemical properties.

[0007] This invention provides, in one aspect, compounds of formula (I) or pharmaceutically acceptable salts, solvates, or prodrugs thereof, including tautomers, cis or trans isomers, meso compounds, racemates, enantiomers, diastereomers, and mixtures thereof:

[0008] in, Ring A is aryl, heteroaryl, cycloalkyl, or heterocyclic, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally substituted by 1, 2, 3, or 4 substituents selected from the group consisting of halogen, amino, cyano, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl and hydroxyalkyl, aryl, heteroaryl, cycloalkyl or heterocyclic, and SF5. Ring B is aryl, heteroaryl, cycloalkyl, or heterocyclic; L1 is a key or -NR a (CR a R b ) n -; L2 is a bond, -C(O)- or –C(O)NR a -; L3 is a key or -(CR) a R b ) n -; Ra and R b Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, oxo, hydroxyl, alkyl, alkoxy, haloalkyl, and hydroxyalkyl; Or, R a and R b Together with the atoms attached to it, they form cycloalkyl or heterocyclic groups; Each R1 is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl, alkyl, alkoxyalkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, alkyl-SO2-, alkyl-N-, haloalkyl-O-, alkylamide, R a1 R b1 The group consisting of N-, SF5, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and alkylene-substituted or unsubstituted heteroaryl; R a1 and R b1 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl or cycloalkyl; Each R2 is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl, alkyl, alkenyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, amamide-alkyl, cycloalkyl-O-alkyl, R a2 R b2 NL a2 -, SF5, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; R a2 and R b2 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, SF5, cycloalkyl or substituted or unsubstituted heterocyclic groups; L a2 Selected from the group consisting of bonds, alkyl groups, or alkyl C(O); Alternatively, R1 and R2, together with the atoms they are attached to, form a cycloalkyl or heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halogens, amino, cyano, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, =O, =CR a3 R b3 The group consisting of alkyl halogens, hydroxyalkyl groups, SF5, cycloalkyl groups, and heterocyclic groups; R a3 and R b3 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, cycloalkyl and substituted or unsubstituted heterocyclic groups; R4 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl and SF5, and cycloalkyl, wherein the cycloalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents, wherein the substituents are selected from the group consisting of halogen, amino, cyano, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl and SF5; R5 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, SF5, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by 1, 2, 3, 4, or 5 R5 groups. a4 Instead, the R a4 Selected from the group consisting of halogen, amino, cyano, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, SF5, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein R a4 The cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogens, amino, cyano, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, and SF5. Alternatively, R4 and R5 together with the atoms they are attached to form heterocyclic groups; m can be 0, 1, 2, 3, or 4; n is 0, 1, 2, or 3; x is 1, 2, 3, or 4; and y is 1, 2 or 3.

[0009] In one implementation, ring A is C6-C. 10 The aryl group, a 5-10 membered heteroaryl group, a C3-C8 cycloalkyl group, or a 5-8 membered heterocyclic group containing one or two heteroatoms selected from N or O; optionally, ring A is substituted by one, two, three, or four substituents selected from the group consisting of halogens, amino groups, cyano groups, hydroxyl groups, C1-C6 alkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, C1-C6 haloalkyl groups, C1-C6 hydroxyalkyl groups, and SF5.

[0010] In one embodiment, ring A is a phenyl, a C3-C8 cycloalkyl, or a 5-8 membered heterocyclic group containing one or two heteroatoms selected from N or O; optionally, ring A is substituted with one, two, three, or four substituents selected from the group consisting of halogens, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, and SF5.

[0011] In one implementation, ring A is , , , , , , , , , , , or .

[0012] In one implementation, ring B is C6-C. 10 Aryl, 5-10 membered heteroaryl, C5-C8 cycloalkyl or 5-10 membered heterocyclic.

[0013] In one embodiment, ring B is a phenyl group, a 5-10 fused heterocyclic group containing one or two heteroatoms selected from N, O, or S, or a 5-10 fused heteroaryl group containing one or two heteroatoms selected from N, O, or S.

[0014] In one embodiment, ring B is a phenyl, a C5-C7 cycloalkyl, a 5-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S, or a 5-10 membered heteroaryl group containing one or two heteroatoms selected from N, O or S.

[0015] In one implementation, ring B is... , , , , , , , , or .

[0016] In one embodiment, L1 is a bond, NH, -NHCH2-, -N(CH2)3OH, -N(CH2)3CONH2-, .

[0017] In one implementation, L2 is a bond, -C(O)- or -C(O)NH-.

[0018] In one implementation, L3 is a bond, -CH2-, or .

[0019] In one embodiment, each R1 is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkyl-SO2-, C1-C6 alkyl-N-, C1-C6 haloalkyl-O-, C1-C6 alkylamide, R a1 R b1 N-, SF5, C3-C 12 Cycloalkyl, 3-12 membered heterocyclic, C6-C 14 The group consisting of aryl and 6-14 heteroaryl groups, wherein the C3-C 12 Cycloalkyl, 3-12 membered heterocyclic, C6-C 14 The aryl and 6-14 heteroaryl groups are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, SF5, and C3-C8 cycloalkyl, wherein R a1 and R b1 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl or C3-C6 cycloalkyl and SF5.

[0020] In one embodiment, each R1 is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkylthio, C1-C3 alkylSO2-, C1-C6 haloalkyl-O-, R a1 R b1 The group consisting of N-, C2-C4 alkoxyalkyl and SF5, wherein R a1 and R b1 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl or C3-C6 cycloalkyl, wherein preferably, the C3-C6 cycloalkyl is cyclopropyl; Alternatively, R1 and R2, together with the atoms they are attached to, form a cycloalkyl or heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halogens, amino groups, cyano groups, hydroxyl groups, C1-C6 alkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, =O, =CR a3 R b3 The group consisting of C1-C6 haloalkyl and C1-C6 hydroxyalkyl; R a3 and R b3Each is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C3-C 12 The group consisting of cycloalkyl groups and substituted or unsubstituted 3-12 membered heterocyclic groups.

[0021] In one embodiment, each R2 is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, amide-C1-C6 alkyl, SF5, C3-C6 cycloalkyl-O-C1-C6 alkyl, R a2 R b2 NL a2 -、C3-C 12 Cycloalkyl, 3-12 membered heterocyclic, C6-C 14 The group consisting of aryl and 6-14 heteroaryl groups, wherein the C3-C 12 Cycloalkyl, 3-12 membered heterocyclic, C6-C 14 The aryl and 6-14-membered heteroaryl groups are optionally substituted by 1, 2, 3, 4, or 5 substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, SF5, C3-C8 cycloalkyl, 3-8-membered heterocyclic groups, C6-C 10 The group consists of aryl and 6-10 heteroaryl groups, wherein R a2 and R b2 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C3-C6 cycloalkyl and substituted or unsubstituted 3-6 membered heterocyclic groups containing one or two heteroatoms selected from N, O or S.

[0022] In one embodiment, each R2 is independently a halogen, SF5, C1-C3 alkyl, or a 9-10 membered heteroaryl containing 1, 2, or 3 N heteroatoms. Optionally, the 9-10 membered heteroaryl containing 1, 2, or 3 N heteroatoms is substituted with 1, 2, 3, 4, or 5 substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, amide-C1-C3 alkyl, C3-C6 cycloalkyl-O-C1-C3 alkyl, R a2 R b2 NL a2 - and SF5 form a group, where R a2 and R b2Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C3-C3 cycloalkyl and substituted or unsubstituted 3-6 membered heterocyclic groups containing one or two heteroatoms selected from N, O or S.

[0023] In one implementation, R4 is hydrogen.

[0024] In one embodiment, R5 is a C3-C8 cycloalkyl group or a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O, or S, or a 5-8 membered heteroaryl group containing one or two heteroatoms selected from N or O; optionally, R5 is substituted with one, two, three, four, or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, and -CONH. Preferably, R5 is , , It is substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and -CONH.

[0025] In one embodiment, R4 and R5, together with the atoms they are attached to, form a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O, or S.

[0026] In one embodiment, the compound of formula (I) may be a compound of formula (II), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0027] in, Ring A is a C3-C8 cycloalkyl group, or a 5-8 membered heterocyclic group containing one or two heteroatoms selected from N or O, or a C6-C... 10 The aryl group or a 5-8 membered heteroaryl group containing one or two heteroatoms selected from N or O, optionally substituted with one, two, three or four substituents selected from halogens, amino groups, cyano groups, hydroxyl groups, C1-C6 alkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, C1-C6 haloalkyl groups, C1-C6 hydroxyalkyl groups, C2-C6 cyanoalkyl groups, and SF5; L1 is a bond, NH or -NHCH2-; Each of R1, R2 and R3 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl and C1-C6 hydroxyalkyl and SF5; R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and SF5; R5 is a C3-C8 cycloalkyl group or a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; optionally, R5 is substituted with one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; m can be 0, 1, 2, 3, or 4; x is 1, 2, 3, or 4; and y is 1, 2 or 3.

[0028] In one embodiment, the compound of formula (I) may be a compound of formula (II), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0029] in, Ring A is a C3-C8 cycloalkyl group or a 5-8 membered heterocyclic group containing one or two heteroatoms selected from N or O; L1 is a bond, NH or -NHCH2-; Each of R1, R2 and R3 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl and SF5; R5 is a C3-C8 cycloalkyl group or a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S, or a 5-8 membered heteroaryl group containing one or two heteroatoms selected from N or O; optionally, R5 is substituted with one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; Alternatively, R4 and R5 together with the atoms they are attached to form a 5-7 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; m can be 0, 1, 2, 3, or 4; x is 1, 2, 3, or 4; and y is 1, 2 or 3.

[0030] In one embodiment, the compound of formula (I) may be a compound of formula (III), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0031] in, Ring B is phenyl, C5-C7 cycloalkyl, 5-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S, or 5-10 membered heteroaryl group containing one or two heteroatoms selected from N, O or S; L3 is a bond, -CH2- or ; Each R1 and R2 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxyalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl and C1-C6 hydroxyalkyl, and SF5; Alternatively, R1 and R2 together with the atoms they are attached to form C7-C. 10 Cycloalkyl or 7-10 membered heterocyclic groups containing 1, 2 or 3 N, O or S heteroatoms, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of halogens, amino, cyano, hydroxyl, deuterated alkyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, SF5, cycloalkyl and heterocyclic groups; R5 is a C3-C8 cycloalkyl group or a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; optionally, R5 is substituted with one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; m is 0 or 1.

[0032] In one embodiment, the compound of formula (I) may be a compound of formula (IV), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0033] in, Ring B is phenyl, C5-C7 cycloalkyl, 5-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S, or 5-10 membered heteroaryl group containing one or two heteroatoms selected from N, O or S; The ring C is a 5-6 membered heterocyclic group containing one or two heteroatoms selected from N, O or S. Optionally, the ring C is substituted by one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5. L3 is a bond, -CH2- or ; Each R1 and R2 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; Alternatively, R1 and R2 together with the atoms they are attached to form C7-C. 10 Cycloalkyl groups or 7-10 membered heterocyclic groups containing 1, 2 or 3 N, O or S heteroatoms; m is 0 or 1.

[0034] In one embodiment, the compound of formula (I) may be a compound of formula (III-A), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0035] in, Ring B is phenyl, C5-C7 cycloalkyl, 5-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S, or 5-10 membered heteroaryl group containing one or two heteroatoms selected from N, O or S; The ring C is a 5-6 membered heterocyclic group containing one or two heteroatoms selected from N, O or S. Optionally, the ring C is substituted by one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5. L3 is a bond, -CH2- or ; Each R1 and R2 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; Alternatively, R1 and R2 together with the atoms they are attached to form C7-C. 10 Cycloalkyl groups or 7-10 membered heterocyclic groups containing 1, 2 or 3 N heteroatoms; R5 is a C3-C8 cycloalkyl group or a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; optionally, R5 is substituted with one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; R6 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; m is 0 or 1.

[0036] In one embodiment, the compound of formula (I) may be a compound of formula (V), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0037] in, Ring A is a C3-C8 cycloalkyl group, a 5-8 membered heterocyclic group containing one or two heteroatoms selected from N or O, or a C6-C...10 The aryl group or a 5-8 membered heteroaryl group containing one or two heteroatoms selected from N or O, optionally substituted by one, two, three or four substituents selected from halogens, amino groups, cyano groups, hydroxyl groups, C1-C6 alkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, C1-C6 haloalkyl groups, C1-C6 hydroxyalkyl groups, C2-C6 cyanoalkyl groups, and SF5; L1 is a bond, NH or -NHCH2-; Each of R1, R2 and R3 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl and SF5; R5 is a C3-C8 cycloalkyl group or a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S, or a 5-8 membered heteroaryl group containing one or two heteroatoms selected from N or O; optionally, R5 is substituted with one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; Alternatively, R4 and R5 together with the atoms they are attached to form a 5-7 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; R6 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; m can be 0, 1, 2, 3, or 4; x is 1, 2, 3, or 4; and y is 1, 2 or 3.

[0038] In one embodiment, the compound of formula (I) may be a compound of formula (VI), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0039] in, Ring A is a C3-C8 cycloalkyl group, a 5-8 membered heterocyclic group containing one or two heteroatoms selected from N or O, or a C6-C... 10 The aryl group or a 5-8 membered heteroaryl group containing one or two heteroatoms selected from N or O, optionally substituted by one, two, three or four substituents selected from halogens, amino groups, cyano groups, hydroxyl groups, C1-C6 alkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, C1-C6 haloalkyl groups, C1-C6 hydroxyalkyl groups, C2-C6 cyanoalkyl groups, and SF5. L1 is a bond, NH or -NHCH2-; Each of R2, R3, R7 and R8 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and SF5; R5 is a C3-C8 cycloalkyl group or a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S, or a 5-8 membered heteroaryl group containing one or two heteroatoms selected from N or O; optionally, R5 is substituted with one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; Alternatively, R4 and R5 together with the atoms they are attached to form a 5-7 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; R6 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; m can be 0, 1, 2, 3, or 4; x is 1, 2, 3 or 4; y is 1, 2, or 3, and z can be 1, 2, or 3.

[0040] In one embodiment, the compound of formula (I) may be a compound of formula (VII), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0041] in, Ring B is phenyl, C5-C7 cycloalkyl, 5-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S, or 5-10 membered heteroaryl group containing one or two heteroatoms selected from N, O or S; L1 is -NR a (CR a R b ) n -; L3 is a key or -(CR) a R b ) n -; R a and R b Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, oxo, hydroxyl, alkyl, alkoxy, haloalkyl, and hydroxyalkyl; Or, R a and R b Together with the atoms attached thereto, a 5-10 membered heteroaryl group is formed containing one or two heteroatoms selected from N, O or S, which is optionally substituted by one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; L3 is a bond, -CH2- or ; Each R1 and R2 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; Alternatively, R1 and R2 together with the atoms they are attached to form C7-C. 10 Cycloalkyl groups or 7-10 membered heterocyclic groups containing 1, 2 or 3 N, O or S heteroatoms; R5 is a C3-C8 cycloalkyl group or a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; optionally, R5 is substituted with one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; R6 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; x is 1, 2, 3 or 4; y is 1, 2, or 3, and n is 0 or 1.

[0042] In one embodiment, the compound of formula (I) may be a compound of formula (VIII), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0043] in, Ring B is phenyl, C5-C7 cycloalkyl, 5-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S, or 5-10 membered heteroaryl group containing one or two heteroatoms selected from N, O or S; L1 is -NR a (CR a R b ) n -; L3 is a key or -(CR) a R b ) n -; R a and R b Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, oxo, hydroxyl, alkyl, alkoxy, haloalkyl, and hydroxyalkyl; Or, R a and R b Together with the atoms attached thereto, a 5-10 membered heteroaryl group is formed containing one or two heteroatoms selected from N, O or S, which is optionally substituted by one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; L3 is a bond, -CH2- or ; K is selected from C(O) or S(O)2; Each R1 and R2 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; Alternatively, R1 and R2 together with the atoms they are attached to form C7-C. 10 Cycloalkyl groups or 7-10 membered heterocyclic groups containing 1, 2 or 3 N, O or S heteroatoms; R5 is a C3-C8 cycloalkyl group or a 4-10 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; optionally, R5 is substituted with one, two, three, four or five substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; R6 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; x is 1, 2, 3 or 4; y is 1, 2, or 3, and n is 0 or 1.

[0044] In one embodiment, compound (I) may be a compound of formula (IX) and (X), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0045] in, A1, A2, and A4 are each independently selected from the group consisting of C, CH, N, NH, S, and O; A3 is selected from the group consisting of C, CH, N, NH, S, O and bonds; B1 is selected from the group consisting of CH and N; B2 is selected from the group consisting of CH, N, and bonds; B3 is selected from the group consisting of CH, N, S, and O; E1 and E2 are each independently selected from CH, CH2, N, NH, S, O, and C. 1-3 Alkoxy, - N(CH3)C 1-3 Alkylene#, - NH-C 1-3 The group consisting of alkylene groups, in which It can be oriented towards D1 or towards B1, and correspondingly, # can be oriented towards B1 or D1; D1 is selected from C and CR. d1 A group consisting of N, S and O; D2 is selected from the group consisting of CH, CH2, N and non-existent. When D2 does not exist, the bond connected to D2 also does not exist. D3 is selected from the group consisting of CH, CH2, N, and NH; R d1 Selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, and amino groups. X1 is selected from the group consisting of C, CH, CH2, N, and NH; X2 is selected from the group consisting of CH, CH2, CH3, N, NH, NH2, bonds, and non-existent bonds; X3 is selected from the group consisting of CH, CH2, N, NH, bonds, and non-existent bonds; X4 is selected from the group consisting of CH, CH2, CH3, N, NH, NH2, bonds, and non-existent bonds; When X1, X2, or X3 does not exist, the key to which it is connected also does not exist; Indicates the double or single bond required to satisfy the valence requirement; R1 is selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, alkenyl, alkoxy, alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio and SF5; (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, wherein the cycloalkyl and heterocyclic are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl and alkyl; R2 is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, deuterated alkyl, alkyl, deuterated alkyl, alkenyl, alkynyl, deuterated alkenyl, deuterated alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, deuterated alkoxy, deuterated alkylthio, deuterated haloalkyl, deuterated hydroxyalkyl, -NR 2a R 2b The group consisting of SF5, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the cycloalkyl, heterocyclic, aryl and heteroaryl are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen and SF5; Or, two R2 atoms together with their two adjacent atoms form a cycloalkyl, heterocyclic, aryl, or heteroaryl group; R 2a and R 2bEach is independently selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, amino, cycloalkyl, heterocyclic, aryl, heteroaryl, and SF5; Ring A is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, and is optionally substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, SF5, cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; L2 is selected from the key, C(O), CR 3a R 3b , C=R 3d , C=NR 3e , O、 S and NR 3f The group formed; R 3a and R 3b Each is independently selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C4 alkenyl, C2-C4 alkynyl, cyano, amino, C3-C6 cycloalkyl, 5-8 membered heterocyclic groups containing one or more heteroatoms selected from N, O and S, aryl and heteroaryl groups; Or R 3a and R 3b Together with the atoms attached thereto, they form a cycloalkyl or heterocyclic group, which is optionally substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano, amino and SF5; R 3d Selected from the group consisting of C1-C3 alkyl groups; R 3e Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano, and amino; R 3f Selected from the group consisting of C1-C3 alkyl groups; L4 is selected from C(O) and Groups composed of CH2; J is selected from CH2、 CH and C(O); L5 is selected from CH2 and A group composed of C(O); Indicates the connection point with the parent structure; R4 is hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, or SF5; R5 is selected from the group consisting of: (i) hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, and SF5; (ii) cycloalkyl, heterocyclic, aryl, heteroaryl, O-cycloalkyl, and S-cycloalkyl, wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, alkyl, halogen, hydroxyl, and alkenyl. The group consisting of alkynyl, cyanoyl, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, oxo, SF5, cycloalkyl, heterocyclic, aryl, heteroaryl and alkylheteroaryl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated, wherein the cycloalkyl, heterocyclic, aryl and heteroaryl groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, oxo and SF5; Alternatively, R4 and R5, together with the atoms they are attached to, form a heterocyclic group, wherein the heterocyclic group is optionally surrounded by 1, 2, 3, 4, or 5 R atoms. 28 replace; R 28 The group consisting of alkyl, hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, SF5, cycloalkyl, heterocyclic, cycloalkyloxy, aryl, heteroaryl, methylene (=CH2), and oxo (=O), wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, cycloalkyl, heterocyclic, cycloalkyloxy, aryl, heteroaryl, and methylene (=CH2) are optionally surrounded by 1, 2, 3, 4, or 5 R's. 29 replace; Each R 29Independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, cyano, oxo (=O), SF5, cycloalkyl, cycloalkoxy, heterocyclic, aryl, heteroaryl, and hydroxyalkyl; preferably, selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkoxythio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4; m can be 0, 1, 2, 3, or 4; t is 0, 1, or 2.

[0046] In one embodiment, compound (I) may be a compound of formula (IX), (X), and (Xa), or a tautomer, cis or trans isomer, intermediate, racemic, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0047] in, A1, A2 and A4 are each independently selected from the group consisting of C, CH, N, NH, S and O, preferably A1 and A4 are independently selected from N and NH, and A2 is CH; A3 is selected from the group consisting of C, CH, N, NH, S, O and bonds, preferably bonds; B1 is selected from the group consisting of C, CH, and N; B2 is selected from the group consisting of C, CH, N and bonds; B3 is selected from the group consisting of CH and N; E1 and E2 are each independently selected from CH, CH2, N, NH, S, O, and C. 1-3 Alkyl group, -N(CH3)C 1-3 Alkylene, -NH-C 1-3 alkylene- and -C 1-3 The group consisting of alkylene-NH-; D1 is selected from C and CR. d1 A group consisting of N, S and O; D2 is selected from CR d1 C(R) d1 )2, N, NRd1 A group consisting of D2 and non-existent elements will also not exist if D2 does not exist. D3 is selected from C and CR. d1 A group consisting of N; X1 is selected from C, CR d1 A group consisting of N; X2 is selected from CR d1 C(R) d1 )2, N, NR d1 A group consisting of a key and a non-existent element; X3 is selected from CR d1 C(R) d1 )2, N, NR d1 A group consisting of a key and a non-existent element; X4 is selected from CR d1 C(R) d1 )2, N, NR d1 A group consisting of a key and a non-existent element; Each R d1 Independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic and alkylheteroaryl; When X1, X2, or X3 does not exist, the key to which it is connected also does not exist; each A double or single bond is required independently to satisfy the valence requirement, provided that the two adjacent bonds are not both double bonds at the same time; Each R1 is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl, alkyl, alkenyl, alkoxy, alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio and SF5; (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl are optionally substituted by 1, 2, 3, 4 or 5 substituents, wherein the substitutions are... The radical is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic and alkylheteroaryl; Each R2 is independently selected from hydrogen, deuterium, halogen, amino, cyano, NO2, oxo (═O), thio (═S), hydroxyl, cyanoalkyl, deuterated alkyl, alkyl, alkenyl, alkynyl, deuterated alkenyl, deuterated alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, deuterated alkoxy, deuterated alkylthio, deuterated haloalkyl, deuterated hydroxyalkyl, methylene (=CH2), -NR 2a R 2b SF5, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the hydroxyl, cyanoalkyl, deuterated alkyl, alkyl, alkenyl, alkynyl, deuterated alkenyl, deuterated alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, deuterated alkoxy, deuterated alkylthio, deuterated haloalkyl, deuterated hydroxyalkyl, methylene (=CH2), -NR 2a R 2bThe cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by 1, 2, 3, 4, or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkylheteroaryl, and SF5. Alternatively, two R2 atoms together with their two adjacent atoms form a cycloalkyl, heterocyclic, aryl, or heteroaryl group, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally surrounded by 1, 2, 3, or 4 R2 atoms. 2c replace; R 2a R 2b and R 2c Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkylheteroaryl and SF5; Cycloalkyl A is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, and is optionally substituted by 1, 2, 3, or 4 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkylheteroaryl, and SF5, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; L2 is selected from the key, C(O), CR3a R 3b , C=R 3d , C=NR 3e , O、 S and NR 3f The group formed; R 3a R 3b R 3e and R 3f Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkylheteroaryl and SF5; Or R 3a and R 3b Together with the atoms attached thereto, they form cycloalkyl or heterocyclic groups, optionally substituted by 1, 2, 3, 4, or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkylheteroaryl, and SF5; R 3d Selected from the group consisting of C1-C3 alkylene groups; L4 is selected from C(O) and Groups composed of CH2; J is selected from CH2、 CH and C(O); L5 is selected from CH2 and A group composed of C(O); Indicates the connection point with the parent structure; R4 is hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, or amino. R5 is selected from the group consisting of: (i) hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, and SF5; (ii) cycloalkyl, heterocyclic, aryl, heteroaryl, O-cycloalkyl, and S-cycloalkyl, wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally represented by 1, 2, 3, 4, or 5 R5 groups. 5b Instead, the R 5b Selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, -C 0-6 Alkylene -S(O)2H, -C 0-6 Alkylene-S(O)2-alkyl, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, SF5, and alkylheteroaryl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated, wherein R 5b The cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by 1, 2, 3, 4, or 5 substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, SF5, and alkylheteroaryl; Alternatively, R4 and R5, together with the atoms they are attached to, form a cycloalkyl or heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally surrounded by 1, 2, 3, 4, or 5 R atoms. 28 replace; R 28 Selected from: non-existent, hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, -NH-C(O)-C 0-6Alkyl, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, SF5, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, methylene (=CH2), oxo (=O), -C 0-6 Alkylene -S(O)2H and -C 0-6 The group consisting of alkylene-S(O)2-alkyl, wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, methylene (=CH2), -C 0-6 Alkylene -S(O)2H, -C 0-6 Alkylene-S(O)2-alkyl is optionally surrounded by 1, 2, 3, 4 or 5 R's. 29 replace; Each R 29 Independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, cyano, oxo (=O), -NH-C(O)-C 0-6 Alkyl, C 0-6 Alkyl-C(O)-, -C 0-6 Alkylene -S(O)2H, -C 0-6 Alkylene-S(O)2-alkyl, SF5, cycloalkyl, cycloalkoxy, heterocyclic, aryl, heteroaryl, and hydroxyalkyl; preferably, selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4; m can be 0, 1, 2, 3, or 4; t can be 0, 1, or 2.

[0048] In a preferred embodiment, ring A is C6-C. 10The aryl group, a 5-10 membered heteroaryl group, a C3-C8 cycloalkyl group, or a 5-8 membered heterocyclic group containing one or two heteroatoms selected from N or O; optionally, ring A is substituted by one or more substituents selected from the group consisting of halogens, amino groups, cyano groups, hydroxyl groups, C1-C6 alkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, C1-C6 haloalkyl groups, and C1-C6 hydroxyalkyl groups. Preferably, ring A is a phenyl, a C3-C8 cycloalkyl, or a 5-8 membered heterocyclic group containing one or two heteroatoms selected from N or O; optionally, ring A is substituted by one or more substituents selected from the group consisting of halogens, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, and C1-C3 hydroxyalkyl. More preferably, ring A is Preferred More preferably , Indicates the site connected to N; More preferably, ring A is , , , , , , , , , , , or .

[0049] In a preferred embodiment, It is selected from phenyl or 5- or 6-membered heteroaryl groups containing no more than 2 heteroatoms selected from N, O or S.

[0050] In a preferred embodiment, It is selected from phenyl or 5- or 6-membered heteroaryl groups containing no more than 2 heteroatoms selected from N, O or S.

[0051] In a preferred embodiment, each R1 is independently selected from (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkoxy, and C1-C6 haloalkylthio; (ii) -O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl, C3-C8 cycloalkyl, and 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O, and S, wherein the cycloalkyl and heterocyclic groups are optionally substituted by one, two, three, four, or five substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, and C1-C6 alkyl.

[0052] In a preferred embodiment, Each R1 is independently selected from (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C2-C4 alkoxyalkyl, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1-C3 haloalkoxy, and C1-C3 haloalkylthio; (ii) -O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, C3-C6 cycloalkyl, and 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O, and S, wherein the cycloalkyl and heterocyclic groups are optionally substituted by one, two, three, four, or five substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 cyanoalkyl, and C1-C3 alkyl; x is 0, 1, 2 or 3.

[0053] In a preferred embodiment, Selected from , , and The group formed Selected from The group consisting of, preferably , R 13 Preferably cyclopropyl or CF3 or SF5, R 12 Preferably CH3OCH2- or CH3, R 14 CH is preferred; in, R 11 R 12 and R 14Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 cyanoalkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; R 13 Selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkylthio, C1-C6 haloalkoxy and SF5, (ii) -O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl, 3-6 membered cycloalkyl and 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O and S, optionally substituted with one, two, three, four or five substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl and C1-C6 alkyl.

[0054] In a preferred embodiment, R 11 R 12 and R 14 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 cyanoalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C2-C4 alkoxyalkyl, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl; R 13 The group consisting of (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1-C3 haloalkylthio and C1-C3 haloalkoxy, (ii) -O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, 3-6 membered cycloalkyl and 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O and S, optionally substituted with one, two, three, four or five substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl.

[0055] In a preferred embodiment, Selected from , , , , , , , , , , and The group formed; Selected from and A group that is formed.

[0056] In a preferred embodiment, Selected from , , , , , , , , , , , , The group consists of, R 21 R 22 and R 23 Each is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkynyl, deuterated C2-C6 alkenyl, deuterated C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, deuterated C1-C6 alkoxy, deuterated C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, deuterated C1-C6 hydroxyalkyl, -NR 2a R 2b And SF5, (ii) 3-8 membered cycloalkyl, 5-8 membered heterocyclic group containing 1 or 2 heteroatoms selected from N, O and S, C6-C 10 Aryl groups and C5-C groups containing one or two heteroatoms selected from N, O, and S. 10 Heteroaryl groups, optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogen, amino, cyano, hydroxyl, C1-C6 haloalkyl and C1-C6 hydroxyalkyl; Or, R 22 and R 23 Together with the atoms attached thereto, they form 3-8 membered cycloalkyl groups, 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O, and S, C6-C 10 Aryl or 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O and S; R 2a and R 2bEach is independently selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 alkoxy, halogen, cyano, amino, 3-6 membered cycloalkyl, 5-8 membered heterocyclic, C6-C 10 The group consists of aryl and 5-8 membered heteroaryl groups.

[0057] In a preferred embodiment, Selected from , , , , , , , , , , , , and The group consists of, R 21 R 22 and R 23 Each is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 cyanoalkyl, C1-C3 alkyl, deuterated C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, -NR 2a R 2b And SF5, (ii) C3-C6 cycloalkyl, 3-6-membered heterocyclic group containing 1 or 2 heteroatoms selected from N, O and S, C6-C8 aryl and 5-8-membered heteroaryl group containing 1 or 2 heteroatoms selected from N, O and S, optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and SF5; Or, R 22 and R 23 Together with the atoms attached thereto, it forms a C3-C6 cycloalkyl group, a 3-6 membered heterocyclic group containing one or two heteroatoms selected from N, O, and S, a C6-C8 aryl group, or a 5-8 membered heteroaryl group containing one or two heteroatoms selected from N, O, and S; it is optionally substituted by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, and SF5; R 2a and R 2bEach of the following is independently selected from the group consisting of: (i) hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, amino and SF5; (ii) C3-C8 cycloalkyl, C3-C6 heterocyclic, C6-C8 aryl and C5-C8 heteroaryl containing one or two heteroatoms selected from N, O and S, optionally substituted by one, two, three, four or five substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and SF5; Preferably, for R 21 CD3 is preferred.

[0058] In a preferred embodiment, R 21 R 22 and R 23 Each is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 cyanoalkyl, C1-C3 alkyl, C1-C3 deuterated alkyl and -NR. 2a R 2b (ii) , , , , , , , and Optionally substituted with 1, 2, 3, 4, or 5 substituents, said substituents being selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxy, C1-C3 haloalkyl, and C1-C3 hydroxyalkyl; or, R 22 and R 23 It forms together with the atoms it is connected to. , or It is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxy, C1-C3 haloalkyl and C1-C3 hydroxyalkyl. R 2a and R 2b Each is independently selected from the group consisting of: (i) hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, and amino; (ii) , , , , , , and It is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

[0059] In a preferred embodiment, Selected from , , , , , and The group consists of, D1 is selected from C and CR. d1 A group consisting of N, S and O; D2 is selected from the group consisting of CH, CH2, and N; D3 is selected from the group consisting of CH, CH2, N, and NH; R d1 Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, and amino; X1 is selected from the group consisting of CH, CH2, N, and NH; X2 is selected from the group consisting of CH, CH2, CH3, N, NH and NH2; X3 is selected from the group consisting of CH, CH2, N, and NH; X4 is selected from the group consisting of CH, CH2, N, NH and NH2.

[0060] In a preferred embodiment, Selected from , , , , , , and A group that is formed.

[0061] In a preferred embodiment, ring A is selected from the group consisting of phenyl, C3-C8 cycloalkyl, 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N or O, and 5-8 membered heteroaryl groups, optionally substituted by one, two, three, or four substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 alkylamino, C1-C3 alkylcyano, and C1-C3 hydroxyalkyl and SF5, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated.

[0062] In a preferred embodiment, ring A is selected from... , , , , , , , , , and The group consisting of, optionally, substituted with 1, 2, 3 or 4 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 alkylamino, C1-C3 alkylcyano, C1-C3 hydroxyalkyl and SF5.

[0063] In a preferred embodiment, ring A is selected from... , , , , , , , , , , , , , , , , , , , , , , , , , and A group that is formed.

[0064] In a preferred embodiment, L2 is selected from key, C=O、 CF2 C-OH, C(F)CH3、 C(OH)CH3、 C=CH2、 C=NH、 C=N-OH CO-CH3, O、 S, , , and Groups composed of NCH3; L4 is selected from C(O) and Groups composed of CH2; J is selected from CH2、 CH and C(O); L5 is selected from CH2 and A group composed of C(O).

[0065] In a preferred embodiment, R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

[0066] R5 is selected from the group consisting of branched or straight-chain C1-C3 alkyl, C3-C8 cycloalkyl, 4-10 membered heterocyclic groups containing 1 or 2 heteroatoms selected from N, O or S, and 5-8 membered heteroaryl groups containing 1 or 2 heteroatoms selected from N or O, optionally substituted by 1, 2, 3, 4 or 5 substituents selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1-C3 cyanoalkyl and C1-C3 aminoalkyl, wherein the cycloalkyl or heterocyclic group is saturated or partially unsaturated; Alternatively, R4 and R5 together with the atoms they are attached to form a 5-7 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; m can be 0, 1, or 2.

[0067] In a preferred embodiment, R5 is selected from... , , , , , , , , , , , , and A group that is formed.

[0068] Each R 28 R 281 R 282Independently selected from the group consisting of non-existent, hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, and methylene (=CH2), wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, and methylene (=CH2) are optionally surrounded by 1, 2, 3, 4, or 5 R's. 29 replace; Each R 29 Independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, cyano, oxo (=O), cycloalkyl, cycloalkoxy, heterocyclic, aryl, heteroaryl, and hydroxyalkyl; preferably, selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkoxythio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; Or R4 and R 5a Together with the atoms attached thereto, they form 3-12 membered heterocyclic groups, wherein the heterocyclic groups are selected from... , , The group consisting of, preferably , , n5 can be 0, 1, 2, 3 or 4.

[0069] In a preferred embodiment, R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

[0070] R5 is selected from -C(CH3)2. , , , , , , , , , , and The group consisting of, wherein these groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl and oxo. Alternatively, R4 and R5 together with the atoms they are attached to form , , or .

[0071] In another aspect, the present invention provides any compound of formula (IX)-(X), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0072] in, A1, A2 and A4 are each independently selected from the group consisting of C, CH, N, NH, S and O, preferably A1 and A4 are independently selected from N and NH, and A2 is CH; A3 is selected from the group consisting of C, CH, N, NH, S, O and bonds, preferably bonds; B1 is selected from the group consisting of C, CH, and N; B2 is selected from the group consisting of C, CH, N and bonds; B3 is selected from the group consisting of CH, N, S, and O; E1 and E2 are each independently selected from CH, CH2, N, NH, S, O, and C. 1-3 Alkyl groups and -N(CH3)C 1-3 The group consisting of alkylene groups; D1 is selected from C and CR. d1 A group consisting of N, S and O; D2 is selected from the group consisting of CH, CH2, N and non-existent. When D2 does not exist, the bond connected to D2 also does not exist. D3 is selected from the group consisting of C, CH, CH2, N, and NH; R d1 Selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, and amino groups. X1 is selected from the group consisting of C, CH, CH2, N, and NH; X2 is selected from the group consisting of CH, CH2, CH3, N, NH, NH2, bonds, and non-existent bonds; X3 is selected from the group consisting of CH, CH2, N, NH, bonds, and non-existent bonds; X4 is selected from the group consisting of CH, CH2, CH3, N, NH, NH2, bonds, and non-existent bonds; When X1, X2, or X3 does not exist, the key to which it is connected also does not exist; Indicates the double or single bond required to satisfy the valence requirement; Each R1 is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, alkenyl, alkoxy, alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio and SF5, (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, wherein the cycloalkyl and heterocyclic are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl and alkyl; Each R2 is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, deuterated alkyl, alkenyl, alkynyl, deuterated alkenyl, deuterated alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, deuterated alkoxy, deuterated alkylthio, deuterated haloalkyl, deuterated hydroxyalkyl, methylene (=CH2), -NR 2a R 2b The group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein the methylene (=CH2), cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkoxy, and halogen groups. Or, two R2 atoms together with their two adjacent atoms form a cycloalkyl, heterocyclic, aryl, or heteroaryl group; R 2a and R 2b Each is independently selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, amino, cycloalkyl, heterocyclic, aryl, and heteroaryl. Ring A is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl, and is optionally substituted by 1, 2, 3, or 4 substituents selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, and aminoalkyl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated. L2 is selected from the key, C(O), CR 3a R 3b , C=R 3d , C=NR 3e , O、 S and NR 3f The group formed; R 3a and R 3b Each is independently selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C4 alkenyl, C2-C4 alkynyl, cyano, amino, C3-C6 cycloalkyl, 5-8 membered heterocyclic groups containing 1, 2, 3, 4 or 5 heteroatoms selected from N, O and S, aryl and heteroaryl groups; Or R 3a and R 3b Together with the atoms attached thereto, they form a cycloalkyl or heterocyclic group, which is optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano and amino. R 3d Selected from the group consisting of C1-C3 alkyl groups; R 3e Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano, and amino; R 3f Selected from the group consisting of C1-C3 alkyl groups; L4 is selected from C(O) and Groups composed of CH2; J is selected from CH2、 CH and C(O); L5 is selected from CH2 and A group composed of C(O); Indicates the connection point with the parent structure; R4 is hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, or amino. R5 is selected from the group consisting of: (i) hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, and cyanoalkyl; (ii) cycloalkyl, heterocyclic, aryl, heteroaryl, O-cycloalkyl, and S-cycloalkyl, wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, heterocyclic, aryl, and heteroaryl are optionally substituted by 1, 2, 3, 4, or 5 substituents selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, heteroaryl, and alkylheteroaryl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4; m can be 0, 1, 2, 3, or 4; t can be 0, 1, or 2.

[0073] In one implementation scheme It is selected from phenyl, or contains no more than two heteroatoms selected from N, O or S, of the form of a 5-6 membered heteroaryl group.

[0074] In one implementation scheme It is selected from phenyl, or a 5-6 membered heteroaryl group containing no more than 2 heteroatoms selected from N, O or S.

[0075] In one embodiment, R1 is independently selected from (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkoxy, and C1-C6 haloalkylthio; (ii) -O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl, C3-C8 cycloalkyl, and 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O, and S, wherein the cycloalkyl and heterocyclic groups are optionally substituted by one, two, three, four, or five substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, and C1-C6 alkyl.

[0076] In one embodiment, R1 is independently selected from (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C2-C4 alkoxyalkyl, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1-C3 haloalkoxy, and C1-C3 haloalkylthio; (ii) -O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, C3-C6 cycloalkyl, and 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O, and S, wherein the cycloalkyl and heterocyclic groups are optionally substituted by one, two, three, four, or five substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 cyanoalkyl, and C1-C3 alkyl; x is 0, 1, 2, or 3.

[0077] In one implementation scheme Selected from , , and A group that is formed.

[0078] In one implementation scheme Selected from The group consists of, R 11 R 12 and R 14 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 cyanoalkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, and C1-C6 hydroxyalkyl; R 13 The group consisting of (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkylthio and C1-C6 haloalkoxy, (ii) -O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl, 3-6 membered cycloalkyl, 5-8 membered heterocyclic group containing 1 or 2 heteroatoms selected from N, O and S, optionally substituted with 1, 2, 3, 4 or 5 substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl and C1-C6 alkyl.

[0079] In one implementation, R 11 R 12 and R 14 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 cyanoalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C2-C4 alkoxyalkyl, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

[0080] In one implementation, R 13 The group consisting of (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1-C3 haloalkylthio and C1-C3 haloalkoxy, (ii) -O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, 3-6 membered cycloalkyl and 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O and S, optionally substituted with one, two, three, four or five substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl and C1-C3 alkyl.

[0081] In one implementation scheme Selected from , , , , , , , , , , and A group that is formed.

[0082] In one implementation scheme Selected from A group that is formed.

[0083] In one implementation scheme Selected from , , , , , , , , , , , and The group consists of, R 21 R 22 and R 23 Each is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and -NR 2a R 2b (ii) 3-8 membered cycloalkyl groups, 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O and S, C6-C 10 Aryl groups and C5-C groups containing one or two heteroatoms selected from N, O, and S. 10 A heteroaryl group, optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogen, amino, cyano, hydroxyl, C1-C6 haloalkyl and C1-C6 hydroxyalkyl.

[0084] Or, R 22 and R 23 Together with the atoms attached thereto, they form 3-8 membered cycloalkyl groups, 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O, and S, C6-C 10 Aryl or 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O and S; R 2a and R 2bEach is independently selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 alkoxy, halogen, cyano, amino, 3-6 membered cycloalkyl, 5-8 membered heterocyclic, C6-C 10 The group consists of aryl and 5-8 membered heteroaryl groups.

[0085] In one implementation scheme Selected from , , , , , , , , , , , , , , , , , , , , , and The group consisting of; among which, R 21 R 22 R 23 R 24 R 25 R 26 and R 27 Each is independently selected from the group consisting of: (i) absent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 cyanoalkyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and -NR 2a R 2b (ii) methylene (=CH2), C3-C6 cycloalkyl, 3-6-membered heterocyclic group containing one or two heteroatoms selected from N, O and S, C6-C8 aryl and 5-8-membered heteroaryl group containing one or two heteroatoms selected from N, O and S, optionally substituted by one, two, three, four or five substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl and C1-C3 hydroxyalkyl; Or, R 21 and R 22Together with the atoms attached thereto, it forms a C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing one or two heteroatoms selected from N, O and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O and S; it is optionally substituted by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl and C1-C3 hydroxyalkyl; Or, R 22 and R 23 Together with the atoms attached thereto, it forms a C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing one or two heteroatoms selected from N, O and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O and S; it is optionally substituted by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl and C1-C3 hydroxyalkyl; Or, R 23 and R 24 Together with the atoms attached thereto, it forms a C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing one or two heteroatoms selected from N, O and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O and S; it is optionally substituted by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, and C1-C3 hydroxyalkyl. Or, R 25 and R 26 Together with the atoms attached thereto, it forms a C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing one or two heteroatoms selected from N, O and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O and S; it is optionally substituted by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl and C1-C3 hydroxyalkyl; R 2a and R 2b Each is independently selected from the group consisting of: (i) hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano and amino; (ii) C3-C8 cycloalkyl, C3-C6 heterocyclic, C6-C8 aryl and C5-C8 heteroaryl containing one or two heteroatoms selected from N, O and S, optionally substituted by one, two, three, four or five substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl and C1-C3 hydroxyalkyl; Preferably, for , , , .

[0086] In one implementation, R 21 R 22 and R 23 Each is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 cyanoalkyl, C1-C3 alkyl and -NR. 2a R 2b (ii) , , , , , , , and Optionally substituted with 1, 2, 3, 4, or 5 substituents, said substituents being selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxy, C1-C3 haloalkyl, and C1-C3 hydroxyalkyl; or, R 22 and R 23 It forms together with the atoms it is connected to. , or It is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxy, C1-C3 haloalkyl and C1-C3 hydroxyalkyl. R 2a and R 2b Each is independently selected from the group consisting of: (i) hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, and amino; (ii) , , , , , , and It is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

[0087] In one implementation scheme Selected from , , , , , and The group consists of, D1 is selected from C and CR. d1 A group consisting of N, S and O; D2 is selected from the group consisting of CH, CH2, and N; D3 is selected from the group consisting of C, CH, CH2, N, and NH; R d1 Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, and amino; X1 is selected from the group consisting of CH, CH2, N, and NH; X2 is selected from the group consisting of CH, CH2, CH3, N, NH and NH2; X3 is selected from the group consisting of CH, CH2, N, and NH; X4 is selected from the group consisting of CH, CH2, N, NH and NH2.

[0088] In one implementation scheme Selected from , , , , , , or A group that is formed.

[0089] In one embodiment, ring A is selected from the group consisting of phenyl, C3-C8 cycloalkyl, 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N or O, and 5-8 membered heteroaryl groups, optionally substituted by one, two, three, or four substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 alkylamino, C1-C3 alkylcyano, and C1-C3 hydroxyalkyl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated.

[0090] In one implementation, ring A is selected from... , , , , , , , , , and The group consisting of, optionally, substituted with 1, 2, 3 or 4 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 alkylamino, C1-C3 alkylcyano and C1-C3 hydroxyalkyl.

[0091] In one implementation, ring A is selected from... , , , , , , , , , , , , , , , , , , , , , , , , , and A group that is formed.

[0092] In one implementation, L2 is selected from key, C=O、 CF2 C-OH, C(F)CH3、 C(OH)CH3、 C=CH2、 C=NH、 C=N-OH CO-CH3, O、 S, , , and The group consists of NCH3.

[0093] In one implementation, L4 is selected from... C(O) and Groups composed of CH2; In one implementation, J is selected from... CH2、 CH and C(O); In one implementation, L5 is selected from... CH2 and A group composed of C(O).

[0094] In one embodiment, R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

[0095] R5 is selected from the group consisting of branched or straight-chain C1-C3 alkyl, C3-C8 cycloalkyl, 4-10-membered heterocyclic groups containing 1 or 2 heteroatoms selected from N, O or S, and 5-8-membered heteroaryl groups containing 1 or 2 heteroatoms selected from N or O, optionally substituted by 1, 2, 3, 4 or 5 substituents selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1-C3 cyanoalkyl and C1-C3 aminoalkyl, wherein the cycloalkyl or heterocyclic group is saturated or partially unsaturated; Alternatively, R4 and R5 together with the atoms they are attached to form a 5-7 membered heterocyclic group containing one or two heteroatoms selected from N, O or S; m can be 0, 1, or 2.

[0096] In one embodiment, R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

[0097] R5 is selected from -C(CH3)2. , , , , , , , , , , and The group formed; Alternatively, R4 and R5 together with the atoms they are attached to form , , or .

[0098] In another aspect, the present invention provides compounds of formula (XI), or tautomers, cis or trans isomers, meso compounds, racemic compounds, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts, solvates, or prodrugs thereof.

[0099] in, R4 and R5, together with the atoms they are attached to, form 5-7 membered heterocyclic groups containing one or two heteroatoms selected from N, O or S; R4 and R5 together with the atoms they are attached to form or .

[0100] In one embodiment, compound (I) may be a compound of formula (XII), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0101] in, Each R1 is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkoxy, C1-C6 haloalkylthio, -NR 2a R 2b and SF5; (ii)-O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl, C3-C8 cycloalkyl and 5-8 membered heterocyclic groups containing 1 or 2 heteroatoms selected from N, O and S, wherein the cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, C1-C6 alkyl and SF5; R 2a and R 2b Each is independently selected from the group consisting of: (i) hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano and amino; (ii) C3-C8 cycloalkyl, C3-C6 heterocyclic, C6-C8 aryl and C5-C8 heteroaryl containing one or two heteroatoms selected from N, O and S, optionally substituted by one, two, three, four or five substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl and C1-C3 hydroxyalkyl; D1 is selected from the group consisting of C, CH, CH2, and N; D2 is selected from the group consisting of CH, CH2, NH and N; D3 is selected from the group consisting of C, CH and N; R d1 Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, amino, -NH-C1-C3 alkyl and -CONH3; X1 is selected from the group consisting of C, CH, CH2, N, and NH; X2 is selected from the group consisting of CH, CH2, N, NH and bonds; X3 is selected from the group consisting of CH, CH2, N, and NH; X4 is selected from the group consisting of CH, CH2, N, and NH; R 15 Selected from the group consisting of: (i) hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, amino and SF5; (ii) C1-C3 alkyl-C3-C8 cycloalkyl, C1-C3 alkyl-5-8 heterocyclic group containing one or two heteroatoms selected from N, O and S, C6-C8 aryl, 5-8 heteroaryl group containing one or two heteroatoms selected from N, O and S, optionally substituted by one, two, three, four or five substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, SF5; R 16 Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, amino, and SF5. x is 2, 3 or 4.

[0102] In one embodiment, compound (I) may be a compound of formula (XIII), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, having a structure selected from formula (XIII).

[0103] in, Each R1 is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkoxy, C1-C6 haloalkylthio, -NR 2a R 2band SF5; (ii)-O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl, C3-C8 cycloalkyl and 5-8 membered heterocyclic groups containing 1 or 2 heteroatoms selected from N, O and S, wherein the cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, C1-C6 alkyl and SF5; Cyclode D is selected from the group consisting of C3-C8 cycloalkyl groups and 5-12 fused heterocyclic groups containing one or two heteroatoms selected from N, O and S, wherein the cycloalkyl group and the 5-10 fused heterocyclic group are optionally substituted by one, two, three, four or five substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, oxo, C1-C6 cyanoalkyl, C1-C6 alkyl and SF5; R 15 Selected from the group consisting of: (i) hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, amino and SF5; (ii) C1-C3 alkyl-C3-C8 cycloalkyl, C1-C3 alkyl-5-8 heterocyclic group containing one or two heteroatoms selected from N, O and S, C6-C8 aryl and 5-8 heteroaryl group containing one or two heteroatoms selected from N, O and S, optionally substituted with one, two, three, four or five substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and SF5; R 16 Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, amino, and SF5. x is 2, 3 or 4.

[0104] In a preferred embodiment, ring D is selected from... and The group consisting of, optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, oxo, C1-C6 cyanoalkyl, C1-C6 alkyl and SF5.

[0105] In one embodiment, compound (I) may be a compound of formula (XIV) or (XV), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0106] in, R17 R 18 and R 19 Each of the following is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, and heterocyclic groups, wherein the cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4, or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, and alkyl. E1 is selected from the group consisting of CH, CH2, N, NH, S, and O; E2 is selected from the group consisting of N, NH, S and O; R 20 and R 20 a is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl, and SF5; preferably, R 20 It is CD3; R 21 and R 22 Each is independently selected from the group consisting of hydrogen, deuterium, F, Cl, Br, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl and SF5; R 23 Selected from the group consisting of hydrogen and cyano groups, or selected from the group consisting of 1, 2, 3 or more R groups that may be unsubstituted or have 1, 2, 3 or more R groups. 23 One of the substituted groups: deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano and C1-C6 hydroxyalkyl, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; R 23s is selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano and C1-C6 hydroxyalkyl, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic and aryl, heteroaryl; r can be 0, 1, 2 or 3.

[0107] In one embodiment, compound (I) may be a compound of formula (XIV)-(XV), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0108] in, R 17 R 18 and R 19 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; E1 is selected from the group consisting of CH, CH2, N, NH, S, and O; E2 is selected from the group consisting of N, NH, S and O; R 20 and R 20 a is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; R 21 and R 22 Each is independently selected from the group consisting of hydrogen, deuterium, F, Cl, Br, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; R 23It is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl.

[0109] In another aspect, the present invention provides compounds of formula (XVI)-(XXIX), or tautomers, cis or trans isomers, meso compounds, racemic compounds, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts, solvates, or prodrugs thereof.

[0110] in, A1, A2 and A4 are each independently selected from the group consisting of C, CH, N, NH, S and O, preferably A1 and A4 are independently selected from N and NH, and A2 is CH; A3 is selected from the group consisting of C, CH, N, NH, S, O and bonds, preferably bonds; B1 is selected from the group consisting of C, CH, and N; B2 is selected from the group consisting of C, CH, N and bonds; B3 is selected from the group consisting of CH, N, S, and O; E1, E2, and E4 are each independently selected from the group consisting of CH, CH2, N, NH, S, and O; E3 is selected from the group consisting of CH, CH2, N, NH, S, O and bonds; D1 is selected from C and CR. d1 A group consisting of N, S and O; D2 is selected from the group consisting of CH, CH2, N and non-existent. When D2 does not exist, the bond connected to D2 also does not exist. D3 is selected from the group consisting of C, CH, CH2, N, and NH; R d1 Selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, and amino; X1 is selected from the group consisting of C, CH, CH2, N, and NH; X2 is selected from the group consisting of CH, CH2, CH3, N, NH, NH2 and bonds; X3 is selected from the group consisting of CH, CH2, N, NH and bonds; X4 is selected from the group consisting of CH, CH2, CH3, N, NH, NH2 and bonds; each Independently represent a double bond or a single bond that satisfies the valence requirement, provided that the two adjacent bonds are not both double bonds; Indicates a double bond or a single bond; Each R 25 R 30 R 31 R 33 Independently selected from the group consisting of: (i) absent, hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl, alkyl, alkenyl, alkoxy, alkylthio, alkoxyalkyl, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio and SF5; (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic group, wherein the amino, hydroxy, cyanoalkyl, alkyl, alkenyl, alkoxy, alkylthio, alkoxyalkyl, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl and heterocyclic group are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl, alkyl and SF5; Preferably, each R 25 R 30 R 31 R 33 Independently selected from the group consisting of: (i) absent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 2-6 Alkoxyalkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkoxy groups, C 1-6(ii)-O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, C3-C8 cycloalkyl, 5-10 membered heterocyclic groups, wherein the amino, hydroxy, cyanoalkyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxy-thio, alkoxyalkyl, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl and alkyl; Each R 26 Independently selected from: non-existent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, methylene (=CH2), alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, hydroxyalkyl, -NR 2a R 2b The group consisting of SF5, cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein hydroxyl, cyanoalkyl, alkyl, methylene (=CH2), oxo (=O), alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, -NR 2a R 2b Cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by 1, 2, 3, 4, or 5 R groups. 26a Replace, where R 26a Selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, oxo (=O), and SF5; preferably, R 26 Selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; Preferably, each R 26 Independently selected from non-existent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C 1-6 Cyanoalkyl, C 1-6 Alkyl, methylene (=CH2), C 2-6 alkenyl, C 2-6 alkynyl group, C 2-6 Alkoxyalkyl, C 2-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 2-6 Alkylthio, C 2-6 Haloalkyl, C 2-6 Hydroxyalkyl, -NR 2a R 2b SF5, C3-8 cycloalkyl, 5-10 membered heterocyclic, C 6-12 Aryl and C 1-9 The group consisting of heteroaryl groups, including hydroxyl, cyanoalkyl, alkyl, methylene (=CH2), alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, and -NR. 2a R 2b Cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by 1, 2, 3, 4, or 5 R groups. 26a replace, Or two Rs 26 Together with the two adjacent atoms it is attached to, it forms a cycloalkyl, heterocyclic, aryl, or heteroaryl group; preferably C10. 3-8 Cycloalkyl, 5-10 membered heterocyclic groups, C 6-12 Aryl or C 1-9 Mixed aromatics; R 2a and R 2b Each is independently selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, amino, cycloalkyl, heterocyclic, aryl, and heteroaryl; preferably, selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, halogen, cyano, amino, C 3-8 Cycloalkyl, 5-10 membered heterocyclic groups, C 6-12 Aryl and C 1-9 Group composed of heteroaryl groups; Ring A is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, and is optionally surrounded by 1, 2, 3, or 4 R groups. 27 Replace, where R 27 Selected from hydrogen, deuterium, alkyl, deuterated The group consisting of alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, oxo (=O), SF5, cycloalkyl, cycloalkyloxy, heterocyclic, aryl, and heteroaryl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; wherein R 27 The alkyl, deuterated alkyl, alkenyl, alkynyl, amino, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by 1, 2, 3, 4, or 5 R groups. 27a Replace, where R 27a Selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, and oxo (=O); preferably, R 27It is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl and SF5; L2 is selected from the key, C(O), CR 3a R 3b , C=R 3d , C=NR 3e , O、 S and NR 3f The group formed; R 3a and R 3b Each is independently selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C4 alkenyl, C2-C4 alkynyl, cyano, amino, C3-C6 cycloalkyl, 5-8 membered heterocyclic groups containing 1, 2, 3, 4 or 5 heteroatoms selected from N, O and S, aryl and heteroaryl groups; Or R 3a and R 3b Together with the atoms attached thereto, they form a cycloalkyl or heterocyclic group, which is optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano and amino. R 3d Selected from the group consisting of C1-C3 alkyl groups; R 3e Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano, and amino; R 3f Selected from the group consisting of C1-C3 alkyl groups; L4 is selected from the group consisting of C(O) and CH2; J is selected from CH2, CH and C(O); L5 is selected from the group consisting of CH2 and C(O); Indicates the connection point with the parent nucleus structure; R4 is selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino and SF5; R 5aSelected from the group consisting of: (i) hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, and SF5; (ii) cycloalkyl, heterocyclic, aryl, heteroaryl, and -alkyl-heterocyclic, wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, and -alkyl-heterocyclic are optionally surrounded by 1, 2, 3, 4, or 5 R groups. 28 replace; Or R4 and R 5a Together with the atoms attached thereto, they form a 3-12 membered heterocyclic group, or a 3-6 membered cycloalkyl group, containing 1, 2, 3, 4, or 5 heteroatoms selected from N, O, and S, wherein the cycloalkyl group and heterocyclic group are optionally surrounded by 1, 2, 3, 4, or 5 R atoms. 28 replace; R 28 Selected from: non-existent, hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, -C 0-6 Alkylene -S(O)2H, -C 0-6 Alkylene -S(O)2-alkyl, amino, -NH-C(O)-C 0-6 The group consisting of alkyl, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, SF5, cycloalkyl, heterocyclic, cycloalkyloxy, aryl, heteroaryl, methylene (=CH2), and oxo (=O), wherein the alkyl, hydroxy, alkenyl, alkynyl, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, cycloalkyl, heterocyclic, cycloalkyloxy, aryl, heteroaryl, and methylene (=CH2) are optionally surrounded by 1, 2, 3, 4, or 5 R's. 29 replace; Each R 24 and R 29 Independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, cyano, -NH-C(O)-C 0-6Alkyl, HC(O)-, -S(O)2H, -S(O)2-alkyl, oxo (=O), SF5, cycloalkyl, cycloalkoxy, heterocyclic, aryl, heteroaryl, and hydroxyalkyl; preferably, selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; m, n1, n2, n3, and n4 are each independently selected from 0, 1, 2, 3, or 4; n5 is independently selected from 0, 1, 2 or 3.

[0111] In some implementation schemes, each and Selected independently , , , , , , , , , , , , , , The group formed E2 The end of.

[0112] In some implementation schemes, each R 25 Independently selected from methyl, -SCH3, -F, -CF3 CH2OCH3, , A group consisting of SF5.

[0113] In some implementation schemes, each R 26 Independently selected from hydrogen, -CH3, A group consisting of elements that do not exist.

[0114] In some implementations, R4 is selected from the group consisting of hydrogen and -CH3.

[0115] In some implementation schemes, R 5a Selected from , , , , , , , , , , and The group consisting of R4 and R 5a Together with the atoms attached thereto, they form 3-6 membered heterocyclic groups, wherein the heterocyclic groups are selected from... , and The group consisting of, preferably , or Each R 281 R 282 Independently selected from the group consisting of non-existent, hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, SF5, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, and methylene (=CH2), wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, and methylene (=CH2) are optionally surrounded by 1, 2, 3, 4, or 5 R's. 29 Replacement; preferably, R 5a for , , , , , , , , , , , , , , Or R4 and R 5a It forms together with the atoms it is connected to. , .

[0116] In some implementation schemes, each R 28 Selected independently , -CH3, -COCH3, -OCH3, -CN, -CH2OCH3, , , , , , , , , , , , , , , , and The group formed by R. 32 The group is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, cyano, cycloalkyl, cycloalkoxy, heterocyclic, aryl, heteroaryl, and hydroxyalkyl; preferably, it is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C2-C6 alkoxyalkyl, C2-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl.

[0117] In some implementation schemes, each R 24 R 27 R 29 Each independently selected -F and A group that is formed.

[0118] In some implementations, in the above formula, for ; for ; for ; for .

[0119] In some implementation schemes, , Independently , Preferred , ; for Preferred ; or, , for , Preferred , , ; Each R251 R 252 R 253 R 254 R 255 R 256 Independently selected from the group consisting of: (i) absent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, alkenyl, alkoxy, alkylthio, alkoxyalkyl, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio and SF5; (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl and heterocyclic, wherein the cycloalkyl and heterocyclic are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl and alkyl; Preferably, each R 251 R 252 R 253 R 254 R 255 R 256 Each is independently selected from the group consisting of: (i) absent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 2-6 Alkoxyalkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 (ii)-O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, C3-C8 cycloalkyl and 5-10 membered heterocyclic groups, wherein the cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl and alkyl.

[0120] In some implementation schemes, and Independently , Preferred , or .

[0121] In some implementations, ring A is Preferred More preferably , Indicates the position connected to N.

[0122] The present invention also provides a pharmaceutical composition comprising a compound of any formula or embodiment of the present invention, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the content of said compound is about 0.1% to 95% by weight of the free base; preferably, about 0.5% to 85% by weight of the free base; more preferably, about 1% to 70% by weight of the free base; preferably, about 1% to 60% by weight of the free base; more preferably, about 1-15% by weight of the free base; or about 15-30% by weight of the free base; or about 30-45% by weight of the free base; or about 15-30% by weight of the free base; or about 45-60% by weight of the free base.

[0123] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of any of the above-described compounds, or tautomers, cis or trans isomers, meso compounds, racemic compounds, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0124] In some embodiments, the content of the compound, its tautomers, cis or trans isomers, meso compounds, racemic compounds, enantiomers, diastereomers or mixtures thereof, or pharmaceutically acceptable salts thereof in the above pharmaceutical composition is about 0.1-95% by weight of the free base; preferably, about 5-70%, for example 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%.

[0125] In some embodiments, the above-mentioned pharmaceutical composition is formulated as tablets, capsules, liquids, or injections.

[0126] In some embodiments, the content of the compound, its tautomers, cis or trans isomers, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, in the above pharmaceutical composition is about 1-1000 mg; preferably about 1-500 mg, more preferably about 1 mg, 2 mg, 3 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg.

[0127] In some embodiments, the compound, its tautomers, cis or trans isomers, meso, racemic, enantiomers, diastereomers or mixtures thereof, or pharmaceutically acceptable salts thereof may be administered via any suitable route of administration, such as oral, parenteral, buccal, sublingual, nasal, rectal, intrathecal or transdermal administration, with appropriate modifications to the pharmaceutical composition.

[0128] In some embodiments, the compound, its tautomers, cis or trans isomers, meso compounds, racemic compounds, enantiomers, diastereomers or mixtures thereof, or pharmaceutically acceptable salts are formulated in solid or liquid form, such as syrups, suspensions, emulsions, tablets, capsules, powders, granules or lozenges.

[0129] On the other hand, the present invention relates to a method for treating KRAS mutation-mediated diseases, comprising administering to a subject in need an effective amount of any (I)-(XXIX) compound, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a pharmaceutical composition comprising the thereof.

[0130] In another aspect, the present invention relates to a method of treating cancer, comprising administering to a subject in need an effective amount of any (I)-(XXIX) compound, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a pharmaceutical composition comprising the thereof.

[0131] In one implementation, the cancer is associated with a KRAS G12C(ON) mutation.

[0132] In a preferred embodiment, the cancer is selected from the group consisting of: heart: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyosarcoma, fibroma, lipoma, and teratoma; lung: bronchial carcinoma (squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondrogenic hamartoma, mesothelioma; gastrointestinal tract: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid, vasoactive intestinal peptide tumor), small intestine (adenocarcinoma, lymphoma, carcinoid, Kaposi's sarcoma, leiomyosarcoma, hemangioma, lipoma, lipoma). Lipomas, neurofibromas, fibromas); colorectal cancer (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); urogenital tract: kidneys (adenocarcinoma, nephroblastoma, lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testes (seminomatous seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenoid tumor, lipoma); liver: hepatocellular carcinoma (hepatocellular carcinoma), bile duct carcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; bile duct: gallbladder carcinoma, ampullary carcinoma, bile duct carcinoma; bone: osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell carcinoma). Cytosarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochondroma), benign chondroma, chondroblastoma, chondromycinoid fibroma, osteoid osteoma and giant cell tumor; Nervous system: Skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), Meninges (meningioma, meningeal sarcoma, gliomatosis), Brain (astrocytoma, medulloblastoma, glioma, ependymoma, germ cell tumor (pineal tumor), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumor), spinal cord neurofibroma, meningioma, glioma, sarcoma; Gynecology: Uterus (endometrial cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-theca cell carcinoma) Cancer: Cytomas, Sertoli-stromal tumors, dysgerminomas, malignant teratomas); vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma); vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonic rhabdomyosarcoma)); fallopian tubes (cancer); hematologic system: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and adrenal glands: neuroblastoma.

[0133] In another aspect, the present invention provides a method for preparing a compound of formula (X), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, deuterated derivative or mixture thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, comprising:

[0134] A1, A2, and A4 are each independently selected from the group consisting of C, CH, N, NH, S, and O; A3 is selected from the group consisting of C, CH, N, NH, S, O and bonds; B1 is selected from the group consisting of C, CH, and N; B2 is selected from the group consisting of C, CH, N and bonds; B3 is selected from the group consisting of C, CH, N, S, and O; E1 and E2 are each independently selected from CH, CH2, N, NH, S, O, and C. 1-3 Alkoxy, - N(CH3)C 1-3 Alkylene-# and - NH-C 1-3 The group consisting of alkylene groups, in which It can be oriented towards D1 or towards B1, and correspondingly, # can be oriented towards B1 or D1; D1 is selected from C and CR. d1 A group consisting of N, S and O; D2 is selected from C and CR. d1 CH2, N and non-existent groups, when D2 does not exist, the bond connected to D2 also does not exist; D3 is selected from C and CR. d1 The group consists of CH2, N and NH; Each R d1 Independently selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, and amino. X1 is selected from C, CR d1 The group consists of CH2, N and NH; X2 is selected from C and CR. d1 The group consisting of CH2, CH3, N, NH, NH2, bonds, and non-existent bonds; X3 is selected from C, CR d1 The group consisting of CH2, N, NH, bonds, and non-existent elements; X4 is selected from C, CR d1 The group consisting of CH2, CH3, N, NH, NH2, bonds, and non-existent bonds; When X1, X2, or X3 does not exist, the key to which it is connected also does not exist; Indicates the double or single bond required to satisfy the valence requirement; R1 is selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, alkenyl, alkoxy, alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, haloalkoxy and haloalkylthio; (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, wherein the cycloalkyl and heterocyclic are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl and alkyl; R2 is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, deuterated alkyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, -NR 2a R 2b The group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, and halogens. Or, two R2 atoms together with their two adjacent atoms form a cycloalkyl, heterocyclic, aryl, or heteroaryl group; R 2a and R 2b Each is independently selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, amino, cycloalkyl, heterocyclic, aryl, and heteroaryl; Ring A is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, and is optionally substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; L2 is selected from the key, C(O), CR 3a R 3b , C=R 3d , C=NR 3e , O、 S and NR 3f The group formed; R 3a and R 3b Each is independently selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C4 alkenyl, C2-C4 alkynyl, cyano, amino, C3-C6 cycloalkyl, 5-8 membered heterocyclic groups containing one or more heteroatoms selected from N, O and S, aryl, and heteroaryl. Or R 3a and R 3b Together with the atoms attached thereto, they form a cycloalkyl or heterocyclic group, which is optionally substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano and amino. R 3d Selected from the group consisting of C1-C3 alkyl groups; R 3e Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano, and amino; R 3f Selected from the group consisting of C1-C3 alkyl groups; L4 is selected from C(O) and Groups composed of CH2; J is selected from CH2、 CH and C(O); L5 is selected from CH2 and A group composed of C(O); Indicates the connection point with the parent nucleus structure; R4 is hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, or amino. R5 is selected from the group consisting of: (i) hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl; (ii) cycloalkyl, heterocyclic, aryl, heteroaryl, optionally substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; R 34 The leaving group is preferably a halogen; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4; m can be 0, 1, 2, 3, or 4; t can be 0, 1, or 2. Invention Details

[0136] The terms used in this application are defined as follows. Any terms not defined herein shall have their ordinary meaning as understood by those skilled in the art.

[0137] "Alkyl" refers to a saturated aliphatic hydrocarbon group, including C1-C64 groups. 20 Straight-chain and branched-chain groups. Preferably, the alkyl group is an alkyl group having 1 to 12, sometimes more preferably 1 to 6, and sometimes more preferably 1 to 4 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl 2,3-Dimethylpentyl, 2,4-Dimethylpentyl, 2,2-Dimethylpentyl, 3,3-Dimethylpentyl, 2-Ethylpentyl, 3-Ethylpentyl, n-Octyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,2-Dimethylhexyl, 3,3-Dimethylhexyl, 4,4-Dimethylhexyl, 2-Ethylhexyl, 3-Ethylhexyl, 4-Ethylhexyl, 2-Methyl-2-Ethylpentyl, 2-Methyl-3-Ethylpentyl, n-Nonyl, 2-Methyl-2-Ethylhexyl, 2-Methyl-3-Ethylhexyl, 2,2-Diethylpentyl, n-Decyl, 3,3-Diethylhexyl, 2,2-Diethylhexyl, and their branched isomers. More preferably, the alkyl group is a lower alkyl group having 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. The alkyl group may be substituted or unsubstituted. When substituted, the substituent can be substituted at any available connection point. Preferably, the substituent is one, two, three, four, or five substituents independently selected from the group consisting of alkyl, halogen, alkoxy, alkenyl, alkynyl, alkylthio, alkylamino, mercapto, hydroxyl, nitro, cyano, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloyl, cycloalkylthio, heterocycloalkylthio, and oxo.

[0138] "Alkenyl" refers to an alkyl group as defined above, having at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, preferably C10. 2-20 Alkenyl, more preferably C 2-12 Alkenyl group, most preferably C 2-6 Alkenyl. The alkenyl group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from the group consisting of alkyl, halogen, alkoxy, alkenyl, alkynyl, alkylsulfinyl, alkylamino, mercapto, hydroxyl, nitro, cyano, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocyclol, cycloalkylthio, heterocycloalkylthio, and oxo.

[0139] "Alkynyl" refers to an alkyl group as defined above, having at least two carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or 3-butynyl, preferably C10. 2-20 Alkyne group, more preferably C 2-12 Alkyne group, most preferably C 2-6 Alkynyl. The alkynyl group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0140] "Alkylene" refers to a saturated straight-chain or branched aliphatic hydrocarbon group having two residues obtained by removing two hydrogen atoms from the same carbon atom or two different carbon atoms of a parent alkane. The straight-chain or branched group contains 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, more preferably 1 to 6 carbon atoms. Non-limiting examples of alkylene include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2-), 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), etc. The alkylene can be substituted or unsubstituted. When substituted, the substituents are preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0141] "Alkenyl" refers to an alkylene group as defined above, having at least two carbon atoms and at least one carbon-carbon double bond, preferably C16-C26. 2-20 alkenyl, more preferably C 2-12 alkenyl groups, with C being the most preferred. 2-6 Idemenyl. Non-limiting examples of imenyl groups include, but are not limited to, -CH=CH-, -CH=CHCH2-, -CH=CHCH2CH2-, -CH2CH=CHCH2-, etc. The imenyl group may be substituted or unsubstituted. When substituted, the substituents are preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0142] "Immyneyl" refers to an ynyl group as defined above, having at least two carbon atoms and at least one carbon-carbon triple bond, preferably C. 2-20 Ethyne group, more preferably C 2-12 The most preferred group is the acetylenic group, C. 2-6 Alynyl group. Non-limiting examples of alynyl groups include, but are not limited to: -CH≡CH-, -CH≡CHCH2-, -CH≡CHCH2CH2-, -CH2CH≡CHCH2-, etc. The alynyl group may be substituted or unsubstituted. When substituted, the substituents are preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0143] As used herein, the term "alkoxyalkyl" refers to an alkoxy group that is attached to an alkyl group via its oxygen atom, wherein the alkyl group is attached to the parent molecule via a carbon atom, such as a methoxymethyl group. 2OCH3). For example, "C2 "Oxyalkyl" refers to alkoxyalkyl groups having 2 to 4 carbon atoms, such as -CH2OCH3, -CH2CH2OCH3, -CH2OCH2CH3 and -CH2CH2OCH2CH3.

[0144] "Cycloalkyl" refers to a saturated and / or partially unsaturated monocyclic or polycyclic hydrocarbon group having 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 10 carbon atoms, and most preferably 3 to 8 carbon atoms or 3 to 6 carbon atoms. Representative examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, and cyclooctyl. Polycyclic cycloalkyl groups include cycloalkyl groups having spirocyclic, fused, or bridged rings.

[0145] "Spirocycloalkyl" refers to a 5- to 20-membered polycyclic group in which rings are interconnected by a shared carbon atom (called a spiro atom), wherein one or more rings may contain 1, 2, 3, 4, or 5 double bonds, but none of the rings have a fully conjugated π-electron system. Preferably, the spirocycloalkyl group is 6 to 14-membered, more preferably 7 to 10-membered. Depending on the number of shared spiro atoms, spirocycloalkyl groups are classified as monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl, preferably monospirocycloalkyl or bispirocycloalkyl, more preferably 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospirocycloalkyl groups. Representative examples of spirocycloalkyl groups include, but are not limited to, the following substituents: , , , and .

[0146] "Fused cycloalkyl" refers to a 5- to 20-membered polycyclic hydrocarbon group, wherein each ring in the system shares a pair of adjacent carbon atoms with another ring, and one or more rings may contain 1, 2, 3, 4, or 5 double bonds, but none of the rings have a fully conjugated π-electron system. Preferably, the fused cycloalkyl is 6- to 14-membered, more preferably 7- to 10-membered. Depending on the number of rings, fused cycloalkyl is classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic fused cycloalkyl, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused cycloalkyl. Exemplary examples of fused cycloalkyl include, but are not limited to, the following substituents: and .

[0147] "Bridged cycloalkyl" refers to a 5- to 20-membered polycyclic hydrocarbon group, wherein each pair of rings shares two unconnected carbon atoms. The rings may have 1, 2, 3, 4, or 5 double bonds, but do not have a fully conjugated π-electron system. Preferably, the bridged cycloalkyl group is 6- to 14-membered, more preferably 7- to 10-membered. Depending on the number of rings, bridged cycloalkyl groups are classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl groups, preferably bicyclic, tricyclic, or tetracyclic bridged cycloalkyl groups, more preferably bicyclic or tricyclic bridged cycloalkyl groups. Representative examples of bridged cycloalkyl groups include, but are not limited to, the following substituents: and .

[0148] The cycloalkyl group may be fused with an aryl, heteroaryl, or heterocycloalkyl ring, wherein the ring attached to the parent structure is a cycloalkyl group. Representative examples include, but are not limited to, indanylacetic acid, tetrahydronaphthalene, and benzocycloheptyl. The cycloalkyl group may optionally be substituted or unsubstituted. When substituted, the substituents are preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three substituents independently selected from the group consisting of alkyl, halogen, alkoxy, alkenyl, alkynyl, alkylsulfinyl, alkylamino, mercapto, hydroxyl, nitro, cyano, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloyl, cycloalkylthio, heterocycloalkylthio, and oxo.

[0149] "Heterocyclic group" refers to a 3- to 20-membered saturated and / or partially unsaturated monocyclic or polycyclic hydrocarbon group, which contains one or more, sometimes preferably one to five, and sometimes more preferably one to three selected from N, O, and S(O). m The heteroatoms in the group consisting of (where m is 0, 1, or 2) are ring atoms, but the ring does not contain -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon atoms. Preferably, the heterocyclic group is a 3- to 12-membered ring having 1 to 4 heteroatoms; more preferably, a 3- to 10-membered ring having 1 to 3 heteroatoms; even more preferably, a 4- to 8-membered ring having 1 to 3 heteroatoms; and most preferably, a 5- to 6-membered ring having 1 to 2 heteroatoms. Representative examples of monocyclic heterocyclic groups include, but are not limited to, oxobutyl, aziridine, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, sulfonylmorpholinyl, and homopiperazinyl. Polycyclic heterocyclic groups include heterocyclic groups having spirocyclic, fused, or bridged rings.

[0150] "Spiroheterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group in which rings are interconnected by a shared carbon atom (called a spiro atom), wherein the rings have one or more, sometimes preferably one to five, and sometimes more preferably one to three selected from N, O, and S(O). m The heteroatoms in the group (where m is 0, 1, or 2) are used as ring atoms, and the remaining ring atoms are carbon atoms. One or more rings may contain 1, 2, 3, 4, or 5 double bonds, but none of the rings have a fully conjugated π-electron system. Preferably, the spiroheterocyclic group is 6 to 14 quinary, more preferably 7 to 10 quinary. Based on the number of shared spiro atoms, spiroheterocyclic groups are classified as monospirocyclic, bispirocyclic, or multispirocyclic groups, preferably monospirocyclic or bispirocyclic, more preferably 4 / 4, 4 / 5, 4 / 6, 5 / 5, or 5 / 6 monospirocyclic groups. Representative examples of spiroheterocyclic groups include, but are not limited to, the following substituents: and .

[0151] "Fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group, wherein each ring in the system shares a pair of adjacent carbon atoms with another ring, and one or more rings may contain 1, 2, 3, 4 or 5 double bonds, but none of the rings have a fully conjugated π-electron system, and wherein the rings have one or more, sometimes preferably one to five, and sometimes more preferably one to three selected from N, O and S(O). p The heteroatoms in the group consisting of (where p is 0, 1, or 2) are used as ring atoms, and the remaining ring atoms are carbon. Preferably, the fused heterocyclic group is 6 to 14 members, more preferably 7 to 10 members. Depending on the number of rings, fused heterocyclic groups are classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic fused heterocyclic groups, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic groups. Representative examples of fused heterocyclic groups include, but are not limited to, the following substituents: , , , , , , , , , , , , , , , , , , and .

[0152] "Bridged heterocyclic group" refers to a 5- to 14-membered polycyclic heterocyclic alkyl group, wherein each pair of rings in the system shares two unconnected atoms. The rings may have 1, 2, 3, 4, or 5 double bonds, but do not have a fully conjugated π-electron system, and the rings have 1, 2, 3, 4, or 5 electrons selected from N, O, and S(O). m (Where m is 0, 1, or 2) heteroatoms are used as ring atoms, and the remaining ring atoms are carbon. Preferably, the bridging heterocyclic group is 6 to 14 members, more preferably 7 to 10 members. Depending on the number of rings, bridging heterocyclic groups are classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridging heterocyclic groups, preferably bicyclic, tricyclic, or tetracyclic bridging heterocyclic groups, more preferably bicyclic or tricyclic bridging heterocyclic groups. Representative examples of bridging heterocyclic groups include, but are not limited to, the following substituents: , , , , , , , , , , , , , and .

[0153] The ring of the heterocyclic group may be fused with the ring of an aryl, heteroaryl, or cycloalkyl group, wherein the ring connected to the parent structure is a heterocyclic group. Representative examples include, but are not limited to, the following substituents: , , and wait.

[0154] The heterocyclic group may be optionally substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0155] "Aryl" refers to a 6- to 14-membered monocyclic or polycyclic fused-ring group (a "fused" ring system refers to a system in which each ring shares a pair of adjacent carbon atoms with another ring in the system) and has a fully conjugated π-electron system. Preferably, the aryl group is 6- to 10-membered, such as phenyl and naphthyl, with phenyl being the most preferred. The aryl group may be fused with a ring of a heteroaryl, heterocyclic, or cycloalkyl group, wherein the ring attached to the parent structure is an aryl group. Representative examples include, but are not limited to, the following substituents: , , , , , , , , , , , and .

[0156] The aryl group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0157] "Heteroaryl" refers to an aryl system having 1 to 4 heteroatoms selected from O, S, and N as ring atoms and having 5 to 14 ring atoms. Preferably, the heteroaryl group is 5 to 10-membered, more preferably 5- or 6-membered, such as thiadiazolyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl, thiazolyl, furanyl, thiophenyl, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl group may be fused with the ring of an aryl, heterocyclic, or cycloalkyl group, wherein the ring connected to the parent structure is a heteroaryl group. Representative examples include, but are not limited to, the following substituents: , , , , , , , , , , and .

[0158] The heteroaryl group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and -NR. 9 R 10 Substituents that make up the group.

[0159] "Alkoxy" refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl) groups, wherein the alkyl group is as defined above. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, etc. The alkoxy group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0160] A "bond" refers to a covalent bond represented by the symbol "—".

[0161] "Hydroxyalkyl" refers to an alkyl group that has been replaced by a hydroxyl group, where the alkyl group is as defined above.

[0162] "Hydroxy" refers to the -OH group.

[0163] "Halogen" refers to fluorine, chlorine, bromine, or iodine atoms.

[0164] "Amino" refers to the -NH2 group.

[0165] “Cyano” refers to the -CN group.

[0166] "Nitro" refers to the -NO2 group.

[0167] "Oxygen group" refers to the =O group.

[0168] "Carboxyl group" refers to the -C(O)OH group.

[0169] "Alkoxycarbonyl" refers to a -C(O)O (alkyl) or (cycloalkyl) group, wherein the alkyl and cycloalkyl groups are as defined above.

[0170] "Optional" or "optionally" means that the event or condition described below may but not necessarily occur, and the description includes instances where the event or condition occurs or does not occur. For example, "optionally alkyl-substituted heterocyclic group" means that the alkyl group may be present but is not required to be present, and the description includes cases where the heterocyclic group is alkyl-substituted and cases where the heterocyclic group is not alkyl-substituted.

[0171] "Substitution" refers to the independent replacement of one or more hydrogen atoms (preferably up to five, more preferably one to three hydrogen atoms) in a group by the corresponding number of substituents. It goes without saying that the substituent exists in its only possible chemical position. Those skilled in the art can determine whether substitution is possible without much experimental or theoretical effort. For example, a combination of an amino or hydroxyl group with free hydrogen and a carbon atom with an unsaturated bond (e.g., an alkene bond) may be unstable.

[0172] "Pharmaceutical composition" refers to a mixture of one or more compounds described in this invention, or their physiologically / pharmaceutical acceptable salts or prodrugs, with other chemical components such as physiologically / pharmaceutical acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate the administration of the compound to a living organism, which is beneficial for the absorption of the active ingredient and thus the expression of biological activity.

[0173] "Pharmaceutically acceptable salt" refers to the salt of the compounds of this invention, which is safe and effective and has corresponding biological activity when used in mammals. Detailed Implementation

[0174] Synthesis process

[0175] Synthesis of 5-bromo-4,6-dichloro-1-methyl-1H-benzo[d]imidazolium BB1

[0176] Step 1: Methylamine (2M THF solution, 36 mL) was added to a THF solution of 1,3,5-trichloro-2-nitrobenzene (5.00 g) (60 mL). After stirring at 50 °C for 16 hours, the reaction solution was concentrated under reduced pressure to obtain crude 3,5-dichloro-N-methyl-2-nitrobenzene. MS: m / z = 221.0, 222.9 (M+H, ESI+).

[0177] The compounds in the table below were synthesized according to the method described above.

[0178]

[0179] Step 2: To a DMF (15 mL) solution of 3,5-dichloro-N-methyl-2-nitroaniline (2.50 g, 11.36 mmol), N-bromosuccinimide (2.02 g, 11.36 mmol) was added at 0 °C. The mixture was heated to 25 °C and stirred for 2 hours under a nitrogen atmosphere. The mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (30 x 2 mL). The organic phase was dried over anhydrous Na₂SO₄. After filtration, the solvent was removed under vacuum, and the mixture was purified by rapid silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1:4) to give a yellow solid of 4-bromo-3,5-dichloro-N-methyl-2-nitroaniline (3.20 g, yield: 94%). MS: m / z = 298.8, 301.0 (M+H, ESI+).

[0180] The compounds in the table below were synthesized according to the method described above.

[0181]

[0182] Step 3: The crude 4-bromo-3,5-dichloro-N-methyl-2-nitroaniline (6.63 g) obtained in Step 2 was mixed with iron powder (6.19 g) in a suspension of 2M ammonium chloride aqueous solution (55 mL), THF (110 mL), and methanol (110 mL) and stirred at 70 °C for 3 hours. The reaction mixture was concentrated under reduced pressure, and the resulting mixture was diluted with water and ethyl acetate, and then the insoluble matter was filtered off. The organic layer was separated and washed with saturated sodium chloride solution, followed by drying with sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography (n-hexane:ethyl acetate) to give 4-bromo-3,5-dichloro-N1-methylphenyl-1,2-diamine (5.25 g) as a yellow solid. MS: m / z = 268.9, 270.9 (M+H, ESI+).

[0183] The compounds in the table below were synthesized according to the method described above.

[0184]

[0185] Step 4: Concentrated hydrochloric acid (0.30 mL) was added to the suspension of 4-bromo-3,5-dichloro-N1-methylphenyl-1,2-diamine (5.25 g) prepared in Step 3 in 1,1,1-triethoxypropane (30 mL), and then stirred overnight at room temperature. The solvent was removed by vacuum distillation, and the residue was purified by column chromatography (n-hexane:ethyl acetate) to give 5-bromo-4,6-dichloro-1-methyl-1H-benzi[d]imidazole, BB1 (5.22 g). MS: m / z = 278.9, 280.9 (M+H, ESI+).

[0186] The compounds in the table below were synthesized according to the method described above.

[0187]

[0188] Synthesis of 5-bromo-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazolium 371 Int Aii

[0189] T3P (18.33 g, 28.8 mmol) was added to a DMF (8.14 mL) solution of 375 Aii (3.51 g, 13.05 mmol) and 2-methoxyacetic acid (1.29 g, 14.34 mmol). After stirring at room temperature for 15 minutes, triethylamine (5.22 g, 51.62 mmol, 7.2 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 2 hours. The mixture was diluted with ethyl acetate, washed with aqueous NaHCO3 solution, water, and NaCl solution, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. Acetic acid was added to the residue, and the mixture was stirred at 50 °C for 2 hours. The mixture was diluted with ethyl acetate, washed with aqueous NaHCO3 solution, water, and NaCl solution, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give 371 Int Aii (2.4 g, yield 56.9%).

[0190] 1 H NMR (400 MHz, DMSO- d 6 ) δ: 8.20 (s, 1H), 8.12 (s, 1H), 4.75 (s, 2H), 3.90 (s, 3H), 3.32 (s, 3H).

[0191] Synthesis of 5-(8-bromoindoleazine-3-carbonyl)-2-((2,4-dimethoxybenzyl)amino)benzonitrile BB2

[0192] Step 1: Copper dibromide (37.6 g) was added to a solution of 5-acetyl-2-fluorobenzonitrile (25.0 g) in ethyl acetate (380 mL), and the mixture was stirred at 70 °C for 16 hours. Another batch of copper dibromide (37.6 g) was added to the reaction mixture, and the mixture was stirred at 70 °C for 2 hours. The reaction mixture was filtered through diatomaceous earth and then washed with saturated sodium bicarbonate solution and concentrated brine. The organic layer was dried over sodium sulfate and concentrated. Diisopropyl ether was added to the resulting residue, and the mixture was stirred at ambient temperature for 30 minutes. The precipitated solid was collected by filtration to give 5-(2-bromoacetyl)-2-fluorobenzonitrile (32.0 g). MS: m / z = 241.9, 243.9 (M+H, ESI+).

[0193] Step 2: Add 3-bromo-2-methylpyridine (30 mL) to a THF (130 mL) solution of 32.0 g of 5-(2-bromoacetyl)-2-fluorobenzonitrile (32.0 g) obtained in Step 1, and stir the mixture at 85 °C for 16 hours. Add n-heptane to the reaction mixture at ambient temperature and stir for 30 minutes. Filter and collect the precipitated solid to give 55.0 g of 3-bromo-l-(2-(3-cyano-4-fluorophenyl)-2-oxoethyl)-2-methylpyridine-l-onium bromide. MS: m / z = 332.9, 335.9 (M+H, ESI+).

[0194] Step 3: The mixture of DMF (41 mL) and dimethyl sulfate (50 mL) was stirred at 80 °C for 3 hours. After cooling the mixture to room temperature, it was added to a solution of 3-bromo-l-(2-(3-cyano-4-fluorophenyl)-2-oxoethyl)-2-methylpyridin-l-onium bromide (14.6 g) in DMF (44 mL) prepared in Step 2. After stirring at room temperature for 30 minutes, N,N-diisopropylethylamine (61 mL) was added to the reaction mixture, followed by stirring at room temperature for 1 hour. Water (230 mL) was added to the reaction mixture, and the precipitated solid was collected. The resulting solid was dried under vacuum overnight, and ethyl acetate was added to the solid, followed by stirring at room temperature for 30 minutes. After adding n-heptane to the solution, the precipitated solid was collected by filtration to give 5-(8-bromoindoleazine-3-carbonyl)-2-fluorobenzonitrile (9.69 g). MS: m / z = 342.8, 344.8 (M+H, ESI+).

[0195] Step 4: 2,4-Dimethoxybenzylamine (100 mL) was added to a solution of 5-(8-bromoindoleazine-3-carbonyl)-2-fluorobenzonitrile (9.69 g) obtained in Step 3, consisting of 60 mL of 1,4-dioxane and 10 mL of 1,2-dimethoxyethane. The mixture was stirred overnight at 115 °C. After cooling to room temperature, water (200 mL) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 3 hours, and the precipitated solid was collected. The solid was dried under vacuum at 60 °C overnight, and ethyl acetate was added to the solid. After stirring for 30 minutes, n-heptane was added to the suspension. The mixture was stirred at room temperature for 30 minutes, and the precipitated solid was collected to give 5-(8-bromoindoleazine-3-carbonyl)-2-((2,4-dimethoxybenzyl)amino)benzonitrile, BB2 (8.06 g). MS: m / z = 489.9, 491.9 (M+H, ESI+).

[0196] Synthesis of (3,4,5-trifluorophenyl)(9,10,12-trimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl) methyl ketone (Key Int 375)

[0197] Step 1: 4-Bromo-N-methyl-2-nitro-5-(trifluoromethyl)aniline, 375-Ai

[0198] NBS (8.89 g, 50.0 mmol) was added to a solution of N-methyl-2-nitro-5-(trifluoromethyl)aniline (10 g, 45.42 mmol) in 100 mL of dimethylacetamide. The mixture was stirred at 50 °C for 1 hour. The mixture was quenched with H₂O and extracted with ethyl acetate. The organic layer was washed with H₂O and concentrated brine. The concentrated residue was used directly. 1 H NMR (400 MHz, DMSO- d 6 ) δ: 8.41 (s, 1H), 8.38 (s, 1H), 7.33 (s, 1H), 3.02-2.99 (m, 3H).

[0199] Step 2: 4-Bromo-N1-methyl-5-(trifluoromethyl)benzene-1,2-diamine, 375-Aii

[0200] 375-Ai (40 g, 133.76 mmol), iron (37.35 g, 668.80 mmol), and NH4Cl (35.77 g, 668.80 mmol) were dissolved in water (1.4 mL), THF (6 mL), and methanol (6 mL). The solution was stirred at 60 °C for 2 hours. Insoluble precipitates were removed by filtration, followed by evaporation of the solvent under reduced pressure. After dilution with ethyl acetate, the mixture was washed with water and a saturated sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by column chromatography to give 375-Aii (32 g, 89% yield). C8H8BrF3N2 mass spectrometry calculated values: 267.98, 269.98; measured values: 266.95, 268.96 (MH). - ESI. 1 H NMR (400MHz, DMSO- d 6) δ: 6.86 (s, 1H), 6.58 (s, 1H), 5.44 (s, 2H), 5.13 (s, 1H), 2.75-2.73 (m, 3H).

[0201] Step 3: 5-Bromo-1,2-dimethyl-6-(trifluoromethyl)-1H-benzi[d]imidazole, 375-Aiii

[0202] Concentrated hydrochloric acid (393 μL, 10.7 mmol) was added to a solution of 375-Aii (29 g, 110 mmol), trimethyl orthoacetate (181 g, 1.51 mol, 192 mL), and acetic acid (6.47 g, 108 mmol, 6.17 mL). The mixture was stirred overnight at room temperature. The reaction was quenched with an aqueous solution of 5 M NaOH. The reaction mixture was diluted with ethyl acetate, washed with H₂O and concentrated brine, dried over Na₂SO₄, and evaporated. The residue was dissolved in ethyl acetate (40 mL) at 50 °C, and n-heptane (150 mL) was added. The mixture was slowly cooled to room temperature to give a precipitate. The precipitate was collected by filtration, washed further with n-heptane, and dried under vacuum at 60 °C to give 375-Aiii (28 g, 70% yield). 10 Calculated values ​​for H8BrF3N2 mass spectrometry: 291.98, 293.98; Measured values: 292.95, 294.96 (M+H) + ESI. 1 H NMR (400 MHz, DMSO- d 6 ) δ: 8.10 (s, 1H), 7.99 (s,1H), 3.82 (s, 3H), 2.58 (s, 3H).

[0203] Step 4: 5-Bromo-1,2-dimethyl-4-nitro-6-(trifluoromethyl)-1H-benzo[d]imidazole, 375-Aiv

[0204] To a mixture of 375-Aiii (28 g, 95.54 mmol) and H₂SO₄ (120 mL), KNO₃ (11.59 g, 114.64 mmol) was added at 0 °C. The mixture was heated to room temperature and stirred for 2 hours. The mixture was then carefully poured into crushed ice, and 30% NH₃ was added. Continue 2O until the reactants are neutral. Filter and collect the precipitate, wash with water, and dry under vacuum at 50 °C to give 375-Aiv (28.5 g, yield 96.8%). 1 HNMR (400 MHz, DMSO- d 6) δ: 8.43(s, 1H), 3.89(s, 3H), 2.63 (s, 3H).

[0205] Step 5: 5-Bromo-1,2-dimethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-4-amine, BB-INT 375-A

[0206] A solution of 375-Aiv (28.5 g, 84.3 mmol), iron (23.54 g, 421.5 mmol), and NH4Cl (22.55 g, 421.50 mmol) in water (2 mL) and ethanol (10 mL) was stirred at 70 °C for 30 minutes. The mixture was diluted with ethyl acetate (100 mL), filtered, and concentrated. Water and CHCl3 were added to the filtrate, the organic layer was separated, washed with concentrated brine, dried over Na2SO4, and evaporated. The residue was diluted with isopropyl ether, filtered, and the precipitate was collected to give BB-INT 375-A (21 g, yield 80.85%). 1 HNMR (400 MHz, DMSO- d 6 ) δ: 7.31(s, 1H), 5.72(s, 3H), 3.74 (s, 3H), 3.74 (s, 3H), 2.55 (s, 3H).

[0207] Step 6: (8-bromoindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 375-Bi

[0208] 3-Bromo-2-methylpyridine (91.8 g, 534 mmol) was added to a THF (250 mL) solution of 2-bromo-1-(3,4,5-trifluorophenyl)ethyl-1-one (45.0 g, 178 mmol). The reaction was heated to 80 °C under a N2 atmosphere and maintained for 16 hours. After cooling, n-heptane (500 mL) was added, the precipitate was collected by filtration, washed with n-heptane again, and dried under vacuum to give a pyridinium intermediate (57 g, yield 75.58%). 1 H NMR (400 MHz, DMSO- d 6 ) δ: 9.02-9.00 (m,1H), 8.97-8.96 (m, 1H), 8.12-8.09 (m, 2H), 8.06-8.03 (m, 1H), 6.45 (s, 2H), 2.80 (s, 3H).

[0209] A mixture of DMF (78.4 g, 1.07 mol) and dimethyl sulfate (135 g, 1.07 mol) was heated to 80 °C and maintained for 2 hours. After cooling, this solution was added to a DMF solution of pyridinium intermediate (57.0 g, 134 mmol), and the reaction was stirred at room temperature for 30 minutes. Then, diisopropylethylamine (139 g, 1.07 mol) was added, and the resulting suspension was stirred for 30 minutes. Water (2.42 g, 134 mmol) was added, the precipitate was collected by filtration, and washed with water. The solid was recrystallized from boiling ethyl acetate (200 mL) to give a yellow solid, 375-Bi (30.5 g, yield 64.2%). 15 Calculated values ​​for H7BrF3NO by mass spectrometry: 352.97, 354.96; Measured values: 354.0, 356.0 (M+H) + ESI. 1 H NMR (400 MHz, DMSO- d 6 ) δ:9.77-9.75 (m, 1H), 7.75-7.71 (m, 3H), 7.56-7.55 (m, 1H), 7.11-7.09 (m, 1H), 6.78-6.77 (m, 1H).

[0210] Step 7: (8-(4,4,5,5-tetramethyl-1,3,2-diaxopentabolane-2-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone, 375-Bii

[0211] A THF solution of 375-Bi (10 g, 28 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-diaxopentaborane) (8.61 g, 33.9 mmol), potassium acetate (5.54 g, 56.5 mmol), and 1,1'-bis(diphenylphosphine)ferrocene palladium dichloromethane dichloride complex (2.29 g, 2.82 mmol) in 10 mL was evacuated and refluxing with N2, then heated to reflux for 4 hours. The mixture was diluted with ethyl acetate and water, extracted once with ethyl acetate, the organic layer was washed with concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give 375-Bii (7.1 g, 65% yield).

[0212] 1 H NMR (400 MHz, DMSO- d 6) δ: 7.75-7.73 (m, 1H), 7.70-7.66 (m, 2H), 7.46-7.44 (m, 1H), 7.19-7.15 (m, 1H), 7.03-7.02 (m, 1H), 3.84(s, 4H), 1.00(s,6H).

[0213] Step 8: (8-(4-amino-1,2-dimethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone, Int 375A

[0214] A solution of BB-INT 375A (17 g, 55 mmol), 375-Bii (33.2 g, 82.8 mmol), SPhos Pd G3 (4.28 g, 5.48 mmol), and K3PO4 (17.5 g, 82.3 mmol) in water (80 mL) and THF (530 mL) was heated to 75 °C for 2 hours under vacuum and refluxing with N2. The mixture was diluted with ethyl acetate and water, extracted once with ethyl acetate, the organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (petroleum ether:ethyl acetate = 1:1) to give Int 375A (16.8 g, yield 89.5%). 25 H 16 F6N4O mass spectrometry calculated value: 502.12; measured value: 503.1 (M+H) + ESI. 1 H NMR (400 MHz, CDCl3- d ) δ: 9.89-9.87 (m, 1H), 7.94 (s,1H), 7.71-7.67 (m, 2H), 7.39-7.38 (m, 1H), 7.30-7.25 (m, 3H), 4.96 (s, 2H), 3.80 (s, 3H), 257 (s, 3H).

[0215] Step 9: (8-(4-amino-1,2-dimethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-iodoindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, BB-INT 375B

[0216] NIS (11.6 g, 51.7 mmol) and TFA (13.4 g, 117 mmol) were added to a THF (250 mL) solution of BB-INT 375A (23.6 g, 47.0 mmol). After stirring at room temperature for 30 minutes, the mixture was diluted with ethyl acetate, washed with aqueous NaHCO3 solution, water, and concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (petroleum ether:ethyl acetate = 1:1) to give BB-INT 375B (3.5 g, 50% yield). 25 H 15 F6IN4O mass spectrometry calculated value: 628.02, measured value: 629.0 (M+H) + ESI. 1 H NMR (400 MHz, DMSO- d 6 ) δ: 9.99-9.97 (m, 1H), 7.70-7.66 (m, 2H), 7.55 (s, 1H), 7.31-7.27 (m, 2H), 7.23-7.21 (m, 1H), 4.94(s, 2H), 3.79 (s, 3H), 2.56 (s, 3H).

[0217] Step 10: (E)-(8-(4-amino-1,2-dimethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-(2-ethoxyvinyl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, BB-INT 375C

[0218] A solution of BB-INT 375B (27.3 g, 43.5 mmol), (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-diaxoxopentane (34.4 g, 174 mmol), Pd(dppf)Cl2 (6.31 g, 8.69 mmol), and 137 mL of 2NNa2CO3 aqueous solution in 1,4-dioxane (1.11 L) was evacuated and refilled with N2, then heated to 95 °C and held for 2 hours. The mixture was diluted with ethyl acetate and water, extracted once with ethyl acetate, the organic layer was washed with concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (dichloromethane:methanol = 50:1) to give BB-INT 375C (19.4 g, yield 77.9%). 29 H 22 F6N4O2 mass spectrometry calculated value: 572.16, measured value: 573.1 (M+H) + ESI.1 H NMR (400 MHz, DMSO- d 6 ) δ: 9.89-9.87 (m, 1H), 7.70-7.66 (m, 2H), 7.40(s, 1H), 7.32 (s, 1H), 7.20-7.14 (m, 2H), 6.86-6.83 (d, J = 12.8 Hz, 1H),5.00 (s, 2H), 4.59-4.56 (d, J = 12.8 Hz, 1H), 3.34 (s, 3H), 3.01-2.99 (m,1H), 2.83-2.80 (m, 1H), 2.51 (s, 3H), 0.86-0.82 (m, 3H).

[0219] Step 11: (9,10-Dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone, BB-INT 375D

[0220] To a solution of BB-INT 375C (10.2 g, 17.8 mmol) in dichloromethane (190 mL), TFA (30.5 g, 267 mmol) and NaBH(OAc)3 (18.88 g, 89.08 mmol) were added at room temperature. The mixture was stirred at room temperature for 0.5 hours. The reaction mixture was diluted with dichloromethane and quenched with an aqueous solution of NaHCO3 at 0 °C. The organic layer was washed with concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (dichloromethane:methanol = 50:1) to give BB-INT 375D (4.8 g, 51% yield). 27 H 18 F6N4O mass spectrometry calculated value: 528.14; measured value: 529.1 (M+H) + ESI. 1 H NMR (400 MHz, DMSO- d 6) δ: 9.88-9.87 (m, 1H), 7.92 (s, 1H), 7.73-7.70(m, 2H), 7.28 (s, 1H), 7.18-7.17 (m, 1H), 7.10-7.08 (m, 1H), 4.41 (br, 1H),3.85 (s, 3H), 3.82-3.80 (m, 1H), 3.50-3.47 (m, 1H), 2.97-2.91 (m, 1H), 2.61(s, 3H), 2.33-2.63 (m, 1H).

[0221] Step 12: (3,4,5-Trifluorophenyl)(9,10,12-Trimethyl-7-(trifluoromethyl)-9,12,13,14-Tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl) methyl ketone, 375 KeyInt 1

[0222] A solution of BB-INT 375D (8.0 g, 15 mmol), 37% formaldehyde aqueous solution (6.14 g, 75.7 mmol), and 0.3 M Zn(BH3CN)2 in MeOH solution (147 mL, 45.4 mmol, prepared from NaBH3CN (90.8 mmol) and ZnCl2 (45.4 mmol)) in THF (86 mL) was stirred at room temperature for 0.5 hours. The resulting suspension was filtered, washed with ethyl acetate, and the filtrate was washed with NaHCO3 aqueous solution, H2O, and concentrated brine, then dried over Na2SO4 and evaporated. The crude product was purified by column chromatography (PE / EA = 1 / 1) to give 375 Key Int 1 (1.16 g, yield 70.6%). 28 H 20 F6N4O mass spectrometry calculated value: 542.15; measured value: 543.1 (M+H) + ESI. 1 H NMR (400 MHz, DMSO- d 6 ) δ: 9.84-9.83 (m, 1H), 8.04(s, 1H), 7.73-7.72 (m, 2H), 7.26 (s, 1H), 7.17-7.15 (m, 1H), 7.07-7.05 (m,1H), 3.88 (s, 3H), 3.03 (s, 3H), 2.82-2.80 (m, 1H), 2.63 (s, 3H), 2.10-2.04 (m, 1H).

[0223] The compounds shown in the table below were synthesized using a route similar to that of Key Int 1 in Example 375.

[0224]

[0225] Synthesis of (E)-4-((4-cyanobicyclo[2.2.2]octane-1-yl)amino)-N-(2,6-difluoro-4-(9,10,14-trimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide, Example 433

[0226] Step 1: 3-Chloro-N-methyl-2-nitro-5-(trifluoromethyl)aniline, 1-ia

[0227] Methylamine (7.65 g, 246.36 mmol) was added to a THF (20 mL) solution of 1-chloro-3-fluoro-2-nitro-5-(trifluoromethyl)benzene (20 g, 82.12 mmol), and the mixture was stirred overnight at room temperature. The mixture was concentrated under vacuum to obtain a crude product, which was used directly in the next step without purification.

[0228] Step 2: 4-Bromo-3-chloro-N-methyl-2-nitro-5-(trifluoromethyl)aniline, 433-1

[0229] NBS (13.98 g, 78.56 mmol) was added to a DMA (100 mL) solution of 1-ia (20 g, 78.56 mmol), and the mixture was stirred at 45 °C for 5 hours. The mixture was diluted with EA, washed with concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was used directly in the next step without purification.

[0230] Step 3: 4-Bromo-3-chloro-N1-methyl-5-(trifluoromethyl)phenyl-1,2-diamine, 433-2

[0231] Fe (12.56 g, 224.89 mmol) and NH4Cl (12.03 g, 224.89 mmol) were added to a solution of 433-1 (15 g, 44.98 mmol) in 20 mL of EtOH and 5 mL of H2O. The mixture was stirred at 70 °C for 1 hour under a nitrogen atmosphere. The mixture was filtered, and the residue was diluted with EA and water, extracted three times with EA, and the organic layer was washed with concentrated brine, dried over Na2SO4 and evaporated to obtain a yellow solid crude product.

[0232] C8H7N2ClBrF3 mass spectrometry calculated value: 301.94, measured value: 303.51 (M+H) + ESI.

[0233] Step 4: 5-Bromo-4-chloro-1,2-dimethyl-6-(trifluoromethyl)-1H-benzo[d]imidazole, 433-3

[0234] HCl (1.44 g, 39.54 mmol) was added to a solution of 433-2 (6 g, 19.77 mmol) in trimethyl orthoacetate (23.75 g, 197.69 mmol) at room temperature. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with DCM and quenched with an aqueous solution of NaHCO3 at 0 °C. The organic layer was washed with concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give 433-3 (4.3 g, 66.41% yield).

[0235] C 10 Calculated value of H7BrN2ClF3 by mass spectrometry: 327.53, Measured value: 329.00 (M+H) + ESI.

[0236] Step 5: (8-(4-chloro-1,2-dimethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone, 433-4

[0237] Int 10 (2 g, 6.11 mmol), Pd(PPh3)4 (1.41 g, 1.22 mmol), and Na2CO3 (1.29 g, 12.21 mmol) were added to a solution of 433-3 (3.67 g, 9.16 mmol) in 10 mL of water and 40 mL of 1,4-dioxane. The mixture was stirred overnight at 85 °C under a nitrogen atmosphere. The resulting suspension was filtered, washed with EA, and the filtrate was washed with H2O and concentrated brine. The solution was then dried over Na2SO4 and evaporated. The crude product was purified by column chromatography to give 433-4 (1.4 g, yield 43.93%).

[0238] C 25 H 14 Calculated value of N3OF6Cl by mass spectrometry: 521.84, Measured value: 522.17 (M+H) + ESI.

[0239] Step 6: (8-(4-chloro-1,2-dimethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 433-5

[0240] 433-4 (500 mg, 958.15 μmol) was dissolved in 1,4-dioxane (2 mL), and the mixture was stirred at 0 °C for 5 minutes. Then, H₂SO₄ (10 mL) was added to the mixture, and stirring was continued for 5 minutes. KNO₃ (87.18 mg, 862.33 μmol) was added to the mixture in two portions, and the mixture was stirred at 0 °C for 1 hour. The mixture was poured into ice water, stirred for 5 minutes, filtered, and the solid was collected and ground with EA to obtain a yellow, solid crude product.

[0241] C 25 H 13 Calculated value of N4O3F6Cl by mass spectrometry: 566.84, Measured value: 567.16 (M+H) + ESI.

[0242] Step 7: (E)-(8-(4-(2-ethoxyvinyl)-1,2-dimethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone with (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-diaxoxopentane (1:1), 433-6

[0243] A solution of 433-5 (800 mg, 1.41 mmol), 2-[(E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-diaxoxopentane (419.31 mg, 2.12 mmol), XPhos Pd G3 (119.46 mg, 141.13 μmol), and K2CO3 (389.53 mg, 2.82 mmol) in 1,4-dioxane (1 mL) and water (0.2 mL) was stirred at 90 °C for 16 hours under N2 atmosphere. The mixture was diluted with EA and water, extracted once with EA, the organic layer was washed with concentrated brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by reverse-phase column chromatography (C18 column) to give 433-6 (160 mg, 18.82%).

[0244] Step 8: (E)-(1-amino-8-(4-(2-ethoxyvinyl)-1,2-dimethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 433-7

[0245] A solution of 433-6 (20 mg, 33.20 μmol), Fe (9.27 mg, 165.98 μmol), NH4Cl (8.88 mg, 165.98 μmol) in EtOH (1 mL) and H2O (0.2 mL) was stirred at 70 °C for 1 hour under a nitrogen atmosphere. The mixture was filtered, and the residue was washed three times with EA, followed by extraction three times with EA into the aqueous phase. The organic phases were combined and washed with concentrated brine, dried over Na2SO4, and concentrated under reduced pressure to give a crude product as a yellow solid.

[0246] C 29 H 22 N4F6O2 mass spectrometry calculated value: 572.50, measured value: 573.24 (M+H) + ESI.

[0247] Step 9: (9,10-Dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone, 433-8

[0248] TFA (0.5 mL) was added dropwise to a solution of 433-7 (30 mg, 52.40 μmol) in DCM (1 mL), and stirred at room temperature for 4 hours. The mixture was diluted with DCM and H2O. The organic phases were combined and washed with concentrated brine, dried over Na2SO4, and concentrated under reduced pressure to give a brown, oily crude product.

[0249] C 27 H 18 N4F6O mass spectrometry calculated value: 528.45, measured value: 529.23 (M+H) + ESI.

[0250] Step 10: (3,4,5-trifluorophenyl)(9,10,14-trimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone, 433-9

[0251] A solution of NaBH3CN (4.76 mg, 75.69 μmol) and ZnCl2 (5.16 mg, 37.85 μmol) in MeOH (0.5 mL) was added dropwise to a solution of 433-8 (20 mg, 37.85 μmol) and formaldehyde (4.55 mg, 151.39 μmol) in THF (1 mL). The mixture was stirred overnight at room temperature under N2 atmosphere. The mixture was diluted with EA and H2O, the organic phase was washed with concentrated brine and dried over Na2SO4, and concentrated under reduced pressure to give an orange oily crude product.

[0252] C 28 H 20 N4F6O mass spectrometry calculated value: 558.47, measured value: 543.25 (M-CH3) + ESI.

[0253] Step 11: (4-azido-3,5-difluorophenyl)(9,10,14-trimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone, 433-10

[0254] Under a nitrogen atmosphere, a DMA solution (1 mL) of 433-9 (80 mg, 147.47 μmol) and NaN3 (38.35 mg, 589.89 μmol) was stirred at 70 °C for 3 hours. The mixture was diluted with EA and water, extracted once with EA, the organic layer was washed with concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was used directly in the next step without purification.

[0255] Step 12: (4-Amino-3,5-Difluorophenyl)(9,10,14-Trimethyl-7-(trifluoromethyl)-9,12,13,14-Tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone, 433-11

[0256] A solution of 433-10 (80 mg, 141.47 μmol) and Pd / C (10 mg) in EA (10 mL) was stirred at 70 °C for 3 hours under H2 atmosphere. The mixture was diluted with EA and water, extracted once with EA, the organic layer was washed with concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was used directly in the next step without purification.

[0257] C 28 H 22N5F5O mass spectrometry calculated value: 539.50, measured value: 540.28 (M+H) + ESI.

[0258] Step 13: (E)-4-chloro-N-(2,6-difluoro-4-(9,10,14-trimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide, 433-12

[0259] (E)-4-chlorobut-2-enoic acid (26.81 mg, 222.43 μmol) was added to a 2 mL solution of 433-11 (80 mg, 148.29 μmol) in DMF. T3p (235.91 mg, 741.43 μmol) was then added to the reaction mixture, and the mixture was stirred at room temperature for 2 hours. The mixture was diluted with EA and water, extracted once with EA, the organic layer was washed with concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was used directly in the next step without purification.

[0260] C 32 H 25 Calculated value of N5F5O2Cl by mass spectrometry: 642.02, Measured value: 642.40 (M+H) + ESI.

[0261] Step 14: (E)-4-((4-cyanobicyclo[2.2.2]octane-1-yl)amino)-N-(2,6-difluoro-4-(9,10,14-trimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide, Example 433

[0262] 4-Aminobicyclo[2.2.2]octane-1-carboxylonitrile (29.08 mg, 155.76 μmol) was added to a 2 mL solution of DMF (50 mg, 77.88 μmol) in 433-12. The mixture was stirred at room temperature for 24 hours under N2 atmosphere. The mixture was diluted with EA and water, extracted once with EA, the organic layer was washed with concentrated brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by reverse-phase column (C18 column) to give the product Example 433 (6.80 mg, yield 11.55%) as a yellow solid.

[0263] C 41 H 38Calculated value for N7F5O2 mass spectrometry: 755.78, Measured value: 756.40 (M+H) + ESI.

[0264] 1 H NMR (400 MHz, DMSO- d 6 ) δ: 9.982-9.935 (m, 1H), 7.973 (s, 1H), 7.566-7.546 (m, 2H), 7.198-7.163 (m, 1H), 7.043-7.025 (m, 2H), 6.358-6.320(m, 1H), 7.07-7.05 (m, 1H), 6.91-6.86 (m, 1H), 3.854 (s, 1H), 3.593-3.553 (m,2H), 3.288-3.280 (m, 3H), 2.951-2.885 (s, 1H), 2.722-2.620 (m, 5H), 1.945-1.906 (m, 6H), 1.595-1.504 (m, 6H).

[0265] Synthesis of Example 564

[0266] Step 1: (8-(4-chloro-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 564-2

[0267] [8-[4-chloro-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)benzimidazol-5-yl]indolazin-3-yl]-(3,4,5-trifluorophenyl)methyl ketone (1.5 g, 2.72 mmol) was slowly added to 25 mL of H₂SO₄. KNO₃ (274.80 mg, 2.72 mmol) was added to the solution, and the mixture was stirred at 0 °C for 1 hour. The mixture was quenched with ice water and extracted with EA. The combined organic layers were washed with aqueous NaHCO₃ solution, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by reversed-phase column chromatography (C18 column) to give (8-(4-chloro-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 564-2 (930 mg, yield 57.33%).

[0268] C 26 H 15 Calculated value of N4ClO4F6 by mass spectrometry: 596.07, Measured value: 597.15 (M+H) + ESI.

[0269] Step 2: (8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 564-3

[0270] A mixture of (8-(4-chloro-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (2.3 g, 3.85 mmol), K₂CO₃ (1.07 g, 7.71 mmol), tert-butyldimethyl-[2-(4,4,5,5-tetramethyl-1,3,2-diaxopentaborane-2-yl)allyloxy]silane (6.32 g, 21.19 mmol), and PdCl₂(dcypf) (582.43 mg, 770.69 μmol) in 1,4-dioxane (92 mL) and water (7.7 mL) was stirred overnight at 100 °C under N₂ atmosphere. The mixture was diluted with EA and water and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography or slurryed with acetonitrile to give (8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 564-3 (1.4 g, yield 42.14%).

[0271] C 35 H 34 Calculated value of N4O5F6Si mass spectrometry: 732.22, Measured value: 733.26 (M+H) + ESI.

[0272] Step 3: (1-Amino-8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzi[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 564-4

[0273] Boronic acid (838 mg, 9.35 mmol) was added to a DMF (13 mL) solution of (8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (1.37 g, 1.87 mmol). After stirring for 10 min, 4-(4-pyridyl)pyridine (59 mg, 374 μmol) was added to the solution at 0 °C. The mixture was stirred at room temperature for 1 h. The mixture was quenched with ice water and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The crude product was used directly for the next step without purification.

[0274] C 35 H 36 Calculated value of N4O3F6Si mass spectrometry: 702.25, Measured value: 703.60 (M+H) + ESI.

[0275] Step 4: (1-Amino-8-(4-(3-hydroxypropyl-1-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzi[d]imidazol-5-yl)indolazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 564-5

[0276] TBAF (967.33 mg, 3.70 mmol) (1 M THF solution) was added to a THF (15 mL) solution of (1-amino-8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzis[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone (1.3 g, 1.85 mmol). The mixture was stirred at room temperature for 2 hours. The mixture was quenched with ice water and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by reverse-phase column (C18 column) to give (1-amino-8-(4-(3-hydroxypropyl-1-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 564-5 (0.96 g, yield 88.36%).

[0277] C 29 H 22 Calculated value of N4O3F6 by mass spectrometry: 588.16, Measured value: 589.12 (M+H)+ ESI.

[0278] Step 5: (10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'': 3',4']benzo[1',2': 5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone, 564-6

[0279] Under a nitrogen atmosphere, DDQ (289.30 mg, 1.27 mmol) was added to a solution of PPh3 (334.26 mg, 1.27 mmol) in dichloromethane (15 mL). Then, (1-amino-8-(4-(3-hydroxypropyl-1-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone (500 mg, 849.62 μmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. The mixture was then concentrated under reduced pressure to obtain the residue. The residue was purified by reverse-phase column (C18 column) to give (10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone, 564-6 (470 mg, yield 96.97%).

[0280] C 29 H 20 Calculated value of N4O2F6 by mass spectrometry: 570.15, Measured value: 571.09 (M+H) + ESI.

[0281] Step 6: 10-(methoxymethyl)-9-methyl-12-methylene-2-(3,4,5-trifluorobenzoyl)-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester, 564-7

[0282] (Boc)₂O (1.08 g, 4.94 mmol) was added to a MeOH (15 mL) solution of (10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (470 mg, 823.86 μmol). The mixture was stirred at 45 °C for 3 hours, and then concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give 10-(methoxymethyl)-9-methyl-12-methylene-2-(3,4,5-trifluorobenzoyl)-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester, 564-7 (460 mg, yield 83.26%).

[0283] C 34 H 28 Calculated value of N4O4F6 by mass spectrometry: 670.20, Measured value: 671.12 (M+H) + ESI.

[0284] Step 7: 2-(4-azido-3,5-difluorobenzoyl)-10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester, 564-8

[0285] Under a nitrogen atmosphere, NaN3 (15.12 mg, 232.63 μmol) was added to a DMA (2 mL) solution of 10-(methoxymethyl)-9-methyl-12-methylene-2-(3,4,5-trifluorobenzoyl)-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazine-14(9H)-carboxylic acid tert-butyl ester (120 mg, 178.94 μmol). The mixture was stirred at 80 °C for 2 hours, quenched with ice water, and extracted with EA. The combined organic layers were washed with aqueous NaHCO3 solution, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The crude product was used directly in the next step without purification.

[0286] C 34 H 28Calculated value for N7O4F5 by mass spectrometry: 693.21, Measured value: 694.21 (M+H) + ESI.

[0287] Step 8: 2-(4-amino-3,5-difluorobenzoyl)-10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester, 564-9

[0288] Under a H2 atmosphere, Lindlar catalyst (133.00 mg, 644.05 μmol) was added to a methanol (6 mL) solution of 2-(4-azido-3,5-difluorobenzoyl)-10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazine-14(9H)-carboxylic acid tert-butyl ester (380 mg, 547.85 μmol). The mixture was stirred at 80 °C for 2 hours, diluted with methanol, filtered, and concentrated under reduced pressure to obtain the residue. The crude product was used directly for the next step without purification.

[0289] C 34 H 30 Calculated value for N5O4F5 by mass spectrometry: 667.22, Measured value: 668.10 (M+H) + ESI.

[0290] Step 9: (E)-2-(4-(4-chlorobut-2-enamido)-3,5-difluorobenzoyl)-10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester, 564-10

[0291] Under a nitrogen atmosphere, Et3N (356 mg, 3.52 mmol) and T3P (2.24 g, 3.52 mmol, 50% purity) were added to an EA (8 mL) solution of 2-(4-amino-3,5-difluorobenzoyl)-10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazine-14(9H)-carboxylic acid tert-butyl ester (470 mg, 704 μmol). The mixture was stirred at room temperature for 1 hour, diluted with EA and water, and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give (E)-2-(4-(4-chlorobut-2-enamido)-3,5-difluorobenzoyl)-10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester, 564-10 (300 mg, yield 55.35%).

[0292] C 38 H 33 Calculated value of N5O5F5Cl by mass spectrometry: 769.21, Measured value: 770.15 (M+H) + ESI.

[0293] Step 10: 2-(4-((E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)but-2-enamido)-3,5-difluorobenzoyl)-10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]inzine-14(9H)-carboxylic acid tert-butyl ester, 564-11

[0294] A mixture of KI (60.35 mg, 363.57 μmol), K3PO4 (308.69 mg, 1.45 mmol), 4-aminocyclohexaneformonitrile (99.33 mg, 799.85 μmol), and (E)-2-(4-(4-chlorobut-2-enamido)-3,5-difluorobenzoyl)-10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester (280 mg, 363.57 μmol) was stirred at 30 °C for 20 hours. The mixture was diluted with EA and water, and then extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The crude product was used directly in the next step without purification.

[0295] C 45 H 44 Calculated value for N7O5F5 mass spectrometry: 857.33, Measured value: 858.30 (M+H) + ESI.

[0296] Step 11: (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide, Example 564

[0297] TFA (1 mL) was added to a solution of 2-(4-((E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)but-2-enamido)-3,5-difluorobenzoyl)-10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazine-14(9H)-carboxylic acid tert-butyl ester (300 mg, 349.71 μmol) in DCM (5 mL). The mixture was stirred at 20 °C for 6 hours, then the pH was adjusted to 7–8 with aqueous NaHCO3 solution. The mixture was diluted with DCM and water, and extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The crude product was used directly in the next step without purification.

[0298] C 40 H 36Calculated value for N7O3F5 by mass spectrometry: 757.28, Measured value: 758.30 (M+H) + ESI.

[0299] Step 12: (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide, Examples 564 P1 and 564 P2

[0300] (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide (Example 564,300) (mg) was separated by supercritical fluid chromatography to obtain (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide (Example 564) P1, 108 mg) and (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide (Example 564 P2, 119 mg).

[0301] Preparative separation method: Instrument: Waters 150 preparative supercritical fluid chromatograph (SFC-26)

[0302] Column: ChiralPak IC, 250×30 mm ID, 10 µm; Mobile phase: A = CO2, B = ethanol (containing 0.1% NH3H2O); Gradient: B 50%; Flow rate: 120 mL / min; Back pressure: 100 bar; Column temperature: 38℃; Wavelength: 220 nm

[0303] Example 564 P1:

[0304] C 40 H 36 Calculated value for N7O3F5 by mass spectrometry: 757.28, Measured value: 758.70 (M+H) + ESI.

[0305] 1 H NMR (400 MHz, DMSO- d 6 ) δ: 10.001-9.99 (m, 1H), 9.84-9.82 (m, 1H), 8.17 (s, 1H), 7.56-7.52 (m, 2H), 7.12-7.11 (m, 1H), 7.09-7.06 (m, 1H), 7.03-7.01 (m, 1H), 6.89-6.85 (m, 1H), 6.36-6.32 (m, 1H), 5.24-5.23 (m, 1H), 4.77-4.74 (m, 2H), 4.36-4.33 (m, 1H), 3.95 (s, 3H), 3.72-3.71 (m, 1H), 3.56-3.53(m, 1H), 2.66-2.62 (m, 1H), 2.44-2.42 (m, 1H), 2.04-1.99 (m, 2H), 1.91-1.87(m, 2H), 1.52-1.49 (m, 2H), 1.12-1.09 (m, 2H).

[0306] Example 564 P2:

[0307] C 40 H 36 Calculated value for N7O3F5 by mass spectrometry: 757.28, Measured value: 758.42 (M+H) + ESI.

[0308] 1 H NMR (400 MHz, DMSO- d 6) δ: 10.003-9.99 (m, 1H), 9.84-9.83 (m, 1H), 8.17 (s, 1H), 7.55-7.53 (m, 2H), 7.12-7.09 (m, 1H), 7.08-7.06 (m, 1H), 7.03-7.01 (m, 1H), 6.89-6.86 (m, 1H), 6.36-6.32 (m, 1H), 5.24-5.23 (m, 1H), 4.77-4.74 (m, 2H), 4.36-4.33 (m, 1H), 3.95 (s, 3H), 3.74-3.72 (m, 1H), 3.56-3.53(m, 1H), 2.66-2.62 (m, 1H), 2.45-2.42 (m, 1H), 2.04-1.99 (m, 2H), 1.91-1.87(m, 2H), 1.52-1.50 (m, 2H), 1.12-1.09 (m, 2H).

[0309] Example 804 - Synthesis of ISO 1

[0310] (E)-4-(tert-butyl(methyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazono[7,8,9-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide,

[0311] Step 1: (8-(4-amino-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 445-8

[0312] A mixture of 445-7 (8.8 g, 26.03 mmol), [8-(4,4,5,5-tetramethyl-1,3,2-diaxopentaborane-2-yl)indolinazin-3-yl]-(3,4,5-trifluorophenyl)methyl ketone (13.57 g, 33.83 mmol), tripotassium phosphate (16.57 g, 78.08 mmol), and SPhox G3 Pd (2.03 g, 2.60 mmol) in 1,4-dioxane (200 mL) and water (40 mL) was stirred at 80 °C for 6 hours under a nitrogen atmosphere. The mixture was quenched with an aqueous solution of NH4Cl. The mixture was diluted with EA and water and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give 445-8 (11.2 g, 80.82%).

[0313] C 26 H 18 Calculated value of F6O2N4 by mass spectrometry: 532.13, measured value: 533.24 (M+H) + ESI.

[0314] Step 2: (8-(4-amino-2-(oxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-iodoindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 804-1

[0315] A mixture of 445-8 (10 g, 18.78 mmol), THF (239.23 mL), TFA (5.35 g, 46.95 mmol, 3.59 mL), and NIS (3.93 g, 17.47 mmol) was stirred at room temperature for 5 hours. The mixture was quenched with saturated NaHCO3 solution. The mixture was diluted with EA and water and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (DCM:MeOH = 20:1) to give 804-1 (10.6 g, 85.73% yield).

[0316] C 26 H 17 N4O2F6I mass spectrometry calculated value: 658.03, measured value: 659.06 (M+H) + ESI.

[0317] Step 3: (8-(4-amino-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-(4,4,5,5-tetramethyl-1,3,2-diaxopentabolane-2-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 804-2

[0318] A solution of 804-1 (10.6 g, 16.10 mmol), 4,4,5,5-tetramethyl-1,3,2-dihexaoxopentane (12.36 g, 96.61 mmol, 14.05 mL), SPhos Pd G3 (1.01 g, 1.29 mmol), triethylamine (9.78 g, 96.61 mmol, 13.47 mL), and 1,4-dioxane (240 mL) was stirred at 95 °C for 2 hours under a nitrogen atmosphere. The mixture was diluted with EA and water and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (DCM:MeOH = 20:1) to give 804-2 (8.1 g, 76.41% yield).

[0319] C 32 H 29 Calculated value of N4O4F6B by mass spectrometry: 658.22, Measured value: 659.31 (M+H) + ESI.

[0320] Step 4: (8-(4-amino-2-(oxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-hydroxyindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 804-3

[0321] A solution of 804-2 (8.1 g, 12.30 mmol), THF (87.70 mL), NaOH (0.5 M, 49.21 mL), and H2O2 (2.09 g, 61.51 mmol) was stirred at room temperature for 1 hour. Sodium thiosulfate (1 M, 12.30 mL) was added and stirred for 10 minutes. The pH of the mixture was adjusted to 7 with dilute sulfuric acid. The mixture was diluted with EA and water and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (DCM:MeOH = 98:2) to give 804-3 (6 g, 88.93% yield).

[0322] C 26 H 18 Calculated value of N4O3F6 by mass spectrometry: 548.13, Measured value: 549.20 (M+H)+ ESI.

[0323] Step 5: (8-(4-amino-2-(oxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-(2-bromoethoxy)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 804-4

[0324] A solution of 804-3 (6 g, 10.94 mmol), K2CO3 (7.56 g, 54.7 mmol), 1,2-dibromoethane (16.44 g, 87.52 mmol, 7.54 mL), and DMF (100 mL) was stirred overnight at 50 °C. The mixture was diluted with EA and water, and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (DCM:MeOH = 98:2) to give 804-4 (5 g, yield 69.73%).

[0325] C 28 H 21 Calculated value of N4O3F6Br by mass spectrometry: 654.07, Measured value: 655.1 (M+H) + ESI.

[0326] Step 6: (10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazanono[7,8,9-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone, 804-5

[0327] A solution of 804-4 (5.4 g, 8.24 mmol), DMF (100 mL), K2CO3 (3.99 g, 28.84 mmol), NaI (1.24 g, 8.24 mmol), and KI (1.37 g, 8.24 mmol) was stirred at 90 °C for 6 hours. The mixture was diluted with EA and water and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (DCM:MeOH = 98:2) to give 804-5 (4 g, yield 84.51%).

[0328] C 28 H 20 Calculated value of N4O3F6 by mass spectrometry: 574.14, Measured value: 575.26 (M+H) + ESI.

[0329] Step 7: (10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazanono[7,8,9-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone, 804-6

[0330] 804-5 (4 g, 6.96 mmol), formaldehyde (2.09 g, 69.63 mmol), and trifluoroacetic acid (1.59 g, 13.93 mmol) were dissolved in THF (60 mL). A solution of sodium cyanoborohydride (875.10 mg, 13.93 mmol) and ZnCl2 (1.71 g, 12.53 mmol) in MeOH (15 mL) was added dropwise. The reaction was stirred at room temperature for 2 hours. After quenching with aqueous NaHCO3 solution, the mixture was diluted with EA and water and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (DCM:MeOH = 98:2) to give 804-6 (3.7 g, 90.30% yield).

[0331] C 29 H 22 N4O3F6 mass spectrometry calculated value: 588.16, measured value: 589.2 (M+H) + ESI.

[0332] Step 8: (4-azido-3,5-difluorophenyl)(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazanono[7,8,9-hi]indolazin-2-yl) methyl ketone, 804-7

[0333] A mixture of 804-6 (3.7 g, 6.29 mmol), DMF (60 mL), and NaN3 (531.35 mg, 8.17 mmol) was stirred at 80 °C for 2 hours under a nitrogen atmosphere. The mixture was diluted with EA and water, and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain residue 804-7. The residue was used directly in the next step without purification.

[0334] C 29 H 22 Calculated value for N7O3F5 by mass spectrometry: 611.17, Measured value: 612.2 (M+H) + ESI.

[0335] Step 9: (4-Amino-3,5-Difluorophenyl)(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazanono[7,8,9-hi]indolazin-2-yl) methyl ketone, 804-8-ISO 1

[0336] A mixture of 804-7 (3.8 g, 6.21 mmol), MeOH (50 mL), and Pd / C (377.36 mg, 3.11 mmol) was stirred at room temperature for 2 hours under a H2 atmosphere. The mixture was filtered through diatomaceous earth and washed with DCM. The organic layer was concentrated under reduced pressure to obtain the residue. The residue was purified by chiral column chromatography to give 804-8-ISO 1 800 mg and 804-8-ISO 2 810 mg.

[0337] Preparation and separation methods: Column: CHIRALPAK IB Column dimensions: 0.46cm × 25cm 5µm Mobile phase: A: 0.01M CH3COONH4 B: ACN B: 0min(5%)-25min(95%)-25.1min(5%)-30min(5%) Flow rate: 1 mL / min Wavelength: UV 254 nm Temperature: 25℃ HPLC equipment: Shimadzu LC-20 C 29 H 24 Calculated value of N5O3F5 by mass spectrometry: 585.18, Measured value: 586.2 (M+H) + ESI.

[0338] Step 10: (E)-4-chloro-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazanono[7,8,9-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide, 804-9-ISO 1

[0339] 804-8-ISO 1 (50 mg, 85.39 μmol) and (E)-4-chlorobutyric acid (12.35 mg, 102.47 μmol) were dissolved in EA (2 mL). After cooling to 0 °C, TEA (86.41 mg, 853.94 μmol, 119.10 μL) and T4P (307.64 mg, 853.94 μmol) were added. The reaction was stirred for 2 hours. The mixture was diluted with EA and water and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give 804-9-ISO 1 (56 mg, 95.31% yield).

[0340] C 33 H 27 Calculated value of N5O4F5Cl by mass spectrometry: 687.17, Measured value: 688.2 (M+H) + ESI.

[0341] Step 11: (E)-4-(tert-butyl(methyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazanono[7,8,9-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide, Example 804 - ISO 1

[0342] A mixture of 804-9-ISO 1 (56 mg, 81.39 μmol), DMF (5 mL), N-tert-butylmethylamine (21.28 mg, 244.17 μmol), KI (13.51 mg, 81.39 μmol), and K3PO4 (34.55 mg, 162.78 μmol) was stirred overnight at room temperature. The mixture was diluted with EA and water and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give Example 804-ISO 1 (12 mg, yield 19.96%).

[0343] C 38 H 39 Calculated value for N6O4F5 by mass spectrometry: 738.74, Measured value: 739.43 (M+H) + ESI.

[0344] 1 H NMR (400 MHz, DMSO- d 6) δ: 9.84-9.82 (m, 1H), 7.97 (s, 1H), 7.51-7.49 (m, 2H), 7.20-7.12 (m, 3H), 6.84-6.77 (m, 1H), 6.34-6.30 (m, 1H), 4.75(s, 2H), 3.95-3.94 (m, 1H), 3.92 (s, 3H), 3.75-3.72 (m, 1H), 3.66-3.60 (m,1H), 3.35 (s, 3H), 3.18-3.16 (m, 2H), 3.13-3.08 (m, 1H), 2.06 (s, 3H), 1.01(s, 9H).

[0345] Example 804 - Synthesis of ISO 2,(E)-4-(tert-butyl(methyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazono[7,8,9-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide

[0346] Step 1: (E)-4-chloro-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazanono[7,8,9-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide, 804-9-ISO 2

[0347] 804-8-ISO 2 (60 mg, 102.47 μmol) and (E)-4-chlorobutyric acid (14.82 mg, 122.97 μmol) were dissolved in EA (3.86 mL). After cooling to 0 °C, TEA (103.69 mg, 1.02 mmol, 142.92 μL) and T4P (369.17 mg, 1.02 mmol) were added. The reaction was stirred for 2 hours. The mixture was diluted with EA and water and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give 804-9-ISO 2 (58 mg, 82.26% yield).

[0348] C 33 H 27Calculated value of N5O4F5Cl by mass spectrometry: 687.17, Measured value: 688.2 (M+H) + ESI.

[0349] Step 2: (E)-4-(tert-butyl(methyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazanono[7,8,9-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide, Example 804-ISO 2

[0350] A mixture of 804-9-ISO 2 (58 mg, 84.30 μmol), DMF (5 mL), N-tert-butylmethylamine (22.04 mg, 252.89 μmol), KI (13.99 mg, 84.30 μmol), and K3PO4 (35.79 mg, 168.59 μmol) was stirred overnight at room temperature. The mixture was diluted with EA and water and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give Example 804-ISO 2 (12 mg, yield 19.96%).

[0351] C 38 H 39 Calculated value for N6O4F5 by mass spectrometry: 738.74, Measured value: 739.30 (M+H) + ESI.

[0352] 1 H NMR (400 MHz, DMSO- d 6 ) δ: 10.00 (s, 1H), 9.88-9.87 (m, 1H), 8.02(s, 1H), 7.56-7.54 (m, 2H), 7.22-7.13 (m, 3H), 6.84-6.77 (m, 1H), 6.38-6.34(m, 1H), 4.78 (s, 2H), 4.00-3.98 (m, 1H), 3.93 (s, 3H), 3.80-3.74 (m, 1H), 3.69-3.63 (m, 1H), 3.38 (s, 3H), 3.19-3.11 (m, 3H), 2.16 (s, 3H), 1.01 (s, 9H).

[0353] Synthesis of Example 805

[0354] ( E )-4-(((4-cyano-2-oxabicyclo[2.1.1]hexane-1-yl)methyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazono[7,8,9-hi]indoleazine-2-carbonyl)phenyl)but-2-eneamide

[0355] Will( E )-4-chloro-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazono[7,8,9-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide (804-9-ISO 2) (31 mg, 45 μmol), dimethyl sulfoxide (0.450 mL) with 1-(aminomethyl)-2-oxabicyclo[2.1.1]hexane-4-carboxynitrile CAS: 2247107-84-0 (13 mg, 90 μmol), KI (11 mg, 68 μmol) and DIPEA (35 mg, 47 µL, 270) A mixture of μmol was stirred overnight at 45°C for 16 hours. The crude reaction mixture was purified by C18 column chromatography to obtain ( E )-4-(((4-cyano-2-oxabicyclo[2.1.1]hexane-1-yl)methyl)amino)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazono[7,8,9-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide (Example 805) (32.9 mg, 91% yield).

[0356] C 40 H 36 Calculated value for F5N7O5 by mass spectrometry: 805.79, Measured value: 806.7 (M+H) + ESI.

[0357] 1H NMR (400 MHz, CDCl3) δ: 9.98-9.96 (m, 1H), 7.68 (s, 1H), 7.44-7.42(m, 2H), 7.17-7.15 (m, 1H), 7.09-6.98 (m, 3H), 6.25-6.21 (m, 1H), 5.30 (s,2H), 4.81 (s, 2H), 4.06-3.81 (s, 9H), 3.51 (m, 1H), 3.45 (s, 3H), 3.20-3.13(m, 1H), 2.61 (s, 2H), 2.22 (m, 1H), 2.02 (m, 1H), 1.27 (4H, bs)

[0358] Synthesis of Example 806

[0359] ( E )-4-((3-Cyclopropyloxetane-3-yl)amino)- N -(2,6-Difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazono[7,8,9- hi Indoleazine-2-carbonyl)phenyl)but-2-enamide,

[0360] ( E )-4-((3-Cyclopropyloxetane-3-yl)amino)- N -(2,6-Difluoro-4-(10-(methoxymethyl)-9,12-dimethyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':5,6][1,4]oxazono[7,8,9- hi Indoleazine-2-carbonyl)phenyl)but-2-enamide (Example 806)

[0361] To a solution of 804-9-Iso 2 (35.61 μmol) in DMSO (316.03 μL), KI (8.87 mg, 53.41 μmol, 2.84 μL) was added, followed by 3-cyclopropyloxacyclobut-3-amine hydrochloride (806-1, CAS: 2127832-65-7) (6.04 mg, 40.40 μmol), and finally DIPEA (27.61 mg, 213.65 μmol, 37.21 μL). The reaction mixture was heated to 45 °C and stirred overnight (16 h). The reaction mixture was cooled to room temperature, and saturated NaHCO3 aqueous solution (3 mL) was added. The mixture was extracted with EtOAc (3 x 3 mL), the combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated to give an oily crude product. The crude product was purified by preparative high-performance liquid chromatography (Agilent InfinityLab Poroshell 1204 HPH-C18 column, 21.2 × 150 mm, 5-95% MeCN aqueous solution + 0.1% FA) to obtain Example 806 (12.20 mg, 15.95 μmol, yield 44.80%). The material was identified and its purity was determined by LC-MS and... 1 H NMR characterization.

[0362] LCMS (ESI-TOF) (m / z): [M+H] + C 39 H 38 Calculated value of N6O5F5: 765; Measured value: 765. 1 H NMR (400 MHz, CDCl3, ):

[0363] 9.97 (d, J = 6.8 Hz, 1H), 7.68 (s, 1H), 7.46 7.41 (m, 2H), 7.22 7.11 (m, 3H), 7.07 6.99 (m, 2H), 6.32 (app d, J = 15.4 Hz, 1H), 4.82 (s, 2H), 4.44 (d, J = 6.5 Hz, 2H), 4.29 (d, J = 6.6 Hz, 2H), 4.06 3.98 (m, 1H), 3.96 3.89 (m, 4H), 3.87 3.78 (m, 1H), 3.63 3.60 (m, 2H), 3.45 (s, 3H), 3.21 3.12(m, 1H), 2.62(s, 3H), 1.08 0.99 (m, 1H), 0.69 0.60 (m, 2H), 0.52 0.44 (m, 2H).

[0364] Synthesis of Example 817

[0365] Step 1: 5-Bromo-3-Fluoro- N 2-Methyl-2-nitroaniline (817-01)

[0366] At 0 °C, a 30% methanol solution of methylamine (13.7 g, 132 mmol) was added to a tetrahydrofuran solution (150 mL) of 5-bromo-1,3-difluoro-2-nitrobenzene (CAS: 147808-42-2, 30.0 g, 126 mmol). The solution was stirred at 0 °C for 1 hour, and then stirred at room temperature for 16 hours. After concentration under reduced pressure, the solution was purified by silica gel column chromatography using a gradient of 0-30% ethyl acetate / petroleum ether to give a brown solid of 5-bromo-3-fluoro-N-methyl-2-nitrobenzene (29.3 g, 118 mmol, yield 93%).

[0367] C7H6BrFN2O2 mass spectrometry calculated value: 247.96, measured value: 249.01 [M+H] + ESI.

[0368] Step 2: 5-Cyclopropyl-3-Fluoro- N 2-Methyl-2-nitroaniline (817-02)

[0369] To 5-bromo-3-fluoro N Pd(dppf)Cl2 (900 mg, 1.09 mmol) and potassium phosphate (6.90 g, 32.8 mmol) were added to a solution of 1,4-dioxane (50 mL) and water (5 mL) containing methyl-2-nitroaniline (2.70 g, 10.9 mmol) and cyclopropylboronic acid (1.40 g, 16.4 mmol) (50 mL). The reaction was stirred at 100 °C for 5 hours under a nitrogen atmosphere. The reaction mixture was treated with water (50 mL) and extracted with ethyl acetate (50 mL). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a brown oily 5-cyclopropyl-3-fluoro-N 2-Methyl-2-nitroaniline (2.65 g, 12.6 mmol, yield 115%).

[0370] C 10 H 11 FN2O2 mass spectrometry calculated value: 210.08, measured value: 211.13 [M+H] + ESI.

[0371] Step 3: 4-Bromo-5-cyclopropyl-3-fluoro- N 2-Methyl-2-nitroaniline (817-03)

[0372] At 0℃, 5-cyclopropyl-3-fluoro- N 2-Methyl-2-nitroaniline (34.0 g, 111 mmol) N,N - Dimethylformamide (170 mL) solution added N- Bromosuccinimide (23.7 g, 133 mmol) was reacted and stirred at room temperature for 16 hours. The reaction mixture was diluted with ethyl acetate (500 mL) and washed with concentrated brine (250 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a brown solid of 4-bromo-5-cyclopropyl-3-fluoro- N 2-Methyl-2-nitroaniline (32.3 g, 111 mmol, 100% yield).

[0373] C 10 H 10 Calculated value of BrFN2O2 mass spectrometry: 287.99, measured value: 289.03 [M+H] + ESI.

[0374] Step 4: N -(4-bromo-5-cyclopropyl-3-fluoro-2-nitrophenyl)-2-methoxy- N -Methylacetamide (817-04)

[0375] To 4-bromo-5-cyclopropyl-3-fluoro- N -Methyl-2-nitroaniline 2-Methoxyacetyl chloride (37.5 g, 346 mmol) was added to a 400 mL solution of toluene (20.0 g, 69.2 mmol), and the mixture was stirred at 80 °C for 5 hours. The reaction mixture was diluted with ethyl acetate (500 mL) and washed with concentrated brine (300 mL). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a brown solid. N -(4-bromo-5-cyclopropyl-3-fluoro-2-nitrophenyl)-2-methoxy- N-Methylacetamide (19.7 g, 54.7 mmol, yield 79%).

[0376] C 13 H 14 Calculated value of BrFN2O4 by mass spectrometry: 360.01, measured value: 362.90 [M+H] + ESI.

[0377] Step 5: N -(3-amino-4-bromo-5-cyclopropyl-2-nitrophenyl)-2-methoxy- N -Methylacetamide (817-05)

[0378] Towards N -(4-bromo-5-cyclopropyl-3-fluoro-2-nitrophenyl)-2-methoxy- N -Methylacetamide (5.00 g, 13.8 mmol) N,N A methanol solution of ammonia (7 M, 15.0 mL) was added to a solution of dimethylformamide (15.0 mL). The mixture was stirred in a sealed tube at 60 °C for 5 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with concentrated brine (50 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a yellow solid. N -(3-amino-4-bromo-5-cyclopropyl-2-nitrophenyl)-2-methoxy- N -Methylacetamide (4.40 g, 12.2 mmol, yield 88%).

[0379] C 13 H 16 Calculated value of BrN3O4 by mass spectrometry: 357.03, measured value: 359.95 [M+H] + ESI.

[0380] Step 6: 5-Bromo-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H -benzo[ d Imidazol-4-amine (817-06)

[0381] Towards N -(3-amino-4-bromo-5-cyclopropyl-2-nitrophenyl)-2-methoxy- NIron powder (2.30 g, 41.9 mmol) was added to a solution of methylacetamide (3.00 g, 8.37 mmol) in acetic acid (15.0 mL), and the mixture was stirred at 60 °C for 5 hours. The reaction mixture was treated with water (50 mL) and ethyl acetate (50 mL), and the pH was adjusted to 8-9 with a saturated sodium carbonate aqueous solution. After filtration, the organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain a yellow solid of 5-bromo-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1-methylacetamide. H -benzo[ d Imidazol-4-amine (2.10 g, 6.77 mmol, yield 81%).

[0382] C 13 H 16 Calculated value of BrN3O by mass spectrometry: 309.05, measured value: 310.01 [M+H] + ESI.

[0383] Step 7: (8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H -Benz[d]imidazol-5-yl)indolazine-3-yl)(3,4,5-trifluorophenyl)methyl ketone (817-07)

[0384] To 5-bromo-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H -benzo[ d A solution of imidazole-4-amine (9.00 g, 29.1 mmol) and [8-(4,4,5,5-tetramethyl-1,3,2-dihexopentylborane-2-yl)indolinazin-3-yl]-(3,4,5-trifluorophenyl)methyl ketone (14.0 g, 34.9 mmol) in tetrahydrofuran (180 mL) and water (36 mL) was added to Sphos Pd G3 [CAS: 1445085-82-4] (2.30 g, 2.91 mmol) and potassium phosphate (9.90 g, 46.7 mmol). The reaction mixture was stirred overnight at 70 °C under a nitrogen atmosphere. After cooling to room temperature, the mixture was diluted with concentrated brine (100 mL) and extracted with ethyl acetate (200 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a 0%-6% methanol / dichloromethane gradient to give a yellow solid compound (8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1-yl) H -Benz[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (19.1 g, 37.9 mmol, 130% yield).

[0385] C28 H 23 F3N4O2 mass spectrometry calculated value: 504.18, measured value: 505.51 [M+H] + ESI

[0386] Step 8: (8-(4-bromo-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzo[d]imidazol-5-yl)indolinazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (817-08)

[0387] To compound (8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H A solution of benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (9.00 g, 17.8 mmol) in N,N-dimethylformamide (90.0 mL) was added at 0 °C with copper(II) bromide (1.99 g, 8.92 mmol) and tert-butyl nitrite (2.76 g, 26.8 mmol). The mixture was heated to room temperature and stirred overnight until the reaction was complete. The reaction mixture was then diluted with ethyl acetate (500 mL) and washed with concentrated brine (200 mL × 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography using a 1%–2% methanol / dichloromethane gradient to give a yellow solid (8-(4-bromo-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone (4.00 g, 7.04 mmol, 39% yield).

[0388] C 28 H 21 Calculated value of BrF3N3O2 by mass spectrometry: 567.08, measured value: 568.21 [M+H] + ESI.

[0389] Step 9: (2-(6-cyclopropyl-2-(methoxymethyl)-1-methyl-5-(3-(3,4,5-trifluorobenzoyl)indoleazine-8-yl)-1H-benzo[d]imidazol-4-yl)allyl)tert-butyl carbamate (817-09)

[0390] To a solution of (8-(4-bromo-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzi[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone (5.50 g, 9.80 mmol) and (2-(4,4,5,5-tetramethyl-1,3,2-dihexane-2-yl)allyl) tert-butyl carbamate (CAS: 1202794-01-1, 3.30 g, 11.8 mmol) in 1,4-dioxane (80 mL) and water (27 mL), Pd(dppf)Cl2 (800 mg, 0.98 mmol) and sodium carbonate (2.1 g, 19.60 mmol) were added. The mixture was stirred at 100 °C for 16 hours under a nitrogen atmosphere. After completion, the reaction was treated with water (200 mL) and extracted with dichloromethane (200 mL). The organic layer was concentrated under reduced pressure to give a brown solid (7.70 g, 11.94 mmol, yield 122%) of tert-butyl (2-(6-cyclopropyl-2-(methoxymethyl)-1-methyl-5-(3-(3,4,5-trifluorobenzoyl)indolazin-8-yl)-1H-benzo[d]imidazol-4-yl)allyl)carbamate.

[0391] C 36 H 35 F3N4O4 mass spectrometry calculated value: 644.26, measured value: 645.16 [M+H] + ESI.

[0392] Step 10: (2-(5-(1-bromo-3-(3,4,5-trifluorobenzoyl)indoleazine-8-yl)-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzo[d]imidazol-4-yl)allyl)tert-butyl carbamate (817-10)

[0393] To tert-butyl carbamate (2-(6-cyclopropyl-2-(methoxymethyl)-1-methyl-5-(3-(3,4,5-trifluorobenzoyl)indoleazin-8-yl)-1H-benzo[d]imidazol-4-yl)allyl)carbamate (3.00 g, 4.65 mmol) N , NN-bromosuccinimide (828 mg, 4.65 mmol) was added to a solution of dimethylformamide (60.0 mL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate (300 mL) and washed with brine (100 mL × 3). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a brown solid (2-(5-(1-bromo-3-(3,4,5-trifluorobenzoyl)indolazine-8-yl)-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzo[d]imidazol-4-yl)allyl)tert-butyl carbamate (3.16 g, 4.37 mmol, yield 93%).

[0394] C 36 H 34 Calculated mass spectrometry value of BrF3N4O4: 722.17, Measured value: 723.20 [M+H] + ESI.

[0395] Step 11: (2-(5-(3-(4-amino-3,5-difluorobenzoyl)-1-bromoindoleazine-8-yl)-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzo[d]imidazol-4-yl)allyl)tert-butyl carbamate (817-11)

[0396] To a solution of tert-butyl (2-(5-(1-bromo-3-(3,4,5-trifluorobenzoyl)inden-8-yl)-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzo[d]imidazol-4-yl)allyl)carbamate (1.54 g, 2.13 mmol) in 1,4-dioxane (30.0 mL), 25% ammonia (60 mL) was added, and the mixture was stirred in a sealed tube at 120 °C for 2 days. The reaction mixture was diluted with water (200 mL) and concentrated brine (100 mL) and extracted with dichloromethane / methanol (20:1, 200 mL). The organic layer was washed with concentrated brine (50 mL) and dried over sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to obtain a brown solid (2-(5-(3-(4-amino-3,5-difluorobenzoyl)-1-bromoindoleazine-8-yl)-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzo[d]imidazol-4-yl)allyl)tert-butyl carbamate (1.34 g, 1.86 mmol, yield 87%).

[0397] C 36 H 36 Calculated value of BrF₂N₅O₄ by mass spectrometry: 719.19, measured value: 720.22 [M+H] + ESI.

[0398] Step 12: (4-Amino-3,5-Difluorophenyl)(8-(4-(3-aminopropyl-1-en-2-yl)-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzo[d]imidazol-5-yl)-1-bromoindoleazine-3-yl) methyl ketone (817-12)

[0399] A solution of tert-butyl carbamate (1.34 g, 1.86 mmol) in dichloromethane (24.0 mL) was added to an ethyl acetate solution of 4 M hydrochloric acid (16 mL), and the mixture was stirred at room temperature for 16 hours. After the reaction was complete, the mixture was concentrated. The residue was diluted with dichloromethane / methanol (20:1, 100 mL) and washed successively with saturated aqueous sodium bicarbonate solution (50 mL) and concentrated brine (50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography with gradient elution of 1%-5% methanol / dichloromethane to give a brown solid compound (4-amino-3,5-difluorophenyl)(8-(4-(3-aminopropyl-1-en-2-yl)-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzo[d]imidazol-5-yl)-1-bromoindoleazine-3-yl) methyl ketone (738 mg, 1.19 mmol, yield 64%).

[0400] C 31 H 28 Calculated value of BrF₂N₅O₂ by mass spectrometry: 619.14, measured value: 620.12 [M+H] + ESI.

[0401] Step 13: (4-Amino-3,5-Difluorophenyl)(7-Cyclopropyl-10-(Methoxymethyl)-9-Methyl-12-methylene-9,12,13,14-Tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazin-2-yl)methyl ketone (817-13)

[0402] Inside a glove box, cuprous iodide (I) (113 mg, 595 μmol), diethylsalicylic acid amide (138 mg, 714 μmol), and cesium carbonate (775 mg, 2.38 mmol) were added to a solution of (4-amino-3,5-difluorophenyl)(8-(4-(3-aminopropyl-1-en-2-yl)-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1H-benzimidazol-5-yl)-1-bromoindolazine-3-yl) methyl ketone (738 mg, 1.19 mmol) in N,N-dimethylformamide (15.0 mL). The mixture was stirred in a sealed tube at 120 °C for 16 hours. The reaction mixture was diluted with ethyl acetate (100 mL) and washed with brine (50 mL × 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography using a 5% methanol / dichloromethane gradient to give a brown solid (4-amino-3,5-difluorophenyl)(7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (340 mg, 630 μmol, yield 53%).

[0403] C 31 H 27 F2N5O2 mass spectrometry calculated value: 539.21, measured value: 540.15 [M+H] + ESI.

[0404] Step 14: (4-Amino-3,5-Difluorophenyl)(7-Cyclopropyl-10-(Methoxymethyl)-9,14-Dimethyl-12-methylene-9,12,13,14-Tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)methyl ketone (817-14)

[0405] To (4-amino-3,5-difluorophenyl)(7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (3.50 g, 6.48 mmol) N,NIn a solution of dimethylformamide (35.0 mL), cesium carbonate (4.22 g, 13.0 mmol) and methyl iodide (1.84 g, 13.0 mmol) were added. The mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with ethyl acetate (500 mL) and washed with concentrated brine (250 mL × 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography using a 3% methanol / dichloromethane gradient to give an orange solid racemic (4-amino-3,5-difluorophenyl)(7-cyclopropyl-10-(methoxymethyl)-9,14-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (1.00 g, 1.81 mmol, yield 27%).

[0406] C 32 H 29 F2N5O2 mass spectrometry calculated value: 553.23, measured value: 554.25 [M+H] + ESI.

[0407] Step 8: (4-Amino-3,5-Difluorophenyl)(7-Cyclopropyl-10-(Methoxymethyl)-9,14-Dimethyl-12-methylene-9,12,13,14-Tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone, 817-INT-ISO-1 and 817-INT-ISO-2

[0408] Analytical separation methods

[0409] Racemic mixtures were separated using a Waters UPC2 analytical supercritical fluid chromatograph (SFC-H); column: ChiralPak AD, 50×4.6 mm ID, 3 µm; mobile phase: A was CO2, B was isopropanol (0.05% diethylamine); gradient: B 5-40%; flow rate: 3.0 ml / min; back pressure: 100 bar; column temperature: 35℃; wavelength: 220 nm.

[0410] Analytical separation was performed by supercritical fluid chromatography (SFC) to obtain 817-INT-ISO-1 (RT=3.157 min, active isomer) and 817-INT-ISO-2 (RT=3.556 min, inactive isomer).

[0411] Preparative separation methods

[0412] Racemates were separated using a Waters 150 preparative SFC (SFC-26); column: ChiralPak AD, 250×30mm ID, 10µm; mobile phase: A was CO2, B was isopropanol; gradient: B 35%; flow rate: 120 ml / min; back pressure: 100 bar; column temperature: 38℃; wavelength: 340 nm; cycle time: 4 min; sample preparation: the compound was dissolved in 20 ml of methanol / dichloromethane mixed solvent; injection: 2 ml per injection; post-processing: after separation, the fraction was dried using a rotary evaporator to obtain the target isomer.

[0413] (1.00 g) was separated by preparative supercritical fluid chromatography to obtain 817-INT-ISO-1 (236 mg, 24% yield, active isomer, yellow solid) and 817-INT-ISO-2 (300 mg, 30% yield, inactive isomer, yellow solid).

[0414] 817-INT-ISO-1

[0415] C 32 H 29 Calculated mass spectrometry values ​​for F2N5O2: 553.23, 554.25 [M+H] + ESI.

[0416] 817-INT-ISO-2

[0417] C 32 H 29 Calculated mass spectrometry values ​​for F2N5O2: 553.23, 554.25 [M+H] + ESI.

[0418] Step 9: ( E )-4-chloro-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9,14-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (817-15)

[0419] To (4-amino-3,5-difluorophenyl)(7-cyclopropyl-10-(methoxymethyl)-9,14-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazin-2-yl) methyl ketone (817-INT-ISO-1) (200 mg, 0.360 mmol) and (E Phosphorus oxychloride (277 mg, 1.81 mmol) was added to a pyridine (2.00 mL) solution of 4-chlorobut-2-enoic acid (87.0 mg, 0.720 mmol) at 0 °C. The mixture was then stirred at 0 °C for 0.5 h. The reaction was treated with a saturated aqueous solution of sodium bicarbonate (20 mL) and extracted with dichloromethane (20 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a black solid. E )-4-chloro-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9,14-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (350 mg, 0.53 mmol, yield 148%).

[0420] C 36 H 32 Calculated value of ClF2N5O3 by mass spectrometry: 655.22, Measured value: 656.15 [M+H] + ESI.

[0421] Step 9: ( R,E )-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9,14-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)-4-(((tetrahydrofuran-2-yl)methyl)amino)but-2-enamide (Example 817)

[0422] ( E )-4-chloro-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9,14-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-formyl)-2,6-difluorophenyl)but-2-enamide (315 mg, 0.48 mmol) with ( RA mixture of 2-(tetrahydrofuran-2-yl)methylamine (CAS: 7202-43-9, 111 mg, 1.10 mmol), potassium phosphate (509 mg, 2.40 mmol), and potassium iodide (239 mg, 1.44 mmol) in N,N-dimethylformamide (3.00 mL) was stirred at 50 °C for 4 hours. The mixture was purified by preparative HPLC (Morphling Triart-C18, 10 μm, 30 nm). 250 mm, eluent A: 0.1% TFA aqueous solution, eluent B: MeCN, gradient: phase B increases from 10% to 25% within 3 minutes, phase B increases from 25% to 90% within 35 minutes, 25℃, flow rate: 30 mL / min), yielding a yellow solid ( R,E )-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9,14-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)-4-(((tetrahydrofuran-2-yl)methyl)amino)but-2-enamide (78.6 mg, 0.11 mmol, yield 23%).

[0423] C 41 H 42 Calculated value of F2N6O4 by mass spectrometry: 720.32, measured value: 721.31 [M+H] + ESI.

[0424] 1 H NMR (400 MHz, CD3OD) δ 10.02 (d, J = 6.9 Hz, 1H), 7.60 (s, 1H), 7.51 (d, J = 7.9 Hz, 2H), 7.38 (d, J = 7.1 Hz, 1H), 7.24 (s, 1H), 7.19-7.15(m, 1H), 6.99-6.95 (m, 1H), 6.61 (d, J = 15.4 Hz, 1H), 5.40 (s, 1H), 5.06 (s,1H), 4.99 (s, 2H), 4.21-4.19 (m, 1H), 4.09 (s, 3H), 3.97-3.80 (m, 5H), 3.58(s, 3H), 3.40 (d, J= 12.3 Hz, 1H), 3.24-3.06 (m, 2H), 2.69 (s, 3H), 2.16-2.00 (m, 4H), 1.70-1.66 (m, 1H), 1.18-1.10 (m, 1H), 0.92-0.83 (m, 3H).

[0425] Synthesis of Example 824

[0426] ( E A mixture of 4-chloro-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9,14-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (817-15) (136 mg, 207 μmol), N-tert-butylmethylamine (54.0 mg, 623 μmol), potassium iodide (103 mg, 623 μmol), and potassium phosphate (220 mg, 1.04 mmol) in N,N-dimethylformamide (10.0 mL) was stirred at 50 °C for 2.5 h. After the reaction was complete, the crude mixture was purified by preparative HPLC (Morphling Triart-C18, 10 μm, 30 μm). 250 mm, eluent A: 0.1% TFA aqueous solution, eluent B: MeCN, gradient: phase B increases from 10% to 98% within 35 minutes, 25 o C, flow rate: 30 mL / min) yielded a brown solid compound ( E )-4-(tert-butyl(methyl)amino)-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9,14-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (58.0 mg, 82 μmol, 39.5%).

[0427] C 41 H 44 F2N6O3 mass spectrometry calculated value: 706.34, measured value: 707.37 [M+H] + ESI.

[0428] 1H NMR (400 MHz, CD3OD) δ 10.02 (dd, J = 7.0, 0.9 Hz, 1H), 7.58 (s,1H), 7.55-7.48 (m, 2H), 7.42-7.35 (m, 1H), 7.24 (s, 1H), 7.17 (t, J = 7.1 Hz,1H), 7.04-6.94 (m, 1H), 6.70 (d, J = 15.3 Hz, 1H), 5.39 (s, 1H), 5.05 (s,1H), 4.98 (s, 2H), 4.37 (dd, J = 14.1, 5.1 Hz, 1H), 4.08 (s, 3H), 3.86-3.81(m, 2H), 3.58 (s, 3H), 3.39 (d, J = 12.4 Hz, 1H), 2.86 (s, 3H), 2.68 (s,3H), 2.09-2.02 (m, 1H), 1.51 (s, 9H), 1.17-1.11 (m, 1H), 0.94-0.81 (m, 3H).

[0429] Synthesis of Example 850

[0430] Step 1: (8-(4-amino-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone, 850-1

[0431] 5-Bromo-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-4-amine (10.0 g, 35.7 mmol) was mixed with int10 (18.6 g, 46.4 mmol) in tetrahydrofuran (120 mL). A solution of potassium phosphate (15.2 g, 71.4 mmol) in H2O (25 mL) was added. SPhos Pd G3 (2.80 g, 3.57 mmol) was added, and the mixture was degassed and re-purged three times with nitrogen. The reaction mixture was heated to 80 °C for 2 hours. TLC (dichloromethane:methanol = 30:1) showed that the starting material had been completely consumed and the title compound was formed. The mixture was cooled to room temperature and partitioned between ethyl acetate and water. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a crude product. The crude product was milled at room temperature with a mixed solvent of dichloromethane (40 mL) and petroleum ether (150 mL) for 16 hours. The precipitate was filtered, and the filter cake was dried to obtain (8-(4-amino-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone (13.6 g, yield 80%).

[0432] C 27 H 21 F3N4O mass spectrometry calculated value: 474.17, measured value: 475.2 [M+H] + ESI.

[0433] Step 2: (8-(4-bromo-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone, 850-2

[0434] To (8-(4-amino-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (10.0 g, 21.1 mmol) N,N Copper(II) bromide (2.36 g, 10.5 mmol) was added to a 100 mL solution of dimethylformamide. After cooling to 0 °C, tert-butyl nitrite (3.26 g, 31.6 mmol) was added in portions and dissolved in... N,N-A solution in dimethylformamide (10 mL). The reaction mixture was heated to 60 °C and maintained for 2–3 hours, with the progress monitored by LC-MS. The mixture was diluted with 14% ammonium hydroxide and partitioned between ethyl acetate and water. The organic layers were combined, washed with 14% ammonium hydroxide, then washed with concentrated brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude residue. The crude product was purified by silica gel column chromatography using a gradient of 30–50% ethyl acetate / petroleum ether to give the product (8-(4-bromo-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone (6.00 g, 53% yield).

[0435] C 27 H 19 Calculated value of BrF3N3O by mass spectrometry: 537.07, Measured value: 538.1 [M+H] + ESI.

[0436] Step 3: (8-(4-bromo-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 850-3

[0437] To a solution of (8-(4-bromo-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone (5.00 g, 9.30 mmol) in acetonitrile (100 mL), 1,1,1,3,3,3-hexafluoroisopropanol (5.00 mL) was added. Ferric nitrate (III) nonahydrate (3.75 g, 9.30 mmol) was added. The reaction mixture was heated to 60 °C and maintained for 4 hours. LC-MS analysis showed complete consumption of the starting material and formation of the title compound. After cooling to room temperature, the mixture was partitioned and separated between ethyl acetate and brine. The organic layer was washed again with concentrated brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude residue. The crude product was purified by silica gel column chromatography using a gradient of 1%-10% methanol / dichloromethane to give the product (8-(4-bromo-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (3.20 g, yield 60%).

[0438] C 27 H 18 Calculated value of BrF3N4O3 by mass spectrometry: 584.05, Measured value: 585.1 [M+H] + ESI.

[0439] Step 4: (8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 850-4

[0440] (8-(4-bromo-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (2.00 g, 3.43 mmol), potassium carbonate (948 mg, 6.90 mmol), tert-butyldimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dihexaoxoborane-2-yl)allyl)oxy)silane (1.53 g, 5.15 mmol), and PdCl2(dcypf) (518 mg, 0.690 mmol) were dissolved in 1,4-dioxane (40 mL) and H2O (3 mL). The mixture was degassed and re-purged with nitrogen three times. The reaction mixture was heated to 100 °C and stirred for 5 hours. The reaction progress was analyzed by LC-MS. The mixture was cooled to room temperature and partitioned between ethyl acetate and brine. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a crude product. The crude product was purified by column chromatography to give the product (8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (1.50 g, 65% yield).

[0441] C 36 H 37 F3N4O4Si mass spectrometry calculated value: 674.25, measured value: 675.3 [M+H] + ESI.

[0442] Step 5: (1-Amino-8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 850-5

[0443] (8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-cyclopropyl-1,2-dimethyl-1H-benzimidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (1.00 g, 1.48 mmol) was mixed with 4-(4-pyridyl)pyridine (46.3 mg, 0.290 mmol) in... N,NMixed in dimethylformamide (5.00 mL). After cooling to room temperature, hypoboronic acid (664 mg, 7.40 mmol) was added in portions. The reaction mixture was stirred at room temperature for 0.5 h. LC-MS showed complete consumption of the starting material and formation of the title compound. The mixture was partitioned between ethyl acetate and water. The mixture was washed with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude residue. The crude residue was purified by silica gel column chromatography to give (1-amino-8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (800 mg, 84% yield).

[0444] C 36 H 39 F3N4O2Si mass spectrometry calculated value: 644.2, measured value: 645.3 [M+H] + ESI.

[0445] Step 6: (1-Amino-8-(6-cyclopropyl-4-(3-hydroxypropyl-1-en-2-yl)cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 850-6

[0446] (1-Amino-8-(4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-cyclopropyl-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolazine-3-yl)(3,4,5-trifluorophenyl)methyl ketone (5.00 g, 7.80 mmol) was dissolved in tetrahydrofuran (100 mL). Tetrabutylammonium fluoride (3.65 g, 14.0 mmol) was added in portions. The reaction mixture was stirred at room temperature for 3 hours. LC-MS showed complete consumption of the starting material and formation of the title compound. The mixture was partitioned between ethyl acetate and water. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude residue. The crude residue was purified by silica gel column chromatography to obtain (1-amino-8-(6-cyclopropyl-4-(3-hydroxypropyl-1-en-2-yl)-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolin-3-yl)(3,4,5-trifluorophenyl) methyl ketone (3.50 g, yield 85%).

[0447] C 30 H 25 F3N4O2 mass spectrometry calculated value: 530.19, measured value: 531.3 [M+H] + ESI.

[0448] Step 7: (7-Cyclopropyl-9,10-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone, 850-7

[0449] Triphenylphosphine (989 mg, 3.77 mmol) was dissolved in dichloromethane (15 mL), and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (856 mg, 3.77 mmol) was added in portions. After 15 minutes, (1-amino-8-(6-cyclopropyl-4-(3-hydroxypropyl-1-en-2-yl)-1,2-dimethyl-1H-benzo[d]imidazol-5-yl)indolinazine-3-yl)(3,4,5-trifluorophenyl)methyl ketone (1.00 g, 1.88 mmol) was added in portions to dichloromethane (10 mL). The mixture was degassed and re-purged with nitrogen three times. The reaction mixture was stirred at room temperature for 1 hour. LC-MS showed complete consumption of the starting material and formation of the title compound. The mixture was diluted with dichloromethane and washed with a saturated aqueous sodium bicarbonate solution. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude residue. The crude product was purified by silica gel column chromatography to obtain the product (7-cyclopropyl-9,10-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (720 mg, yield 75%).

[0450] C 30 H 23 F3N4O mass spectrometry calculated value: 512.18, measured value: 513.2 [M+H] + ESI.

[0451] Step 8: (4-Amino-3,5-Difluorophenyl)(7-Cyclopropyl-9,10-Dimethyl-12-methylene-9,12,13,14-Tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone, 850-8

[0452] (7-Cyclopropyl-9,10-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (2.00 g, 3.90 mmol) was mixed in 1,4-dioxane (30 mL) and ammonia (30.0 mL). The reaction mixture was microwaved to 120 °C, and the reaction was monitored by LC-MS. After the reaction was complete, the mixture was cooled to room temperature and partitioned between dichloromethane and water. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a yellow solid (4-amino-3,5-difluorophenyl)(7-cyclopropyl-9,10-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (1.80 g, 90% yield).

[0453] C 30 H 25 F2N5O mass spectrometry calculated value: 509.20, measured value: 510.3 [M+H] + ESI.

[0454] Step 9: 2-(4-amino-3,5-difluorobenzoyl)-7-cyclopropyl-9,10-dimethyl-12-methylene-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester, 850-9

[0455] Di-tert-butyl dicarbonate (2.55 g, 11.7 mmol) was added to a methanol (10.00 g, 1.95 mmol) solution of (4-amino-3,5-difluorophenyl)(7-cyclopropyl-9,10-dimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone. The reaction mixture was heated to 45 °C and stirred at room temperature for 12 hours. LC-MS showed complete consumption of the starting material and formation of the title compound. The mixture was partitioned between ethyl acetate and water. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified by reverse-phase column (C18 column) to give 2-(4-amino-3,5-difluorobenzoyl)-7-cyclopropyl-9,10-dimethyl-12-methylene-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester (1 g, yield 84%).

[0456] C 35 H 33 F2N5O3 mass spectrometry calculated value: 609.26, measured value: 610.2 (M+H) + ESI.

[0457] Step 10: 2-(4-amino-3,5-difluorobenzoyl)-7-cyclopropyl-9,10-dimethyl-12-methylene-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester, 850-INT-01, and 2-(4-amino-3,5-difluorobenzoyl)-7-cyclopropyl-9,10-dimethyl-12-methylene-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid ester, 850-INT-02

[0458] 2-(4-amino-3,5-difluorobenzoyl)-7-cyclopropyl-9,10-dimethyl-12-methylene-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid ester, 850-9 (15 g), was separated by supercritical fluid chromatography to obtain 2-(4-amino-3,5-difluorobenzoyl)-7-cyclopropyl-9,10-dimethyl-12-methylene-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid ester, 850-INT-01 (5.69 g). g) and 2-(4-amino-3,5-difluorobenzoyl)-7-cyclopropyl-9,10-dimethyl-12-methylene-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid ester. 850-INT-02 (5.54 g).

[0459] Preparation and separation methods: Instrument: Thar 350 preparative supercritical fluid chromatograph (SFC-20) Column: ChiralPak AD, 300×50mm ID, 10µm Mobile phase: A is CO2, B is ethanol Gradient: B 40% Flow rate: 200 mL / min Back pressure: 100 bar Column temperature: 38℃ Wavelength: 340nm Cycle time: ~4min 850-INT-01 (RT= 2.170 min): C 35 H 33 F2N5O3 mass spectrometry calculated value: 609.26, measured value: 610.2 (M+H) + ESI.

[0460] 1 H NMR (400 MHz, DMSO- d 6 ) δ: 9.74 (dd, J = 7.0, 1.0 Hz, 1H), 7.38 (dd, J= 7.3, 2.4 Hz, 2H), 7.27-7.23 (m, 2H), 7.21 (s, 1H), 7.07 (t, J = 7.0 Hz,1H), 5.67 (s, 1H), 5.55 (s, 2H), 5.11 (t, J = 1.8 Hz, 1H), 4.98 (dt, J =13.7, 2.0 Hz, 1H), 4.73 (t, J = 1.7 Hz, 1H), 3.74 (s, 3H), 2.97 (s, 1H), 2.54(s, 3H), 2.09-1.94 (m, 1H), 0.88 (s, 9H), 0.67 (ddd, J = 11.1, 5.6, 4.0 Hz,1H), 0.55-0.40 (m, 2H) ppm.

[0461] 850-INT-02 (RT=3.107 min):

[0462] C 35 H 33 F2N5O3 mass spectrometry calculated value: 609.26, measured value: 610.2 (M+H) + ESI.

[0463] 1 H NMR (400 MHz, DMSO- d 6 ) δ: 9.74 (dd, J = 7.0, 1.0 Hz, 1H), 7.37 (dd, J = 7.3, 2.4 Hz, 2H), 7.27-7.23 (m, 2H), 7.22 (s, 1H), 7.07 (t, J = 7.1 Hz,1H), 5.55 (s, 2H), 5.11 (t, J = 1.8 Hz, 1H), 4.98 (dt, J = 13.8, 2.0 Hz, 1H), 4.73 (t, J = 1.7 Hz, 1H), 3.74 (s, 3H), 2.97 (s, 1H), 2.54 (s, 3H), 2.01 (tt, J= 8.3, 5.3 Hz, 1H), 0.88 (s, 9H), 0.72-0.64 (m, 1H), 0.47 (q, J = 5.0 Hz, 2H) ppm.

[0464] Step 11: (4-Amino-3,5-Difluorophenyl)(7-Cyclopropyl-9,10-Dimethyl-12-methylene-9,12,13,14-Tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone, 850-1

[0465] Hydrochloric acid / dioxane (4.0 mL) was added to a solution of 2-(4-amino-3,5-difluorobenzoyl)-7-cyclopropyl-9,10-dimethyl-12-methylene-12,13-dihydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-14(9H)-carboxylic acid tert-butyl ester (2.00 g, 3.28 mmol) in dichloromethane (20.0 mL). The reaction mixture was stirred at room temperature for 2 hours. LC-MS was performed. After the reaction was complete, the reaction mixture was adjusted to pH 8.0 with aqueous sodium bicarbonate solution. The organic layer was partitioned between dichloromethane and water. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was used directly for the next step without purification.

[0466] C 30 H 25 N5F2O mass spectrometry calculated value: 509.20, measured value: 510.2 (M+H) + ESI.

[0467] Step 12: (4-Amino-3,5-Difluorophenyl)(7-Cyclopropyl-9,10,14-Trimethyl-12-Methylene-9,12,13,14-Tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone, 850-2

[0468] (4-Amino-3,5-Difluorophenyl)(7-Cyclopropyl-9,10-Dimethyl-12-methylene-9,12,13,14-Tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (1.20 g, 2.36 mmol) was dissolved in tetrahydrofuran (10.0 mL) with formaldehyde (141.42 mg, 4.71 mmol). After 10 minutes, another solution of sodium cyanoborohydride (511 mg, 8.24 mmol) and zinc chloride (480 mg, 3.53 mmol) in methanol (5.00 mL) was added in portions. The reaction mixture was stirred at room temperature for 2 hours. LC-MS showed complete consumption of the starting material and formation of the title compound. The reaction mixture was partitioned between ethyl acetate and water. The organic layers were combined and concentrated under reduced pressure to give the crude product. The crude product was purified by reversed-phase column chromatography (C18 column) to give the title compound (4-amino-3,5-difluorophenyl)(7-cyclopropyl-9,10,14-trimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (1.50 g, 98% yield).

[0469] C 31 H 27 N5OF2 mass spectrometry calculated value: 523.22, measured value: 524.21 (M+H) + ESI.

[0470] Step 13: ( E )-4-chloro-N-(4-(7-cyclopropyl-9,10,14-trimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide, 850-3

[0471] To (4-amino-3,5-difluorophenyl)(7-cyclopropyl-9,10,14-trimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazin-2-yl) methyl ketone (60.0 mg, 114 μmol) and ( ETriethylamine (116 mg, 1.15 mmol, 160 μL) and propyl phosphate cycloanhydride (729 mg, 1.15 mmol, 50% by weight ethyl acetate solution) were added to a solution of 4-chlorobut-2-enoic acid (19.3 mg, 160 μmol) in ethyl acetate (2.00 mL). The reaction mixture was stirred at room temperature for 2 hours. LC-MS showed complete consumption of the starting material and formation of the title compound. The reaction mixture was partitioned between ethyl acetate and water. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography to give ( E )-4-chloro-N-(4-(7-cyclopropyl-9,10,14-trimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (50 mg, 70% yield).

[0472] C 35 H 30 Calculated value of N5F2O2Cl by mass spectrometry: 625.21, Measured value: 626.2 (M+H) + ESI.

[0473] Step 14: ( E )-N-(4-(7-cyclopropyl-9,10,14-trimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)-4-(((1r,4r)-4-methoxycyclohexyl)amino)but-2-eneamide

[0474] Towards( E )-4-chloro-N-(4-(7-cyclopropyl-9,10,14-trimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (50.0 mg, 80.0 μmol) and 4-methoxycyclohexylamine (15.5 mg, 120 μmol) N,N-Potassium iodide (13.3 mg, 80.0 μmol) and potassium phosphate (33.9 mg, 160 μmol) were added to dimethylformamide (2.00 mL), and the reaction mixture was stirred at 30 °C for 16 hours. LC-MS showed partial consumption of the starting material and formation of the title compound. The mixture was partitioned between ethyl acetate and water. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified by reversed-phase column chromatography (C18 column chromatography) to give the title compound as a yellow solid. E )-N-(4-(7-cyclopropyl-9,10,14-trimethyl-12-methylene-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)-4-(((1r,4r)-4-methoxycyclohexyl)amino)but-2-enamide (22.0 mg, yield 38.3%).

[0475] C 42 H 44 Calculated value of N6F2O3 by mass spectrometry: 718.54, measured value: 719.43 (M+H) + ESI.

[0476] 1 H NMR (400 MHz, DMSO- d 6 ) δ: 9.97 (s, 1H), 9.92-9.90 (m, 1H), 7.55-7.53 (m, 2H), 7.28-7.27 (m, 1H), 7.17-7.11 (m, 3H), 6.90-9.87 (m, 1H), 6.37-6.33 (m, 1H), 5.10 (s, 1H), 4.70 (s, 1H), 3.74-3.71 (m, 4H), 3.38-3.37 (m,2H), 3.23 (s, 3H), 3.19-3.18 (m, 1H), 3.16-3.15 (m, 1H), 2.55 (s, 3H), 2.40-2.38 (m, 1H), 2.00-1.86 (m, 6H), 1.15-1.07 (m, 4H).

[0477] Synthesis of Example 570A

[0478] Step 1: 5-Bromo-3-Fluoro- N2-Methyl-2-nitroaniline (570-01)

[0479] At 0 °C, a 30% methanol solution of methylamine (13.7 g, 132 mmol) was added to a tetrahydrofuran solution (150 mL) of 5-bromo-1,3-difluoro-2-nitrobenzene (CAS: 147808-42-2, 30.0 g, 126 mmol). The solution was stirred at 0 °C for 1 hour, and then stirred at room temperature for 16 hours. After concentration under reduced pressure, the solution was purified by silica gel column chromatography using a gradient of 0-30% ethyl acetate / petroleum ether to give a brown solid of 5-bromo-3-fluoro-N-methyl-2-nitrobenzene (29.3 g, 118 mmol, yield 93%).

[0480] C7H6BrFN2O2 mass spectrometry calculated value: 247.96, measured value: 249.01 [M+H] + ESI.

[0481] Step 2: 5-Cyclopropyl-3-Fluoro- N 2-Methyl-2-nitroaniline (570-02)

[0482] To 5-bromo-3-fluoro N Pd(dppf)Cl2 (900 mg, 1.09 mmol) and potassium phosphate (6.90 g, 32.8 mmol) were added to a solution of 1,4-dioxane (50 mL) and water (5 mL) containing 2.70 g (10.9 mmol) of methyl-2-nitroaniline and cyclopropylboronic acid (1.40 g, 16.4 mmol) (50 mL). The reaction was stirred at 100 °C for 5 h under a nitrogen atmosphere. The reaction mixture was treated with water (50 mL) and extracted with ethyl acetate (50 mL). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a brown oily 5-cyclopropyl-3-fluoro-N-methyl-2-nitroaniline (2.65 g, 12.6 mmol, yield 115%).

[0483] C 10 H 11 FN2O2 mass spectrometry calculated value: 210.08, measured value: 211.13 [M+H] + ESI.

[0484] Step 3: 4-Bromo-5-cyclopropyl-3-fluoro- N 2-Methyl-2-nitroaniline (570-03)

[0485] At 0℃, 5-cyclopropyl-3-fluoro- N 2-Methyl-2-nitroaniline (34.0 g, 111 mmol) N,N- Dimethylformamide (170 mL) solution added N- Bromosuccinimide (23.7 g, 133 mmol) was reacted and stirred at room temperature for 16 hours. The reaction mixture was diluted with ethyl acetate (500 mL) and washed with concentrated brine (250 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a brown solid of 4-bromo-5-cyclopropyl-3-fluoro- N 2-Methyl-2-nitroaniline (32.3 g, 111 mmol, 100% yield).

[0486] C 10 H 10 Calculated value of BrFN2O2 mass spectrometry: 287.99, measured value: 289.03 [M+H] + ESI.

[0487] Step 4: N -(4-bromo-5-cyclopropyl-3-fluoro-2-nitrophenyl)-2-methoxy- N -Methylacetamide (570-04)

[0488] To 4-bromo-5-cyclopropyl-3-fluoro- N -Methyl-2-nitroaniline 2-Methoxyacetyl chloride (37.5 g, 346 mmol) was added to a 400 mL solution of toluene (20.0 g, 69.2 mmol), and the mixture was stirred at 80 °C for 5 hours. The reaction mixture was diluted with ethyl acetate (500 mL) and washed with concentrated brine (300 mL). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a brown solid. N -(4-bromo-5-cyclopropyl-3-fluoro-2-nitrophenyl)-2-methoxy- N -Methylacetamide (19.7 g, 54.7 mmol, yield 79%).

[0489] C 13 H 14 Calculated value of BrFN2O4 by mass spectrometry: 360.01, measured value: 362.90 [M+H] + ESI.

[0490] Step 5: N -(3-amino-4-bromo-5-cyclopropyl-2-nitrophenyl)-2-methoxy- N -Methylacetamide (570-05)

[0491] Towards N -(4-bromo-5-cyclopropyl-3-fluoro-2-nitrophenyl)-2-methoxy- N-Methylacetamide (5.00 g, 13.8 mmol) N,N A methanol solution of ammonia (7 M, 15.0 mL) was added to a solution of dimethylformamide (15.0 mL). The mixture was stirred in a sealed tube at 60 °C for 5 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with concentrated brine (50 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a yellow solid. N -(3-amino-4-bromo-5-cyclopropyl-2-nitrophenyl)-2-methoxy- N -Methylacetamide (4.40 g, 12.2 mmol, yield 88%).

[0492] C 13 H 16 Calculated value of BrN3O4 by mass spectrometry: 357.03, measured value: 359.95 [M+H] + ESI.

[0493] Step 6: 5-Bromo-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H -benzo[ d Imidazol-4-amine (570-06)

[0494] Towards N -(3-amino-4-bromo-5-cyclopropyl-2-nitrophenyl)-2-methoxy- N Iron powder (2.30 g, 41.9 mmol) was added to a solution of methylacetamide (3.00 g, 8.37 mmol) in acetic acid (15.0 mL), and the mixture was stirred at 60 °C for 5 hours. The reaction mixture was treated with water (50 mL) and ethyl acetate (50 mL), and the pH was adjusted to 8-9 with a saturated sodium carbonate aqueous solution. After filtration, the organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain a yellow solid of 5-bromo-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1-methylacetamide. H -benzo[ d Imidazol-4-amine (2.10 g, 6.77 mmol, yield 81%).

[0495] C 13 H 16 Calculated value of BrN3O by mass spectrometry: 309.05, measured value: 310.01 [M+H] + ESI.

[0496] Step 7: (8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H -Benz[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (570-07)

[0497] To 5-bromo-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H -benzo[ d A solution of imidazole-4-amine (9.00 g, 29.1 mmol) and [8-(4,4,5,5-tetramethyl-1,3,2-dihexopentylborane-2-yl)indolinazin-3-yl]-(3,4,5-trifluorophenyl)methyl ketone (14.0 g, 34.9 mmol) in tetrahydrofuran (180 mL) and water (36 mL) was added to Sphos Pd G3 [CAS: 1445085-82-4] (2.30 g, 2.91 mmol) and potassium phosphate (9.90 g, 46.7 mmol). The reaction mixture was stirred overnight at 70 °C under a nitrogen atmosphere. After cooling to room temperature, the mixture was diluted with concentrated brine (100 mL) and extracted with ethyl acetate (200 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a 0%-6% methanol / dichloromethane gradient to give a yellow solid compound (8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1-yl) H -Benz[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (19.1 g, 37.9 mmol, 130% yield).

[0498] C 28 H 23 F3N4O2 mass spectrometry calculated value: 504.18, measured value: 505.51 [M+H] + ESI

[0499] Step 8: (8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H -Benz[d]imidazol-5-yl)-1-iodoindoleazine-3-yl)(3,4,5-trifluorophenyl)methyl ketone (570-08)

[0500] To (8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H 1,1,1,3,3,3-hexafluoro-2-propanol (150 mL) of benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 570-INT-01 (14.7 g, 29.1 mmol), was added at 0 °C to a solution of 1,1,1,3,3,3-hexafluoro-2-propanol (150 mL), and then trifluoroacetic acid (4.50 mL, 58.8 mmol) was added in portions. N-Iodosuccinimide (6.11 g, 27.2 mmol). The mixture was stirred at room temperature for 1 hour. After the reaction was complete, the mixture was quenched with a saturated aqueous solution of sodium thiosulfate (100 mL) and extracted with ethyl acetate (200 mL × 4). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a crude residue. Diisopropyl ether (100 mL) was added to the residue, and the suspension was stirred overnight at room temperature. The suspension was filtered, and the wet cake was dried under reduced pressure to give a yellow solid (8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1-yl) H -Benz[d]imidazol-5-yl)-1-iodoindoleazine-3-yl)(3,4,5-trifluorophenyl)methyl ketone (22.2 g, 35.2 mmol, 120% yield).

[0501] C 28 H 22 F3IN4O2 mass spectrometry calculated value: 630.07, measured value: 631.41 [M+H] + ESI

[0502] Step 9: (E)-(8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H -Benz[d]imidazol-5-yl)-1-(2-ethoxyvinyl)indolazine-3-yl)(3,4,5-trifluorophenyl)methyl ketone (570-09)

[0503] Under a nitrogen atmosphere, towards ( E )-(8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H 1,4-dioxane (210 mL) solution of benzo[d]imidazol-5-yl)-1-(2-ethoxyvinyl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone, 570-INT-02 (20.7 g, 32.9 mmol) was added to ( E 2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-diaxoxopentane, CAS: 1201905-61-4 (32.3 g, 164 mmol), Pd(PPh3)4 (3.80 g, 3.29 mmol) and 1M sodium carbonate aqueous solution (65.8 mL, 131.56 mmol). The mixture was stirred overnight at 100 °C. After the reaction was complete, the mixture was quenched with water (100 mL) and extracted with ethyl acetate (200 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a gradient of 0%–6% methanol / dichloromethane to give a yellow solid compound ( E)-(8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H -Benz[d]imidazol-5-yl)-1-(2-ethoxyvinyl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (21 g, 36.6 mmol, yield 130%).

[0504] C 32 H 29 F3N4O3 mass spectrometry calculated value: 574.22, measured value: 575.60 [M+H] + ESI.

[0505] Step 10: (7-Cyclopropyl-10-(Methoxymethyl)-9-methyl-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indoleazin-2-yl)(3,4,5-trifluorophenyl)methyl ketone (570-7)

[0506] To compounds ( E )-(8-(4-amino-6-cyclopropyl-2-(methoxymethyl)-1-methyl-1 H Sodium triacetoxyborohydride (22.2 g, 105 mmol) was added to a solution of benzo[d]imidazol-5-yl)-1-(2-ethoxyvinyl)indolazin-3-yl)(3,4,5-trifluorophenyl) methyl ketone (20.0 g, 34.8 mmol) in dichloromethane (400 mL). Trifluoroacetic acid (79.9 mL, 1.05 mol) was then added dropwise. The resulting mixture was stirred at room temperature for 5 minutes. After the reaction was complete, the mixture was quenched with a saturated aqueous sodium carbonate solution (100 mL) and extracted with dichloromethane (200 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a gradient of 0%-6% methanol / dichloromethane to give a yellow solid (7-cyclopropyl-10-(methoxymethyl)-9-methyl-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (7.23 g, 13.6 mmol, yield 39%).

[0507] C 30 H 25 F3N4O2 mass spectrometry calculated value: 530.19, measured value: 531.55 [M+H] + ESI

[0508] Step 11: (7-Cyclopropyl-10-(Methoxymethyl)-9-methyl-12-(Methyl-d3)-9,12,13,14-Tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolinazin-2-yl)(3,4,5-trifluorophenyl)methyl ketone (570-11)

[0509] To (7-cyclopropyl-10-(methoxymethyl)-9-methyl-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (7.23 g, 13.6 mmol) N , N In 140 mL of dimethylformamide, 2.97 g (20.5 mmol) of deuterated iodomethane and 8.89 g (27.3 mmol) of cesium carbonate were added. The mixture was stirred at 65 °C for 1 hour. After cooling to room temperature, the reaction mixture was diluted with 500 mL of ethyl acetate and washed with concentrated brine (250 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a gradient of 0%-6% methanol / dichloromethane to give a yellow solid (7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-(methyl-d3)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (6.00 g, 11.0 mmol, 80% yield).

[0510] C 31 H 24 D3F3N4O2 mass spectrometry calculated value: 547.23, measured value: 548.60 [M+H] + ESI.

[0511] Step 12: (4-Amino-3,5-Difluorophenyl)(7-Cyclopropyl-10-(Methoxymethyl)-9-Methyl-12-(Methyl-d3)-9,12,13,14-Tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indoleazin-2-yl)methyl ketone (570-12)

[0512] Add 25% ammonia (180 mL) to a solution of (7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-(methyl-d3)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (6.00 g, 11.0 mmol) in 1,4-dioxane (180 mL). Stir the mixture in a sealed tube at 120 °C for 48 hours. After cooling to room temperature, dilute the mixture with concentrated brine (100 mL) and extract with ethyl acetate (200 mL × 4). Dry the organic phase with sodium sulfate, filter, and concentrate under reduced pressure. The residue was purified by silica gel column chromatography using a 0-6% methanol / dichloromethane gradient to give a yellow solid racemic compound (4-amino-3,5-difluorophenyl)(7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-(methyl-d3)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl) methyl ketone (5.50 g, 10.1 mmol, 92% yield).

[0513] C 31 H 26 Calculated value of D3F2N5O2 by mass spectrometry: 544.25, Measured value: 545.62 [M+H] + ESI.

[0514] Step 13: (4-Amino-3,5-Difluorophenyl)(7-Cyclopropyl-10-(Methoxymethyl)-9-Methyl-12-(Methyl-d3)-9,12,13,14-Tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl) methyl ketone, 570-INT-ISO-1 and 570-INT-ISO-2

[0515] Analytical separation methods

[0516] Racemic mixtures were separated using a Waters UPC2 analytical supercritical fluid chromatograph (SFC-H); column: ChiralCel OJ, 150×4.6 mm ID, 3 µm; mobile phase: A was CO2, B was ethanol (0.05% diethylamine); gradient: B 40%; flow rate: 2.5 ml / min; back pressure: 100 bar; column temperature: 35℃; wavelength: 220 nm.

[0517] Analytical separation was performed by supercritical fluid chromatography (SFC) to obtain 570-INT-ISO-1 (RT=2.023 min, active isomer) and 570-INT-ISO-2 (RT=3.145 min, inactive isomer).

[0518] Preparative separation methods

[0519] Racemates were separated using a Thar 200 preparative SFC (SFC-27); column: ChiralCel OJ, 300×50mm ID, 10µm; mobile phase: A was CO2, B was ethanol; gradient: B 50%; flow rate: 200 ml / min; back pressure: 100 bar; column temperature: 38℃; wavelength: 340 nm; cycle time: 8 min; sample preparation: the compound was dissolved in 150 ml of methanol / dichloromethane mixed solvent; injection: 10 ml per injection; post-processing: after separation, the fraction was dried using a rotary evaporator to obtain the target isomer.

[0520] (6.07 g) was separated by preparative supercritical fluid chromatography to obtain 570-12-ISO-1 (2.29 g, yield 38%, active isomer, yellow solid) and 570-12-ISO-2 (2.45 g, yield 40%, inactive isomer, yellow solid).

[0521] 570-INT-ISO-1

[0522] C 31 H 26 Calculated value of D3F2N5O2 by mass spectrometry: 544.25, Measured value: 545.62 [M+H] + ESI.

[0523] 570-INT-ISO-2

[0524] C 31 H 26 Calculated value of D3F2N5O2 by mass spectrometry: 544.25, Measured value: 545.62 [M+H] + ESI.

[0525] Step 14: (E)-4-chloro-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-(methyl-d3)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (570-13)

[0526] Phosphorus oxychloride (6.05 g, 39.5 mmol) was slowly added to a pyridine (40 mL) solution of (4-amino-3,5-difluorophenyl)(7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-(methyl-d3)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indolazin-2-yl) ketone, 570-INT-ISO-1 (2.15 g, 3.95 mmol), and (E)-4-chlorobut-2-enoic acid (1.43 g, 11.9 mmol) at 0 °C. The mixture was stirred at this temperature for 10 minutes. After the reaction was complete, the mixture was quenched with saturated sodium bicarbonate aqueous solution (20 mL) and extracted with dichloromethane / methanol (10:1, 100 mL × 3). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a 0-6% methanol / dichloromethane gradient to give a brown solid (E)-4-chloro-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-(methyl-d3)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (1.58 g, 2.45 mmol, yield 62%).

[0527] C 35 H 29 Calculated value of D3ClF2N5O3 by mass spectrometry: 646.24, Measured value: 648.14 [M+H] + ESI.

[0528] Step 15: (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)- N -(4-(7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-(methyl-d3)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (Example 570A)

[0529] To (E)-4-chloro-N-(4-(7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-(methyl-d3)-9,12,13,14-tetrahydroimidazole[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (1.41 g, 2.18 mmol)N,N A solution of dimethylformamide (28.0 mL) was supplemented with trans-4-aminocyclohexane-1-carboxynitrile hydrochloride (CAS: 873537-33-8) (1.05 g, 6.55 mmol), potassium iodide (1.09 g, 6.55 mmol), and potassium phosphate (2.30 g, 10.9 mmol). The mixture was stirred at 50 °C for 1 hour. After the reaction was complete, the mixture was purified by preparative HPLC (Morphling Triart-C18, 30). 250 mm, 10 μm; mobile phase: A: 0.1% trifluoroacetic acid aqueous solution; B: acetonitrile; 0-25 min, B from 10%-98%; flow rate: 30 ml / min; wavelength: UV 254 nm, 220 nm; temperature: 25℃, retention time = 11.2 min), directly yielded a yellow solid (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)- N -(4-(7-cyclopropyl-10-(methoxymethyl)-9-methyl-12-(methyl-d3)-9,12,13,14-tetrahydroimidazo[4'',5'':5',6']benzo[1',2':2,3]azaoctano[4,5,6-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide, Example 570A (1.16 g, 1.58 mmol, 72%).

[0530] C 42 H 40 Calculated mass spectrometry value for D3F2N7O3: 734.36, Measured value: 735.87 [M+H] + ESI.

[0531] 1 H NMR (400 MHz, CD3OD) δ 10.07 (d, J = 6.8 Hz, 1H), 7.65-7.63 (m,2H), 7.54 (d, J = 7.6 Hz, 2H), 7.41 (s, 1H), 7.30 (t, J = 6.8 Hz, 1H), 6.99-6.92 (m, 1H), 6.63 (d, J= 15.6 Hz, 1H), 4.87 (s, 2H), 4.02-3.97 (m, 6H), 3.56-3.52 (m, 4H), 3.28-3.22 (m, 1H), 2.94-2.90 (m, 1H), 2.74-2.66 (m, 1H),2.43-2.35 (m, 1H), 2.30-2.21 (m, 4H), 2.03-1.94 (m, 1H), 1.78-1.69 (m, 2H),1.55-1.44 (m, 2H), 1.13-1.06 (m, 1H), 0.94-0.84 (m, 1H), 0.79-0.62 (m, 2H).

[0532] Synthesis of Example 721:

[0533] Step 1: (10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolinazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (721-1)

[0534] Formaldehyde (1.14 g, 14.02 mmol) was added to a solution of (10-(methoxymethyl)-9-methyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (564-6) (2.0 g, 3.51 mmol) in THF (20 mL). ZnCl2 (716.74 mg, 5.26 mmol) and NaBH3CN (660.93 mg, 10.52 mmol) in CH3OH (12 mL) were added, and the mixture was stirred at room temperature for 2 hours. The mixture was diluted with aqueous NaHCO3 solution, EA, and water, and extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was used directly in the next step without purification.

[0535] C 30 H 22 Calculated value of N4O2F6 by mass spectrometry: 584.16, Measured value: 585.23 (M+H) + ESI.

[0536] Step 2: (4-Azide-3,5-Difluorophenyl)(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (721-2)

[0537] Under a nitrogen atmosphere, NaN3 (293.62 mg, 4.52 mmol) was added to a DMA (20 mL) solution of (10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (721-1) (2.2 g, 3.76 mmol). The mixture was stirred at 80 °C for 2.5 h. The mixture was diluted with aqueous NaHCO3 solution, EA, and water, and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was used directly for the next step without purification.

[0538] C 30 H 22 Calculated value for N7O2F5 by mass spectrometry: 607.18, Measured value: 608.21 (M+H) + ESI.

[0539] Step 3: (4-Amino-3,5-Difluorophenyl)(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazin-2-yl) methyl ketone (721-3)

[0540] Under a H2 atmosphere, Lindlar catalyst (1.20 g, 5.81 mmol) was added to a solution of (4-amino-3,5-difluorophenyl)(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (2.0 g, 3.29 mmol) in CH3OH (30 mL). The mixture was stirred at room temperature for 6 hours. The mixture was filtered and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give (4-amino-3,5-difluorophenyl)(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (1.349 g / L). g) and (4-amino-3,5-difluorophenyl)(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazin-2-yl) methyl ketone (721-3) (1.367 g).

[0541] C 30 H 24 Calculated value of N5O2F5 by mass spectrometry: 581.19, Measured value: 582.33 (M+H) + ESI.

[0542] Step 4: (E)-4-chloro-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-formyl)phenyl)but-2-enamide (721-4)

[0543] (4-Amino-3,5-Difluorophenyl)(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl) methyl ketone (721-3) (500 mg, 859.79 μmol) was dissolved in EA (5 mL). Et3N (870.02 mg, 8.60 mmol, 1.20 mL) and T4P (6.19 g, 8.60 mmol, 50% purity) were added at 0 °C, and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with EA and water and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give (E)-4-chloro-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide (721-4) (440 mg, yield 74.81%).

[0544] C 34 H 27 Calculated value of N5O3F5Cl by mass spectrometry: 683.17, Measured value: 684.4 (M+H) + ESI.

[0545] Step 5: (E)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)-4-(((1r,4r)-4-(1-methyl-1H-tetrazol-5-yl)cyclohexyl)amino)but-2-enamide (Example 721).

[0546] KI (101.92 mg, 613.99 μmol) was added to a 2 mL solution of (E)-4-chloro-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)but-2-enamide (140 mg, 204.66 μmol) and 4-(1-methyltetrazole-5-yl)cyclohexylamine (74.18 mg, 409.32 μmol). The mixture was stirred at 50 °C for 4–5 hours. The mixture was diluted with EA and water and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by reverse-phase column chromatography (C18 column) to give (E)-N-(2,6-difluoro-4-(10-(methoxymethyl)-9,14-dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)phenyl)-4-(((1r,4r)-4-(1-methyl-1H-tetrazol-5-yl)cyclohexyl)amino)but-2-enamide (80 mg, yield).

[0547] C 42 H 41 N 10 F5O3 mass spectrometry calculated value: 828.33, measured value: 829.35 (M+H) + ESI.

[0548] 1 H NMR (400 MHz, DMSO- d 6) δ: 10.00-9.99 (m, 1H), 9.90-9.89 (m, 1H), 8.18 (m, 1H), 7.58-7.56 (m, 2H), 7.18-7.13 (m, 2H), 7.05-7.04 (m, 1H), 6.93-6.90 (m, 1H), 6.40-6.36 (m, 1H), 5.22-5.21 (m, 1H), 4.82-4.81 (m, 1H), 4.78-4.77 (m, 2H), 4.03 (s, 3H), 3.96 (s, 3H), 3.70-3.67 (m, 1H), 3.45-3.44 (m,2H), 3.38 (s, 3H), 3.26-3.23 (m, 1H), 3.00-2.94 (m, 1H), 2.56 (s, 3H), 2.06-1.95 (m, 4H), 1.60-1.57 (m, 2H), 1.24-1.18 (m, 2H).

[0549] Synthesis of Example 742:

[0550] Step 1: 2-(but-2-yn-1-yloxy)tetrahydro-2H-pyran (742-1)

[0551] Buty-2-yn-1-ol (10 g, 142.67 mmol) and 3,4-dihydro-2H-pyran (18.00 g, 214.01 mmol) were dissolved in THF (150 mL). After cooling to 0 °C and stirring for 10 min, TsOH (594.55 mg, 11.41 mmol) was added, and the mixture was stirred at room temperature for 4 h. The mixture was diluted with EA and water and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography to give 2-(buty-2-yn-1-yloxy)tetrahydro-2H-pyran (19.0 g, 79.17% yield).

[0552] Mass spectrometry calculation of C9H 14 O2

[0553] 1 H NMR (400 MHz, DMSO- d 6) δ: 4.80-4.78 (m, 1H), 4.29-4.24 (m, 1H), 4.18-4.13 (m, 1H), 3.83-3.80 (m, 1H), 3.53-3.50 (m, 1H), 1.85-1.84 (m, 3H),1.73-1.71 (m, 2H), 1.64-1.50 (m, 4H).

[0554] Step 2: (E)-4,4,5,5-Tetramethyl-2-(1-(tetrahydro-2H-pyran-2-yl)but-2-en-2-yl)-1,3,2-diaxoxopentaborane (742-2)

[0555] Under a nitrogen atmosphere, CuCl (192.60 mg, 1.95 mmol), t-BuONa (1.12 g, 11.67 mmol), and IPr (186.96 mg, 1.95 mmol) were dissolved in toluene (100 mL). The mixture was cooled to 0 °C and stirred for 15 minutes. Then, 4,4,5,5-tetramethyl-1,3,2-diaxopentane (16.60 g, 129.70 mmol) was added at 0 °C. After stirring for 0.5 hours, 2-but-2-alkynoxytetrahydropyran (10 g, 64.85 mmol) was added at 0 °C, and the mixture was stirred overnight at room temperature. The mixture was filtered through diatomaceous earth, concentrated under reduced pressure, and purified by column chromatography to give (E)-4,4,5,5-tetramethyl-2-(1-(tetrahydro-2H-pyran-2-yl)but-2-en-2-yl)-1,3,2-diaxopentaborane (5.8 g, yield 33.60%), which was confirmed by TLC.

[0556] Step 3: (Z)-(8-(2-(methoxymethyl)-1-methyl-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)but-2-en-2-yl)-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (742-4)

[0557] The mixture of [8-[4-chloro-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)benzimidazol-5-yl]-1-nitro-indoleazine-3-yl]-(3,4,5-trifluorophenyl)methyl ketone (742-3) (2 g, 3.35 mmol), K2CO3 (926.21 mg, 6.70 mmol), 4,4,5,5-tetramethyl-2-[(Z)-1-(tetrahydropyran-2-yloxymethyl)prop-1-enyl]-1,3,2-diaxoxopentoborane (742-2) (2.84 g, 10.05 mmol), PdCl2(dcypf) (506.46 mg, 670.17 μmol), 1,4-dioxane (40 mL) and H2O (3.2 mL) was stirred overnight at 100 °C. The mixture was diluted with EA and water, and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by reverse-phase column (C18 column) to give (Z)-(8-(2-(methoxymethyl)-1-methyl-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)but-2-en-2-yl)-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindoleazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (1.4 g, yield 58.30%).

[0558] C 35 H 30 Calculated value of N4O6F6 by mass spectrometry: 716.21, measured value: 717 (M+H) + ESI.

[0559] Step 4: (Z)-(1-amino-8-(2-(methoxymethyl)-1-methyl-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)but-2-en-2-yl)-6-(trifluoromethyl)-1H-benzi[d]imidazol-5-yl)indolazine-3-yl)(3,4,5-trifluorophenyl)methyl ketone (742-5)

[0560] Boronic acid (925.75 mg, 10.33 mmol) was added to a DMF (20 mL) solution of (Z)-(8-(2-(methoxymethyl)-1-methyl-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)but-2-en-2-yl)-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-nitroindazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (1.48 g, 2.07 mmol). After stirring for 10 min, 4-(4-pyridyl)pyridine (64.51 mg, 413.05 μmol) was added, and the mixture was stirred at room temperature for 2 h. The mixture was diluted with aqueous solutions of EA and NaHCO3 and extracted with EA. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was used directly for the next step without purification.

[0561] C 35 H 32 Calculated value of N4O4F6 by mass spectrometry: 686.23, Measured value: 687.2 (M+H) + ESI.

[0562] Step 5: (Z)-(1-amino-8-(4-(1-hydroxybut-2-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzi[d]imidazol-5-yl)indolazine-3-yl)(3,4,5-trifluorophenyl)methyl ketone (742-6)

[0563] HCl (75.40 mg, 2.07 mmol, 15 mL) in 1,4-dioxane was added to a solution of (Z)-(1-amino-8-(2-(methoxymethyl)-1-methyl-4-(1-((tetrahydro-2H-pyran-2-yl)oxy)but-2-en-2-yl)-6-(trifluoromethyl)-1H-benzis[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (1.42 g, 2.07 mmol) in 1,4-dioxane (20 mL). The mixture was stirred at room temperature for 2 hours. The mixture was diluted with aqueous solutions of EA and NaHCO3 and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by reverse-phase column (C18 column) to give (Z)-(1-amino-8-(4-(1-hydroxybut-2-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzi[d]imidazol-5-yl)indazine-3-yl)(3,4,5-trifluorophenyl) methyl ketone (800 mg, yield 57.1%).

[0564] C 30 H 24Calculated value of N4O3F6 by mass spectrometry: 602.18, measured value: 603 (M+H) + ESI.

[0565] Step 6: (Z)-(12-ethylidene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (742-7)

[0566] Under a nitrogen atmosphere, DDQ (395.58 mg, 1.74 mmol) was added to a 15 mL solution of PPh3 (457.08 mg, 1.74 mmol) in DCM. (Z)-(1-amino-8-(4-(1-hydroxybut-2-en-2-yl)-2-(methoxymethyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (700 mg, 1.16 mmol) was added, and the mixture was stirred overnight at room temperature. The mixture was diluted with EA and water, and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by reverse-phase column (C18 column) to give (Z)-(12-ethylidene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (760 mg, 90% yield).

[0567] C 30 H 22 N4O2F6 mass spectrometry calculated value: 584.16, measured value: 585.17 (M+H) + ESI.

[0568] Step 7: ((1r,4r)-4-cyanocyclohexyl)((E)-4-((4-(((Z)-12-ethylidene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)amino)-4-oxobut-2-en-1-yl)tert-butyl carbamate (742-9)

[0569] At 0°C in a glove box, N-[(E)-4-amino-4-oxo-but-2-enyl]-N-(4-cyanocyclohexyl)carbamate tert-butyl ester (94.66 mg, 307.95 μmol) and DMAc (5 mL) were added to NaH (35.93 mg, 898.19 μmol, 3.66e-1 μL, 60% purity). After stirring for 0.5 hours, a DMAc solution (5 mL) of (Z)-(12-ethylidene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indolazin-2-yl)(3,4,5-trifluorophenyl) methyl ketone (150 mg, 256.62 μmol) was added, and the mixture was stirred at room temperature for 1 hour. The mixture was quenched with ice water and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by reverse-phase column (C18 column) to give ((1r,4r)-4-cyanocyclohexyl)((E)-4-((4-(((Z)-12-ethylene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)amino)-4-oxobut-2-en-1-yl) tert-butyl carbamate (100 mg, 50% yield).

[0570] C 46 H 46 Calculated value for N7F5O5 by mass spectrometry: 871.35, Measured value: 872.38 (M+H) + ESI.

[0571] Step 8: (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(4-(((Z)-12-ethylene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4]benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (Example 742)

[0572] TFA (0.6 mL) was added to a solution of ((1r,4r)-4-cyanocyclohexyl)((E)-4-((4-(((Z)-12-ethylene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)amino)-4-oxobut-2-en-1-yl)tert-butyl carbamate (85 mg, 97.49 μmol) in DCM (2.5 mL). The mixture was stirred at room temperature for 2 hours. The mixture was quenched with aqueous NaHCO3 solution, diluted with EA and water, and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by reverse-phase column (C18 column) to give (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(4-(((Z)-12-ethylene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azacyclooctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (4.45 mg, 7% yield).

[0573] C 41 H 38 Calculated value for N7O3F5 by mass spectrometry: 771.30, Measured value: 772.35 (M+H) + ESI.

[0574] 1 H NMR (400 MHz, DMSO- d 6) δ: 9.99 (s, 1H), 9.85-9.83 (m, 1H), 8.13 (s,1H), 7.55-7.53 (m, 2H), 7.11-7.08 (m, 2H), 7.02-7.00 (m, 1H), 6.90-6.86 (m,1H), 6.36-6.32 (m, 1H), 5.35-5.32 (m, 1H), 4.76 (s, 2H), 4.30-4.29 (m, 1H),3.94 (s, 3H), 3.91-3.90 (m, 1H), 3.38-3.37 (m, 6H), 2.67-2.66 (m, 1H), 2.45-2.44 (m, 1H), 2.04-1.99 (m, 2H), 1.91-1.87 (m, 2H), 1.52-1.49 (m, 2H), 1.47-1.45 (m, 3H), 1.12-1.09 (m, 2H).

[0575] Step 9: (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(4-(((Z)-12-ethylene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-ene Amides and (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(4-((Z)-12-ethylene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-eneamides

[0576] (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(4-((Z)-12-ethylene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (70) (mg) was separated by supercritical fluid chromatography to obtain (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(4-((Z)-12-ethylene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (26 mg). (mg) and (E)-4-(((1r,4r)-4-cyanocyclohexyl)amino)-N-(4-(((Z)-12-ethylene-10-(methoxymethyl)-9-methyl-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5,6]azaoctano[4,3,2-hi]indoleazine-2-carbonyl)-2,6-difluorophenyl)but-2-enamide (22 mg).

[0577] Preparative separation methods: Instrument: Waters 150 preparative supercritical fluid chromatograph (SFC-26); Column: ChiralPak IH, 250×30mm ID, 10 µm; Mobile phase: A is CO2, B is methanol (0.1% NH3H2O); Gradient: B 35%; Flow rate: 120 mL / min; Back pressure: 100 bar; Column temperature: 38℃; Wavelength: 220 nm; Cycle time: ~5 min.

[0578] Example 742 P1:

[0579] C 41 H 38 Calculated value for N7O3F5 by mass spectrometry: 771.30, Measured value: 772.35 (M+H) + ESI.

[0580] 1 H NMR (400 MHz, DMSO- d 6) δ: 10.00 (s, 1H), 9.85-9.83 (m, 1H), 8.13(s, 1H), 7.55-7.53 (m, 2H), 7.11-7.08 (m, 2H), 7.02-7.00 (m, 1H), 6.90-6.86(m, 1H), 6.36-6.32 (m, 1H), 5.34-5.32 (m, 1H), 4.76 (s, 2H), 4.30-4.29 (m,1H), 3.94 (s, 3H), 3.91-3.90 (m, 1H), 3.42-3.37 (m, 6H), 2.68-2.67 (m, 1H),2.04-2.00 (m, 2H), 1.92-1.88 (m, 2H), 1.52-1.51 (m, 2H), 1.47-1.45 (m, 3H),1.13-1.10 (m, 2H).

[0581] Example 742 P2:

[0582] C 41 H 38 Calculated value for N7O3F5 by mass spectrometry: 771.30, Measured value: 772.57 (M+H) + ESI.

[0583] 1 H NMR (400 MHz, DMSO- d 6 ) δ: 10.00 (s, 1H), 9.85-9.83 (m, 1H), 8.13(s, 1H), 7.55-7.53 (m, 2H), 7.11-7.08 (m, 2H), 7.02-7.00 (m, 1H), 6.91-6.86(m, 1H), 6.37-6.33 (m, 1H), 5.34-5.33 (m, 1H), 4.76 (s, 2H), 4.30-4.29 (m,1H), 3.94 (s, 3H), 3.91-3.90 (m, 1H), 3.42-3.37 (m, 6H), 2.68-2.67 (m, 1H),2.04-2.00 (m, 2H), 1.92-1.88 (m, 2H), 1.53-1.51 (m, 2H), 1.47-1.45 (m, 3H),1.13-1.10 (m, 2H).

[0584] Synthesis of Example 905:

[0585] Step 1: 2-Chloro-6-fluoro-4-(trifluoromethyl)aniline (905-1)

[0586] Add to a CH3CN (1000 mL) solution of 50 g (279.15 mmol) of 2-fluoro-4-(trifluoromethyl)aniline. N 2-Chlorosilicate (41.00 g, 307.07 mmol) was stirred overnight at 75 °C. The solution was concentrated under reduced pressure, water (1000 mL) was added to the mixture, and it was extracted with ethyl acetate (500 mL × 3). The mixture was washed with aqueous NaHCO3 solution and concentrated brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with petroleum ether and EtOAc (10:1), to give a yellow oily 2-chloro-6-fluoro-4-(trifluoromethyl)aniline (905-1) (59 g, 98%).

[0587] Step 2: 1-Chloro-3-fluoro-2-nitro-5-(trifluoromethyl)benzene (905-2)

[0588] A mixture of sodium perborate tetrahydrate (212.49 g, 1.38 mol) in HOAc (1000 mL) was added to 2-chloro-6-fluoro-4-(trifluoromethyl)aniline 905-1 (59 g, 276.27 mmol) at 50 °C and stirred overnight at 50 °C. The solution was poured into water, extracted with petroleum ether, washed with water and an aqueous solution of NaHCO3, and the combined layers were washed with concentrated brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with petroleum ether and EtOAc (10:1), to give 1-chloro-3-fluoro-2-nitro-5-(trifluoromethyl)benzene 905-2 (30 g, 45%) as a brown solid.

[0589] Step 3: 3-Chloro- N 2-Methyl-2-nitro-5-(trifluoromethyl)aniline (905-3)

[0590] To a THF (70 mL) solution of 1-chloro-3-fluoro-2-nitro-5-(trifluoromethyl)benzene 905-2 (13.40 g, 55.02 mmol), CH3NH2 (30% CH3OH solution, 70 mL) was added, and the mixture was stirred at room temperature for 30 minutes. The mixture was concentrated under reduced pressure to give the crude product. The crude product mixture was purified by silica gel column chromatography, eluting with petroleum ether and EtOAc (10:1) to give an orange solid of 3-chloro- N 905-3 methyl-2-nitro-5-(trifluoromethyl)aniline (12.81 g, 91% yield).

[0591] Step 4: 4-Bromo-3-chloro- N 2-Methyl-2-nitro-5-(trifluoromethyl)aniline (905-4)

[0592] To 3-chloro- N Add 270 mL of HOAc solution of 270 mL containing 27.8 g (109.19 mmol) of methyl-2-nitro-5-(trifluoromethyl)aniline 905-3. N 4-Bromosuccinimide (21.38 g, 120.11 mmol) was stirred at 40 °C for 16 hours. Water (1000 mL) was added to the mixture, and the mixture was extracted with ethyl acetate (500 mL × 3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with petroleum ether and EtOAc (10:1) to give a crude, red solid, 4-bromo-3-chloro- N 905-4 methyl-2-nitro-5-(trifluoromethyl)aniline (23.0 g, 63%).

[0593] Step 5: 4-Bromo-3-chloro- N 1 5-Methyl-5-(trifluoromethyl)benzene-1,2-diamine (905-5)

[0594] To 4-bromo-3-chloro- N A solution of 4-methyl-2-nitro-5-(trifluoromethyl)aniline 905-4 (10.5 g, 31.49 mmol) in CH3OH (40 mL), THF (40 mL), and water (20 mL) was mixed with iron powder (8.79 g, 157.43 mmol) and NH4Cl (4.21 g, 78.71 mmol) and stirred at 60 °C for 2 hours. The mixture was filtered through a diatomaceous earth filter, and the filtrate was washed successively with water and concentrated brine, then dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with petroleum ether, EtOAc, and DCM (10:1:1) to give a white solid 4-bromo-3-chloro- N 1 905-5-methyl-5-(trifluoromethyl)benzene-1,2-diamine (7.98 g, 84%).

[0595] Step 6: 5-Bromo-4-chloro-1,2-dimethyl-6-(trifluoromethyl)-1 H -Benz[d]imidazolium

[0596] To 4-bromo-3-chloro- N 1HOAc (5.10 g, 85.01 mmol) and HCl (12 M aqueous solution, 0.5 mL) were added to a solution of 25.8 g (85.01 mmol) of 905-5 in trimethyl orthoacetate (130 mL). The mixture was stirred at room temperature for 16 hours. The reaction was quenched with 5 M NaOH aqueous solution, diluted with EtOAc, washed with water and concentrated brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM and CH3OH (20:1), to give a white solid 5-bromo-4-chloro-1,2-dimethyl-6-(trifluoromethyl)-1 H -Benz[d]imidazole 905-6 (22.1 g, 79%).

[0597] LCMS-ESI ( m / z ): [M+H] + C 10 Calculated value of H8BrClF3N2: 326.94; Measured value: 326.85.

[0598] Step 7: (8-(4-chloro-1,2-dimethyl-6-(trifluoromethyl)-1) H -benzo[ d Imidazol-5-yl)indolin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (905-7)

[0599] 5-bromo-4-chloro-1,2-dimethyl-6-(trifluoromethyl)-1 H -benzo[ d Imidazole 905-6 (5 g, 15.27 mmol), (8-(4,4,5,5-tetramethyl-1,3,2-dihexylpentaborane-2-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone (9.19 g, 22.90 mmol), RuPhos Pd G3 (2.56 g, 3.05 mmol), and Na2CO3 (3.24 g, 30.53 mmol) in 1,4-dioxane (20 mL) and water (2 mL) were stirred at 90 °C under N2 for 16 hours. The mixture was filtered through a diatomaceous earth mat, the filtrate was washed with water and concentrated brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using petroleum ether and ethyl acetate (10:1 to 1:1) to give a yellow solid (8-(4-chloro-1,2-dimethyl-6-(trifluoromethyl)-1 H -benzo[ d Imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone 905-7 (7 g, 70%, 80% purity).

[0600] LCMS-ESI ( m / z ): [M+H] + C 25 H 15 Calculated value of ClF6N3O: 522.07; Measured value: 522.12.

[0601] Step 8: (2-(1,2-dimethyl-5-(3-(3,4,5-trifluorobenzoyl)indoleazine-8-yl)-6-(trifluoromethyl)-1 H -benzo[ d Imidazol-4-yl)allyl)tert-butyl carbamate (905-8)

[0602] (8-(4-chloro-1,2-dimethyl-6-(trifluoromethyl)-1 H A mixture of benzo[d]imidazol-5-yl)indolazin-3-yl)(3,4,5-trifluorophenyl)methyl ketone 905-7 (2.76 g, 5.29 mmol), (2-(4,4,5,5-tetramethyl-1,3,2-dihexylborane-2-yl)allyl)tert-butyl carbamate (3.00 g, 10.58 mmol), Cs₂CO₃ (3.45 g, 10.58 mmol), and Ad₂nBuP G₃ (385.18 mg, 528.90 μmol) in toluene (75 mL) and water (15 mL) was stirred at 100 °C for 16 hours under N₂. The mixture was filtered through a diatomaceous earth mat and extracted with EtOAc (100 mL × 3). The combined organic phases were washed with concentrated brine (100 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using DCM and CH3OH (20:1) to give a yellow solid (2-(1,2-dimethyl-5-(3-(3,4,5-trifluorobenzoyl)indolazin-8-yl)-6-(trifluoromethyl)-1 H -benzo[ d Imidazol-4-yl)allyl)tert-butyl carbamate 905-8 (3.35 g, 98%).

[0603] LCMS-ESI ( m / z ): [M+H] + C 33 H 29 Calculated value of F6N4O3: 643.21; Measured value: 642.94

[0604] Step 9: (2-(5-(1-bromo-3-(3,4,5-trifluorobenzoyl)indolazin-8-yl)-1,2-dimethyl-6-(trifluoromethyl)-1 H -benzo[ dImidazol-4-yl)allyl)tert-butyl carbamate (905-9)

[0605] (2-(1,2-dimethyl-5-(3-(3,4,5-trifluorobenzoyl)indolazin-8-yl)-6-(trifluoromethyl)-1 H -benzo[ d A mixture of imidazole-4-yl)allyl)tert-butyl carbamate 905-8 (3.35 g, 5.21 mmol) and N-bromosuccinimide (1.02 g, 5.73 mmol) in DMF (50 mL) was stirred at room temperature for 2 hours. The mixture was then extracted with water (250 mL) using EtOAc (100 mL × 3). The combined organic phases were washed with concentrated brine (100 mL), dried over Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using DCM and CH3OH (20:1) to give a yellow solid (2-(5-(1-bromo-3-(3,4,5-trifluorobenzoyl)indolazine-8-yl)-1,2-dimethyl-6-(trifluoromethyl)-1 H -benzo[ d Imidazol-4-yl)allyl)tert-butyl carbamate 905-9 (3.7 g, 98%).

[0606] LCMS-ESI ( m / z ): [M+H] + C 33 H 28 Calculated value of BrF6N4O3: 721.12; Measured value: 721.13.

[0607] Step 10: (2-(5-(3-(4-amino-3,5-difluorobenzoyl)-1-bromoindoleazine-8-yl)-1,2-dimethyl-6-(trifluoromethyl)-1 H -benzo[ d Imidazol-4-yl)allyl)tert-butyl carbamate (905-10)

[0608] (2-(5-(1-bromo-3-(3,4,5-trifluorobenzoyl)indoleazine-8-yl)-1,2-dimethyl-6-(trifluoromethyl)-1 H -benzo[ dImidazol-4-yl)allyl)tert-butyl carbamate 905-9 (3.7 g, 5.13 mmol) was added to a solution of 1,4-dioxane (80 mL) in NH3 (28% aqueous solution, 80 mL), and the mixture was stirred at 115 °C for 2 days. The mixture was extracted with DCM (100 mL × 3). The combined organic phases were washed with concentrated brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using DCM and CH3OH (20:1) to give a yellow solid (2-(5-(3-(4-amino-3,5-difluorobenzoyl)-1-bromoindoleazine-8-yl)-1,2-dimethyl-6-(trifluoromethyl)-1 H -benzo[ d Imidazol-4-yl)allyl)tert-butyl carbamate 905-10 (3.0 g, yield 81%).

[0609] LCMS-ESI ( m / z ): [M+H] + C 33 H 30 Calculated value of BrF5N5O3: 718.14; Measured value: 718.18.

[0610] Step 11: (4-Amino-3,5-Difluorophenyl)(8-(4-(3-aminopropyl-1-en-2-yl)-1,2-dimethyl-6-(trifluoromethyl)-1 H -benzo[ d Imidazol-5-yl)-1-bromoindoleazine-3-yl)methyl ketone

[0611] (2-(5-(3-(4-amino-3,5-difluorobenzoyl)-1-bromoindoleazine-8-yl)-1,2-dimethyl-6-(trifluoromethyl)-1 H -benzo[ d Imidazol-4-yl)allyl)tert-butyl carbamate 905-10 (3 g, 4.18 mmol) was added to a DCM (60 mL) solution and HCl (15 mL of 4 M ethyl acetate solution) was added. The mixture was stirred overnight at room temperature. The mixture was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using DCM and CH3OH (20:1) to give a yellow solid (4-amino-3,5-difluorophenyl)(8-(4-(3-aminopropyl-1-en-2-yl)-1,2-dimethyl-6-(trifluoromethyl)-1-yl) H -benzo[ d Imidazol-5-yl)-1-bromoindoleazine-3-yl)methyl ketone 905-11 (2.05 g, yield 79%).

[0612] LCMS-ESI (m / z ): [M+H] + C 28 H 22 Calculated value of BrF5N5O: 618.08; measured value: 618.10.

[0613] Step 12: (4-Amino-3,5-Difluorophenyl)(9,10-Dimethyl-12-methylene-7-(trifluoromethyl)-9,12,13,14-tetrahydroimidazo[4'',5'':3',4']benzo[1',2':5...

Claims

1. Compounds of formula (X) or (Xa): Or its tautomers, cis or trans isomers, meso compounds, racemic compounds, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein... A1, A2 and A4 are each independently selected from the group consisting of C, CH, N, NH, S and O, preferably A1 and A4 are independently selected from N and NH, and A2 is CH; A3 is selected from the group consisting of C, CH, N, NH, S, O and bonds, preferably bonds; B1 is selected from the group consisting of C, CH, and N; B2 is selected from the group consisting of C, CH, N and bonds; B3 is selected from the group consisting of CH and N; E1 and E2 are each independently selected from CH, CH2, N, NH, S, O, and C. 1-3 Alkyl group, -N(CH3)C 1-3 Alkylene, -NH-C 1-3 alkylene- and -C 1-3 The group consisting of alkylene-NH-; D1 is selected from C and CR. d1 A group consisting of N, S, and O; D2 is selected from CR d1 C(R) d1 )2, N, NR d1 A group consisting of D2 and non-existent elements will also not exist if D2 does not exist. D3 is selected from C and CR. d1 A group consisting of N; X1 is selected from C, CR d1 A group consisting of N; X2 is selected from CR d1 C(R) d1 )2, N, NR d1 A group consisting of a key and a non-existent element; X3 is selected from CR d1 C(R) d1 )2, N, NR d1 A group consisting of a key and a non-existent element; X4 is selected from CR d1 C(R) d1 )2, N, NR d1 A group consisting of a key and a non-existent element; Each R d1 Independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic and alkylheteroaryl; When X1, X2, or X3 does not exist, the key to which it is connected also does not exist; each A double or single bond is required independently to satisfy the valence requirement, provided that the two adjacent bonds are not both double bonds. Each R1 is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl, alkyl, alkenyl, alkoxy, alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio and SF5, (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl are optionally substituted by 1, 2, 3, 4 or 5 substituents, wherein the substitutions The radical is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic and alkylheteroaryl; Each R2 is independently selected from hydrogen, deuterium, halogen, amino, cyano, NO2, oxo (═O), thio (═S), hydroxyl, cyanoalkyl, deuterated alkyl, alkyl, alkenyl, alkynyl, deuterated alkenyl, deuterated alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, deuterated alkoxy, deuterated alkylthio, deuterated haloalkyl, deuterated hydroxyalkyl, methylene (=CH2), -NR 2a R 2b SF5, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the hydroxyl, cyanoalkyl, deuterated alkyl, alkyl, alkenyl, alkynyl, deuterated alkenyl, deuterated alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, deuterated alkoxy, deuterated alkylthio, deuterated haloalkyl, deuterated hydroxyalkyl, methylene (=CH2), -NR 2a R 2b The cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by 1, 2, 3, 4, or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkyl heteroaryl, and SF5. Alternatively, two R2 atoms together with their two adjacent atoms form a cycloalkyl, heterocyclic, aryl, or heteroaryl group, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally surrounded by 1, 2, 3, or 4 R2 atoms. 2c replace; R 2a R 2b and R 2c Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkylheteroaryl and SF5; Cycloalkyl A is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, and is optionally substituted by 1, 2, 3, or 4 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, methylene (=CH2), oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkylheteroaryl, and SF5, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; L2 is selected from the key, C(O), CR 3a R 3b , C=R 3d , C=NR 3e , O、 S and NR 3f The group formed; R 3a R 3b R 3e and R 3f Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkylheteroaryl and SF5; Or R 3a and R 3b Together with the atoms attached thereto, a cycloalkyl or heterocyclic group is formed, which is optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl, alkyl, NO2, oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, alkylheteroaryl and SF5; R 3d Selected from the group consisting of C1-C3 alkylene groups; L4 is selected from C(O) and Groups composed of CH2; J is selected from CH2、 CH and C(O); L5 is selected from CH2 and A group composed of C(O); Indicates the connection point with the parent nucleus structure; R4 can be hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, or amino. R5 is selected from the group consisting of: (i) hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, and SF5; (ii) cycloalkyl, heterocyclic, aryl, heteroaryl, O-cycloalkyl, and S-cycloalkyl, wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally represented by 1, 2, 3, 4, or 5 R5 groups. 5b Instead, the R 5b Selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, oxo (═O), thio (═S), -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, -C 0-6 Alkylene -S(O)2H, -C 0-6 Alkylene-S(O)2-alkyl, cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, SF5, and alkylheteroaryl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated, wherein R 5b The cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by 1, 2, 3, 4, or 5 substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, NO2, oxo (═O), thio (═S), and -SH, alkoxy, haloalkyl, alkenyl, alkynyl, alkylthio, hydroxyalkyl, aminoalkyl, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)NH2, -OC(O)NH2, -NHC(O)OH, -COOH, -OC(O)H, -S(O)H, -S(O)2H, and cycloalkyl, haloalkoxy, hydroxyalkoxy, -O-haloalkyl, aryl, heteroaryl, heterocyclic, SF5, alkylheteroaryl; Alternatively, R4 and R5, together with the atoms they are attached to, form a cycloalkyl or heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally surrounded by 1, 2, 3, 4, or 5 R atoms. 28 replace; R 28 Selected from: non-existent, hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, -NH-C(O)-C 0-6 Alkyl, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, SF5, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, methylene (=CH2), oxo (=O), -C 0-6 Alkylenes -S(O)2H and -C 0-6 The group consisting of alkylene-S(O)2-alkyl, wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, methylene (=CH2), -C 0-6 Alkylene -S(O)2H, -C 0-6 The alkylene-S(O)2-alkyl group is optionally surrounded by 1, 2, 3, 4 or 5 R groups. 29 replace; Each R 29 Independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, cyano, oxo (=O), -NH-C(O)-C 0-6 Alkyl, C 0-6 Alkyl-C(O)-, -C 0-6 Alkylene -S(O)2H, -C 0-6 Alkylene-S(O)2-alkyl, SF5, cycloalkyl, cycloalkoxy, heterocyclic, aryl, heteroaryl, and hydroxyalkyl; preferably, selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4; m can be 0, 1, 2, 3, or 4; t can be 0, 1, or 2.

2. The compound of claim 1, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Each R1 is independently selected from (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkoxy, C1-C6 haloalkylthio; (ii) -O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl, C3-C8 cycloalkyl, 5-8 membered heterocyclic groups containing 1 or 2 heteroatoms selected from N, O and S, wherein the cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl and C1-C6 alkyl; Preferably, each R1 is independently selected from (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C2-C4 alkoxyalkyl, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1-C3 haloalkoxy, C1-C3 haloalkylthio; (ii) -O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclic groups containing 1 or 2 heteroatoms selected from N, O and S, wherein the cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 cyanoalkyl and C1-C3 alkyl; x is 0, 1, 2 or 3.

3. The compound of any one of claims 1 to 2, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, for Preferred , R 12 and R 14 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C2-C6 cyanoalkyl, C2-C6 alkenyl, C2-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and SF5; R 13 Selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkylthio, C1-C6 haloalkoxy and SF5, (ii) -O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl, 3-6 membered cycloalkyl and 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O and S, optionally substituted with one, two, three, four or five substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl and C1-C6 alkyl; Preferably, R 12 and R 14 Each is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 cyanoalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C2-C4 alkoxyalkyl, C1-C3 alkylthio, C1-C3 haloalkyl, and C1-C3 hydroxyalkyl; more preferably, R 12 It is CH3OCH2- or CH3; more preferably, R 14 It is CH3; Preferably, R 13 Selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1-C3 haloalkylthio, C1-C3 haloalkoxy; (ii) -O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, 3-6 membered cycloalkyl, 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O and S, optionally substituted with 1, 2, 3, 4 or 5 substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl and C1-C3 alkyl; more preferably, R 13 Preferably, it is cyclopropyl, CF3 or SF5.

4. The compound of any one of claims 1 to 3, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Selected from , A group that is formed.

5. The compound of any one of claims 1 to 4, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Selected from , , , , , , , , , , , , The group consists of, R 21 R 22 and R 23 Each is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 cyanoalkyl, C1-C6 alkyl, deuterated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, deuterated C2-C6 alkenyl, deuterated C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkylthio, deuterated C1-C6 alkoxy, deuterated C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, deuterated C1-C6 hydroxyalkyl, -NR 2a R 2b And SF5, (ii) 3-8 membered cycloalkyl, 5-8 membered heterocyclic group containing 1 or 2 heteroatoms selected from N, O and S, C6-C 10 Aryl group, C5-C containing one or two heteroatoms selected from N, O, and S. 10 Heteroaryl groups, optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogen, amino, cyano, hydroxyl, C1-C6 haloalkyl and C1-C6 hydroxyalkyl; Or, R 22 and R 23 Together with the atoms attached thereto, they form 3-8 membered cycloalkyl groups, 5-8 membered heterocyclic groups containing one or two heteroatoms selected from N, O, and S, C6-C 10 Aryl or 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O and S; R 2a and R 2b Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 alkoxy, halogen, cyano, amino, 3-6 membered cycloalkyl, 5-8 membered heterocyclic, C6-C 10 The group consists of aryl and 5-8 membered heteroaryl groups.

6. The compound of any one of claims 1-5, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , and The group formed; in, R 21 R 22 R 23 R 24 R 25 R 26 and R 27 Each is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 cyanoalkyl, C1-C3 alkyl, deuterated C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, -NR 2a R 2b And SF5, (ii) methylene (=CH2), C3-C6 cycloalkyl, 3-6-membered heterocyclic group containing 1 or 2 heteroatoms selected from N, O and S, C6-C8 aryl and 5-8-membered heteroaryl group containing 1 or 2 heteroatoms selected from N, O and S, optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and SF5; Or, R 21 and R 22 Together with the atoms attached thereto, it forms a C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing one or two heteroatoms selected from N, O, and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O, and S; it is optionally substituted by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, and SF5; Or, R 22 and R 23 Together with the atoms attached thereto, it forms a C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing one or two heteroatoms selected from N, O, and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O, and S; it is optionally substituted by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, and SF5; Or, R 23 and R 24 Together with the atoms attached thereto, it forms a C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing one or two heteroatoms selected from N, O, and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O, and S; optionally substituted by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, and SF5; Or, R 25 and R 26 Together with the atoms attached thereto, it forms a C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing one or two heteroatoms selected from N, O, and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing one or two heteroatoms selected from N, O, and S; optionally substituted by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, and SF5; R 2a and R 2b Each of the following is independently selected from the group consisting of: (i) hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, amino and SF5; (ii) C3-C8 cycloalkyl, C3-C6 heterocyclic, C6-C8 aryl and C5-C8 heteroaryl containing one or two heteroatoms selected from N, O and S, optionally substituted by one, two, three, four or five substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and SF5; Preferably, for , , , , More preferably, R 21 It is CD3.

7. The compound of any one of claims 1-6, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R 21 R 22 and R 23 Each is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 cyanoalkyl, C1-C3 alkyl, C1-C3 deuterated alkyl and -NR. 2a R 2b (ii) , , , , , , , and Optionally substituted with 1, 2, 3, 4, or 5 substituents, said substituents being selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxy, C1-C3 haloalkyl, and C1-C3 hydroxyalkyl; or, R 22 and R 23 It forms together with the atoms it is connected to. , or It is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halogen, amino, cyano, hydroxy, C1-C3 haloalkyl and C1-C3 hydroxyalkyl. R 2a and R 2b Each is independently selected from the group consisting of: (i) hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, and amino; (ii) , , , , , , and It is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

8. The compound of any one of claims 1-7, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Selected from , , , , , and The group consists of, D1 is selected from C and CR. d1 A group consisting of N, S, and O; D2 is selected from the group consisting of CH, CH2, and N; D3 is selected from the group consisting of C, CH, CH2, N, and NH; R d1 Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, and amino; X1 is selected from the group consisting of CH, CH2, N, and NH; X2 is selected from the group consisting of CH, CH2, CH3, N, NH and NH2; X3 is selected from the group consisting of CH, CH2, N, and NH; X4 is selected from the group consisting of CH, CH2, N, NH and NH2.

9. The compound of any one of claims 1-8, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Selected from , , , , , , and A group that is formed.

10. The compound of any one of claims 1-9, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Cyclone A is selected from the group consisting of phenyl, C3-C8 cycloalkyl, 5-8 membered heterocyclic or 5-8 membered heteroaryl containing one or two heteroatoms selected from N or O, optionally substituted by one, two, three or four substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 alkylamino, C1-C3 alkylcyano and C1-C3 hydroxyalkyl and SF5, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated.

11. The compound of any one of claims 1-10, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Ring A is selected from , , , , , , , , , and The group consisting of, optionally, substituted with 1, 2, 3 or 4 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 alkylamino, C1-C3 alkylcyano, C1-C3 hydroxyalkyl and SF5.

12. The compound of any one of claims 1-11, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Ring A is selected from , , , , , , , , , , , , , , , , , , , , , , , , , and A group that is formed.

13. The compound of any one of claims 1-12, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, L2 is selected from the key, C=O、 CF2 C-OH, C(F)CH3、 C(OH)CH3、 C=CH2、 C=NH、 C=N-OH CO-CH3, O、 S, , , and Groups composed of NCH3; L4 is selected from C(O) and Groups composed of CH2; J is selected from CH2、 CH and C(O); L5 is selected from CH2 and A group composed of C(O).

14. The compound of any one of claims 1-13, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl; R5 is selected from the group consisting of branched or straight-chain C1-C3 alkyl, C3-C8 cycloalkyl, or 4-10-membered heterocyclic groups containing one or two heteroatoms selected from N, O, and S, and 5-8-membered heteroaryl groups containing one or two heteroatoms selected from N and O, optionally substituted by 1, 2, 3, 4, or 5 substituents selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1-C3 cyanoalkyl, and C1-C3 aminoalkyl, wherein the cycloalkyl or heterocyclic group is saturated or partially unsaturated; Alternatively, R4 and R5 together with the atoms they are attached to form a 5-7 membered heterocyclic group containing one or two heteroatoms selected from N, O and S; m can be 0, 1, or 2.

15. The compound of any one of claims 1-14, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 haloalkyl and C1-C3 hydroxyalkyl; R5 is selected from -C(CH3)2. , , , , , , , , , , , , and The group formed; Alternatively, R4 and R5 together with the atoms they are attached to form , , or .

16. The compound of any one of claims 1 to 15, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, having a structure selected from formula (XIV), in, R 17 R 18 and R 19 Each is independently selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkynyl, deuterated C2-C6 alkenyl, deuterated C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 Alkylthio, deuterated C1-C6 alkylthio, C1-C6 haloalkyl, cyano, C1-C6 hydroxyalkyl and SF5; (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl and heterocyclic, wherein the cycloalkyl and heterocyclic are optionally substituted by 1, 2, 3, 4 or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl, alkyl and SF5; E1 is selected from the group consisting of CH, CH2, N, NH, S, and O; E2 is selected from the group consisting of N, NH, S and O; R 20 and R 20 a is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, C1-C6 hydroxyalkyl, and SF5; preferably, R 20 For CD3; R 21 and R 22 Each is independently selected from the group consisting of hydrogen, deuterium, F, Cl, Br, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, C1-C6 hydroxyalkyl and SF5; R 23 Selected from the group consisting of hydrogen, deuterium, halogen, cyano, and SF5, or selected from the group consisting of unsubstituted or substituted R groups (1, 2, 3, or more). 23 One of the substituted groups: amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl; R 23 Selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, C1-C6 hydroxyalkyl, SF5, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl; Preferably, R 17 It is CH3OCH2-; Preferably, R 18 It is CH3; Preferably, R 19 It is cyclopropyl; Preferably, R 20 For CD3; Preferably, R 21 and R 22 For F; t can be 0, 1, or 2.

17. The compound of claim 16, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, C1-C6 deuterated alkyl groups are selected from -CD3, -CHD2, -CH2D, -CD2CH3 and -CH2CD3.

18. A compound of formula (XVI)-(XXVIII), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof. in, A1, A2 and A4 are each independently selected from the group consisting of C, CH, N, NH, S and O, preferably A1 and A4 are independently selected from N and NH, and A2 is CH; A3 is selected from the group consisting of C, CH, N, NH, S, O and bonds, preferably bonds; B1 is selected from the group consisting of C, CH, and N; B2 is selected from the group consisting of C, CH, N and bonds; B3 is selected from the group consisting of CH, N, S, and O; E1, E2, and E4 are each independently selected from the group consisting of CH, CH2, N, NH, S, and O; E3 is selected from the group consisting of CH, CH2, N, NH, S, O and bonds; D1 is selected from C and CR. d1 A group consisting of N, S, and O; D2 is selected from the group consisting of CH, CH2, N and non-existent. When D2 does not exist, the bond connected to D2 also does not exist. D3 is selected from the group consisting of C, CH, CH2, N, and NH; R d1 Selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, and amino groups. X1 is selected from the group consisting of C, CH, CH2, N, and NH; X2 is selected from the group consisting of CH, CH2, CH3, N, NH, NH2 and bonds; X3 is selected from the group consisting of CH, CH2, N, NH and bonds; X4 is selected from the group consisting of CH, CH2, CH3, N, NH, NH2 and bonds; each Independently represent a double bond or a single bond that satisfies the valence requirement, provided that the two adjacent bonds are not both double bonds; Indicates a double bond or a single bond; Each R 25 R 30 R 31 R 33 Independently selected from the group consisting of: (i) absent, hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl, alkyl, alkenyl, alkoxy, alkylthio, alkoxyalkyl, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio and SF5; (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl and heterocyclic groups, wherein the amino, hydroxy, cyanoalkyl, alkyl, alkenyl, alkoxy, alkylthio, alkoxyalkyl, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl and alkyl; Preferably, each R 25 R 30 R 31 R 33 Independently selected from the group consisting of: (i) absent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 2-6 Alkoxyalkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 (ii)-O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, C3-C8 cycloalkyl and 5-10 membered heterocyclic groups, wherein the amino, hydroxy, cyanoalkyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxy-thio, alkoxyalkyl, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio, -O-cycloalkyl, -S-cycloalkyl, cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl and alkyl; Each R 26 Independently selected from: non-existent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, methylene (=CH2), alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, -NR 2a R 2b The group consisting of SF5, cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein hydroxyl, cyanoalkyl, alkyl, methylene (=CH2), oxo (=O), alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, -NR 2a R 2b Cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by 1, 2, 3, 4, or 5 R groups. 26a Replace, where R 26a Selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, oxo (=O), and SF5; preferably, R 26 Selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; Preferably, each R 26 Independently selected from non-existent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C 1-6 Cyanoalkyl, C 1-6 Alkyl, methylene (=CH2), C 2-6 alkenyl, C 2-6 alkynyl group, C 2-6 Alkoxyalkyl, C 2-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 2-6 Alkylthio, C 2-6 Haloalkyl, C 2-6 Hydroxyalkyl, -NR 2a R 2b SF5, C 3-8 Cycloalkyl, 5-10 membered heterocyclic groups, C 6-12 Aryl and C 1-9 The group consisting of heteroaryl groups, including hydroxyl, cyanoalkyl, alkyl, methylene (=CH2), alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, and -NR. 2a R 2b Cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by 1, 2, 3, 4, or 5 R groups. 26a replace; Or two Rs 26 Together with the two adjacent atoms it is attached to, it forms a cycloalkyl, heterocyclic, aryl, or heteroaryl group; preferably C10. 3-8 Cycloalkyl, 5-10 membered heterocyclic groups, C 6-12 Aryl or C 1-9 Mixed aromatics; R 2a and R 2b Each is independently selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, amino, cycloalkyl, heterocyclic, aryl, and heteroaryl; preferably, selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, halogen, cyano, amino, C 3-8 Cycloalkyl, 5-10 membered heterocyclic groups, C 6-12 Aryl and C 1-9 Group composed of heteroaryl groups; Ring A is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, and is optionally surrounded by 1, 2, 3, or 4 R groups. 27 replace; R 27 The group is selected from the group consisting of hydrogen, deuterium, alkyl, deuterated alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, oxo (=O), cycloalkyl, cycloalkyloxy, heterocyclic, aryl, and heteroaryl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; wherein R 27 The alkyl, deuterated alkyl, alkenyl, alkynyl, amino, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by 1, 2, 3, 4, or 5 R groups. 27a Replace, where R 27a Selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, oxo (=O), and SF5; preferably, R 27 It is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; L2 is selected from the key, C(O), CR 3a R 3b , C=R 3d , C=NR 3e , O、 S and NR 3f The group formed; R 3a and R 3b Each is independently selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C4 alkenyl, C2-C4 alkynyl, cyano, amino, C3-C6 cycloalkyl, 5-8 membered heterocyclic groups containing 1, 2, 3, 4 or 5 heteroatoms selected from N, O and S, aryl and heteroaryl groups; Or R 3a and R 3b Together with the atoms attached thereto, they form a cycloalkyl or heterocyclic group, which is optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano and amino. R 3d Selected from the group consisting of C1-C3 alkyl groups; R 3e Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano, and amino; R 3f Selected from the group consisting of C1-C3 alkyl groups; L4 is selected from the group consisting of C(O) and CH2; J is selected from CH2, CH and C(O); L5 is selected from the group consisting of CH2 and C(O); Indicates the connection point with the parent nucleus structure; R4 is selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino and SF5; R 5a Selected from the group consisting of: (i) hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, and SF5; (ii) cycloalkyl, heterocyclic, aryl, heteroaryl, and -alkyl-heterocyclic, wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, and -alkyl-heterocyclic are optionally surrounded by 1, 2, 3, 4, or 5 R groups. 28 replace; Or R4 and R 5a Together with the atoms attached thereto, they form a 3-12 membered heterocyclic group or a 3-6 membered cycloalkyl group containing 1, 2, 3, 4 or 5 heteroatoms selected from N, O and S, wherein the cycloalkyl group or heterocyclic group is optionally surrounded by 1, 2, 3, 4 or 5 R atoms. 28 replace; R 28 Selected from: non-existent, hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, -C 0-6 Alkylene -S(O)2H, -C 0-6 Alkylene -S(O)2-alkyl, amino, -NH-C(O)-C 0-6 The group consisting of alkyl, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, SF5, cycloalkyl, heterocyclic, cycloalkyloxy, aryl, heteroaryl, methylene (=CH2), and oxo (=O), wherein the alkyl, hydroxy, alkenyl, alkynyl, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, cycloalkyl, heterocyclic, cycloalkyloxy, aryl, heteroaryl, and methylene (=CH2) are optionally surrounded by 1, 2, 3, 4, or 5 R's. 29 replace; Each R 24 R 29 Independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkynyl, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, cyano, -NH-C(O)-C 0-6 Alkyl, HC(O)-, -S(O)2H, -S(O)2-alkyl, oxo (=O), SF5, cycloalkyl, cycloalkoxy, heterocyclic, aryl, heteroaryl, and hydroxyalkyl; preferably, selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 alkoxyalkyl, C1-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl; m, n1, n2, n3, and n4 are each independently selected from 0, 1, 2, 3, or 4; n5 is independently selected from 0, 1, 2 or 3.

19. The compound of claim 18, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, each and Selected independently , , , , , , , , , , , , , and The group formed This indicates the end of E2.

20. The compound of any one of claims 18 to 19, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Each R 25 Independently selected from methyl, -SCH3, -F, -CF3 CH2OCH3, , A group consisting of SF5.

21. The compound of any one of claims 18 to 20, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Each R 26 Independently selected from hydrogen, -CH3, A group consisting of elements that do not exist.

22. The compound of any one of claims 18 to 21, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R4 is selected from the group consisting of hydrogen and -CH3.

23. The compound of any one of claims 18 to 22, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R 5a Selected from , , , , , , , , , , and The group formed; Or R4 and R 5a Together with the atoms attached thereto, they form 3-12 membered heterocyclic groups, wherein the heterocyclic groups are selected from... , and The group consisting of, preferably , or ; Each R 281 R 282 Independently selected from the group consisting of non-existent, hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, SF5, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, and methylene (=CH2), wherein the alkyl, hydroxyl, alkenyl, alkynyl, amino, HC(O)-, alkyl-C(O)-, alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, alkylcarbonyl, cycloalkyl, heterocyclic, cycloalkoxy, aryl, heteroaryl, and methylene (=CH2) are optionally surrounded by 1, 2, 3, 4, or 5 R's. 29 replace; Preferably, R 5a for , , , , , , , , , , , , , or Or R4 and R 5a It forms together with the atoms it is connected to. or .

24. The compound of any one of claims 18 to 23, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Each R 28 Selected independently , -CH3, -COCH3, -OCH3, -CN, -CH2OCH3, , , , , , , , , , , , , , , , and The group formed; R 32 The group is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkoxy, deuterated alkoxy, alkoxyalkyl, deuterated alkoxyalkyl, alkylthio, haloalkyl, cyano, SF5, cycloalkyl, cycloalkoxy, heterocyclic, aryl, heteroaryl, and hydroxyalkyl; preferably, it is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C1-C6 deuterated alkoxy, C2-C6 alkoxyalkyl, C2-C6 deuterated alkoxyalkyl, C1-C6 alkylthio, C1-C6 haloalkyl, cyano, and C1-C6 hydroxyalkyl.

25. The compound of any one of claims 18 to 24, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Each R 24 R 27 R 29 Each independently selected -F and A group that is formed.

26. The compound of any one of claims 18 to 25, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, for ; for ; for ; for .

27. The compound of any one of claims 18-26, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, , Independently , Preferred , ; for Preferred ; or, , for , Preferred , , ; Each R 251 R 252 R 253 R 254 R 255 R 256 Independently selected from the group consisting of: (i) absent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, alkenyl, alkoxy, alkylthio, alkoxyalkyl, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkylthio and SF5, (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl, heterocyclic, wherein the cycloalkyl and heterocyclic are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl and alkyl; Preferably, each R 251 R 252 R 253 R 254 R 255 R 256 Each is independently selected from the group consisting of: (i) absent, hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 2-6 Alkoxyalkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 (ii)-O-C3-C6 cycloalkyl, -S-C3-C6 cycloalkyl, C3-C8 cycloalkyl and 5-10 membered heterocyclic groups, wherein the cycloalkyl and heterocyclic groups are optionally substituted by 1, 2, 3, 4 or 5 substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, cyanoalkyl and alkyl.

28. The compound of any one of claims 18-27, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, and Independently , Preferred , or .

29. The compound of any one of claims 18-28, or a tautomer, cis or trans isomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Ring A is Preferred More preferably , Indicates the position connected to N.

30. A compound, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound comprises: 。 31. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claims 1 to 30, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

32. A method of treating a KRAS mutation-mediated disease, comprising administering to a subject in need an effective amount of a compound as described in any one of claims 1 to 30, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a pharmaceutical composition as described in claim 31.

33. The method of claim 32, wherein the KRAS mutation contains a KRAS G12C, KRAS G12V, or KRASG13D mutation.

34. A method of treating cancer, comprising administering to a subject in need an effective amount of a compound as described in any one of claims 1 to 30, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a pharmaceutical composition as described in claim 31.

35. The method of claims 32 to 34, wherein the cancer is selected from the group consisting of: heart; sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyosarcoma, fibroma, lipoma and teratoma; Lungs: Bronchial carcinoma (squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatosis, mesothelioma; Gastrointestinal tract: Esophageal carcinoma (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), Stomach (carcinoma, lymphoma, leiomyosarcoma), Pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid, vasoactive intestinal peptide tumor), Small intestine (adenocarcinoma, lymphoma, carcinoid, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma) (e.g., colon (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); genitourinary tract: kidney (adenocarcinoma, Wilms' tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminomatous seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenoma-like tumor, lipoma); liver: hepatocellular carcinoma (hepatocellular carcinoma), bile duct carcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;) Biliary tract cancer: gallbladder cancer, ampullary cancer, bile duct cancer; Bone: Osteoblastic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochondroma), benign chondroma, chondroblastoma, chondromycinoid fibroma, osteoid osteoma, and giant cell tumor; Nervous system: Skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningeal sarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germ cell tumor (pineal tumor), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors) Spinal cord neurofibroma, meningioma, glioma, sarcoma; Gynecology: Uterus (endometrial cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-theca cell tumor, Sertoli-stromal cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonic rhabdomyosarcoma)), fallopian tube (cancer); Hematologic system: Blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and adrenal glands: neuroblastoma.

36. A method for preparing a compound of formula (X), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, deuterated derivative, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, comprising: A1, A2, and A4 are each independently selected from the group consisting of C, CH, N, NH, S, and O; A3 is selected from the group consisting of C, CH, N, NH, S, O and bonds; B1 is selected from the group consisting of C, CH, and N; B2 is selected from the group consisting of C, CH, N and bonds; B3 is selected from the group consisting of C, CH, N, S, and O; E1 and E2 are each independently selected from CH, CH2, N, NH, S, O, and C. 1-3 Alkoxy, - N(CH3)C 1-3 Alkylene-# and - NH-C 1-3 The group consisting of alkylene groups, in which It can be oriented towards D1 or towards B1, and correspondingly, # can be oriented towards B1 or D1; D1 is selected from C and CR. d1 A group consisting of N, S, and O; D2 is selected from C and CR. d1 CH2, N and non-existent groups, when D2 does not exist, the bond connected to D2 also does not exist; D3 is selected from C and CR. d1 The group consists of CH2, N and NH; Each R d1 Independently selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, and amino. X1 is selected from C, CR d1 A group composed of CH2, N, and NH; X2 is selected from C and CR. d1 The group consisting of CH2, CH3, N, NH, NH2, bonds, and non-existent bonds; X3 is selected from C, CR d1 The group consisting of CH2, N, NH, bonds, and non-existent elements; X4 is selected from C, CR d1 The group consisting of CH2, CH3, N, NH, NH2, bonds, and non-existent bonds; When X1, X2, or X3 does not exist, the key to which it is connected also does not exist; Indicates the double or single bond required to satisfy the valence requirement; R1 is selected from the group consisting of: (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, alkyl, alkenyl, alkoxy, alkoxyalkyl, alkylthio, haloalkyl, hydroxyalkyl, haloalkoxy and haloalkylthio; (ii) -O-cycloalkyl, -S-cycloalkyl, cycloalkyl and heterocyclic, wherein the cycloalkyl and heterocyclic are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl and alkyl; R2 is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyanoalkyl, deuterated alkyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, -NR 2a R 2b The group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, and halogens. Or, two R2 atoms together with their two adjacent atoms form a cycloalkyl, heterocyclic, aryl, or heteroaryl group; R 2a and R 2b Each is independently selected from the group consisting of hydrogen, deuterium, alkyl, alkoxy, halogen, cyano, amino, cycloalkyl, heterocyclic, aryl, and heteroaryl; Ring A is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, and is optionally substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; L2 is selected from the key, C(O), CR 3a R 3b , C=R 3d , C=NR 3e , O、 S and NR 3f The group formed; R 3a and R 3b Each is independently selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C4 alkenyl, C2-C4 alkynyl, cyano, amino, C3-C6 cycloalkyl, 5-8 membered heterocyclic groups containing one or more heteroatoms selected from N, O and S, aryl and heteroaryl groups; Or R 3a and R 3b Together with the atoms attached thereto, they form a cycloalkyl or heterocyclic group, which is optionally substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano and amino. R 3d Selected from the group consisting of C1-C3 alkyl groups; R 3e Selected from the group consisting of hydrogen, deuterium, C1-C3 alkyl, halogen, hydroxyl, C2-C3 alkenyl, C2-C3 alkynyl, cyano, and amino; R 3f Selected from the group consisting of C1-C3 alkyl groups; L4 is selected from C(O) and Groups composed of CH2; J is selected from CH2、 CH and C(O); L5 is selected from CH2 and A group composed of C(O); Indicates the connection point with the parent structure; R4 is hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, or amino. R5 is selected from the group consisting of: (i) hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, and cyanoalkyl; (ii) cycloalkyl, heterocyclic, aryl, and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, halogen, hydroxyl, alkenyl, alkynyl, cyano, amino, alkylthio, haloalkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the cycloalkyl and heterocyclic groups are saturated or partially unsaturated; R 34 The leaving group is preferably a halogen; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4; m can be 0, 1, 2, 3, or 4; t can be 0, 1, or 2.

Citation Information

Patent Citations

  • KRAS g12d inhibitors

    WO2021041671A1